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ABSTRACT
Following acute brain injury (ABI), cellular hypoxia-ischaemia (CH-I) is central to the
pathophysiological cascades that lead to death and neurological disability. Thus, a key
tenet of neurocritical care is the avoidance of CH-I, and a key prerequisite to doing so
is the availability of a bedside clinical monitor that can identify CH-I as it occurs.
This thesis describes normal cerebral physiology, how this is deranged and clinically
manipulated following ABI, and the use of near infrared spectroscopy (NIRS), a non-
invasive optical technique, to monitor for CH-I in a variety of clinical contexts. I then
present my work investigating the use of NIRS, with an emphasis on the measurement
of the oxidation state of cytochrome c oxidase (CCO), in healthy volunteers who are
subjected to a variety of challenges designed to manipulate cerebral oxygen delivery
with both isovolaemic and hyper/hypovolaemic challenges.
Finally, I describe experiments in a cohort of a patients who have suffered from
ABI, manipulating cerebral oxygen delivery by means of normobaric hyperoxia. The
results suggest that the measurement of CCO with NIRS in patients with ABI provides a
useful adjunct to established monitors of cerebral haemodynamics and metabolism; an
in-depth discussion of the observed changes in different haemodynamic and metabolic
parameters, and their relevance to normal physiology and pathophysiology of ABI is
carried out.
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Part I
BACKGROUND AND PR INC IPL ES
1
REV I EW OF CEREBRAL PHYS IOLOGY
This thesis concerns the monitoring of brain haemodynamic & metabolic function and
dysfunction – during a number of functional and physiological challenges — in healthy
volunteers and ultimately in a cohort of patients who have suffered from acute brain
injury (ABI). In order to understand the nature of brain haemodynamic and metabolic
dysfunction following ABI and interpret the data collected during experiments in healthy
volunteers and brain-injured patients, an understanding of the normal mechanisms of
the supply and utilisation of substrate to yield the primary product of adenosine 5‘-
triphosphate (ATP), as well as additional by-products of cellular metabolism, is crucial.
In this chapter, I describe these mechanisms that are central to brain tissue survival and
function.
1.1 GROSS ANATOMICAL AND PHYS IOLOG ICAL PERSPECT IVE
The adult human brain is a 1.5 kilogram organ contained within the cranial vault
comprising 2x1010 neurons and 4x1010 glial cells arranged in a highly organised
fashion, with an estimated 15x1010 synapses formed between neurons [1,2]. The
human central nervous system (CNS) is responsible for the generation of signals that
lead to locomotor activity in response to stimuli in the surrounding environment – it is
the anatomical and physiological substrate that co-ordinates behaviour. The evolutionary
advantage conferred on humans through the development of this highly specialised and
intricate organ – and thus complex behaviour – is undeniable. Yet this ability comes at
a cost: neural tissue is exquisitely fragile as a consequence of the extraordinary amount
of energy that is required to sustain it.
1.1.1 Electrochemical basis of neuronal function – the resting and action potentials
The resting potential, an electrostatic potential across cell membranes that is maintained
through the action of an ATP-consuming membrane pump, the sodium potassium
ATPase pump (Na+/K+ATPase ), exists across the membranes of mammalian cells. It is
the result from the differences in ion concentration across the membrane, generated
by the Na+/K+ATPase. At rest, the isostatic balance between electrostatic force and
ion diffusion determines the flow of ions across leakage channels in the neuronal
membrane, thus generating the potential [3].
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The resting potential is exploited in a number of ways; one of its significant roles is
as a useable store of energy, which membrane-bound pumps can utilise to perform
secondary active transport of molecules across membranes. In neuronal cells, the resting
potential gives rise to the possibility of communication – through the action potential
and the excitatory and inhibitory postsynaptic potentials. However, this carries a high
metabolic price: at least half the oxygen consumed in the brain is utilised in maintaining
the resting potential [4].
1.1.2 Biochemical basis of energy generation
The survival and function of neural tissue is thus predicated on the ability of cells to
generate energy. For the purposes of this thesis, the term cellular energy generation
is taken to be synonymous with ATP synthesis. Each endothermic metabolic process
– that is, each that must be driven ‘thermodynamically uphill’ – must be coupled to
an exothermic process, or an ‘engine’. ATP acts as that driver, and the hydrolysis one
inorganic phosphate ion, given by the equation
ATP+H2O −−→ ADP+ Pi(∆G 0′ = −30.5kJ.mol−1),
or two phosphate ions, given by the equation
ATP+ 2H2O −−→ AMP+ 2Pi(∆G 0′ = −45.0kJ.mol−1). (1.1)
ATP can be synthesised from the oxidation of carbohydrate via a combination of
glycolysis followed by either anaerobic respiration or aerobic respiration. ATP synthesis
is also possible by the beta-oxidation of fatty acids. ATP synthesis by glycolysis and
aerobic respiration is summarised by the equation
C6H12O6 + 6 O2 + 38 ADP+ 38 Pi −−→ 6 CO2 + 6 H2O+ 38 ATP; (1.2)
anaerobic respiration can be summarised by the equation
C6H12O6 + 6 O2 + 2 ADP+ 2 Pi −−→ 2 C2H5COOH+ 2 ATP. (1.3)
The process of aerobic respiration is summarised in Figure 1.5.
Whilst these processes are described in detail below, a gross comparison highlights
points of physiological and clinical importance:
• glucose is a primary substrate for both anaerobic and aerobic respiration;
• aerobic respiration requires the presence of oxygen to act as an electron acceptor;
• the complete oxidation of glucose during aerobic respiration yields carbon dioxide
(CO2) as a waste product;
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• the incomplete oxidation of glucose during anaerobic respiration yields lactate;
• the amount of ATP generated by the oxidation of glucose is an order of magnitude
higher when performed by aerobic rather than anaerobic respiration.
The important stages in cellular energy generation – supply of metabolic substrate
to neural tissue, glycolysis, Kreb’s cycle, fermentation, and mitochondrial oxidative
phosphorylation – are described below.
1.2 SUPPLY OF METABOL IC SUBSTRATE TO T I S SUE
Oxygen and glucose are the key substrates required for cellular energy generation. The
brain can use alternative fuels – namely ketone bodies and lactate, the latter of which
is discussed below – and does so in disease states, but glucose remains the primary
substrate for oxidation for the purposes of brain cellular energy generation [5].
Glucose supply is achieved by means of nutrition (typically 350g/day) with further
stores of 400g in the liver as glycogen. Plasma glucose levels are subject to homeostatic
control primarily via the pancreatic hormones insulin and glucagon, which maintain
plasma glucose levels in the range 4.0–6.0 mM.
Figure 1.1 – The haemoglobin–oxygen dissociation curve. From [6].
The presence of oxygen (O2) is prerequisite to aerobic respiration. Ambient air
contains 21% O2 by volume, which equates to a arterial partial pressure of oxygen
(PaO2) of 19.8 kPa. Oxygen diffuses from alveolar air to pulmonary blood, is pumped
by the heart to the cerebral circulation, and then diffuses freely across the blood–brain
barrier (BBB) to neural cells and ultimately to mitochondria. Diffusion gradients and
barriers are present at each stage.
At the pulmonary level, oxygen diffuses across the alveolar membrane into pulmonary
blood, where a small proportion, corresponding to roughly 1.5 percent of the total
oxygen carrying capacity of blood, is transported as simply dissolved oxygen.
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The remaining 98.5% of oxygen is transported by reversible binding to haemoglobin,
a tetrameric erythrocytic protein that has a characteristic sigmoidal saturation curve
(shown in Figure 1.1), with a high affinity for oxygen at lower partial pressures, and
a lower affinity at higher concentrations. The affinity of haemoglobin for oxygen, is
also influenced by other factors such as tissue/capillary pH, arterial partial pressure
of carbon dioxide (PaCO2), temperature and allosteric binding by co-factors such as
2,3-diphosphoglycerate (DPG) [6,7]. These factors, combined, result in haemoglobin
being an effective transporter of oxygen from the lungs (neutral pH, low PaCO2, high
PaO2) to the tissues, particularly cerebral tissue (where the converse conditions exist).
1.2.1 Cerebrovascular supply
GROSS ANATOMY After being pumped through the left side of the heart and the
extracranial circulation, oxygenated blood is transported through the cerebrovascular
system to neural tissue. The arterial system, depicted in Figure 1.2, is grossly divided in
to anterior and posterior circulations based on the extracranial origins of these systems:
the anterior circulation is derived from the bifurcation of the internal carotid arteries,
and the posterior circulation derived from the vertebrobasilar system, which refers to
the two vertebral arteries and the basilar artery formed where they fuse.
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Figure 1.2 – The circle of Willis. From [8].
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The anterior and posterior circulations meet in an anastamotic circle, the circle of
Willis, in the midline of the skull base. Though incomplete in up to 40% of individuals,
this structure provides a degree of vascular redundancy, and acts as a partial guard
against ischaemia resulting from the stenosis or occlusion of a parent vessel. The
anterior circulation comprises the two anterior cerebral arteries (ACAs), which are
joined in the midline by the anterior communicating artery (AComm), the middle
cerebral arteries (MCAs). Each MCA is joined by a posterior communicating artery
(PComm) to the ipsilateral posterior cerebral artery (PCA). The PCAs are the major
arteries of the posterior circulation, and are formed by the bifurcation of the basilar
artery at its terminal tip. In both anterior and posterior circulations, arteries display a
variable pattern of arborisation, with cortical arterioles originating along the length of
the vessels. Deeper structures in the midbrain – such as the basal ganglia and thalamus
– are supplied by small lenticulostriate arteries that originate from the ACA and MCA.
The cortical arterial networks terminate in anastamotic plexuses – with the extracranial
circulation in the leptomeningial plexus, and in the ‘watershed areas’ at the borders
between the territories served by the anterior, middle and posterior cerebral arteries
[9].
The flow of blood through the cerebral vasculature is subject to tight, active regulation.
The two most important components of this regulation are neurovascular coupling and
cerebrovascular autoregulation (CA).
CEREBRAL AUTOREGULAT ION CA describes the ability of the brain to main-
tain cerebral blood flow (CBF) within a relatively stable range across a wide range of
mean arterial pressures. The current concept of CA was formulated by Lassen, who
Figure 1.3 – Lassen curves depicting the relationship between CBF and arterial blood pressure at different
levels of PaCO2. SAP – systolic arterial pressure. From [10].
first plotted CBF against arterial blood pressure (ABP), giving the classic autoregulatory
curve that bears his name, depicted in Figure 1.3 [11]. Ironically, the phenomena
underlying this pressure-flow relationship – where pial blood vessels dilate in response
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to hypotension and constrict in response to hypertension – were directly observed via
a cranial window by Fog in the 1930s [12,13], but elude simple measurement in the
adult human in the clinical setting. A variety of methods are currently used to measure
CBF and characterise CA, including transcranial Doppler (TCD) ultrasonography and
near infrared spectroscopy (NIRS). CA is disturbed in a variety of diseases, both neuro-
logical and systemic (discussed in Chapter 2.2.2) and there is burgeoning interest in
the potential to use knowledge of CA to guide treatment following ABI [14].
NEUROVASCULAR COUPL ING Whilst the process of CA acts to maintain con-
stant CBF in the face of potential extracranial variability (in the form of variations in
ABP), there also a need to vary CBF in order to meet variations in metabolic demand.
Neuronal activation induces an increase in metabolic demand, as the resting membrane
potential is re-established after the depolarising action potentials and post-synaptic
potentials. Neurovascular coupling is the phenomenon by which brain activation is
accompanied by a functional hyperaemia, thus ensuring that the increase in metabolic
demand that is induced by activation is met by increased CBF [15].
Mediators of neurovascular coupling include vasoactive ions, substrates and products
of metabolism and vasoactive neurotransmitters. Some of these factors (for example,
blood and interstitial K+ concentrations or glutamate concentrations) are subject to
intense homeostatic control and show transient changes that correlate closely with
neuronal activation. Other factors, such as interstitial CO2 levels, vary not only with
regional activation metabolic activity, but also as a result of extra- and intra-cranial
factors. Thus, changes in extracellular CO2 concentrations can act to modulate regional
CBF in response to functional activation, but can also modulate regional or global CBF as
a result of systemic changes in PaCO2. There is thus a complex and non-linear interplay
between neurovascular coupling and cerebral autoregulation, one aspect of which is
illustrated in Figure 1.3. Similarly, hypoxia reliably produces cerebral vasodilatation,
and this effect is thought to be primarily mediated by nitric oxide (NO·) [16].
BLOOD–BRA IN BARR I ER The final stage of delivery of metabolic substrate to
tissue is traversal of the BBB. Rather than being a discernible physical entity, the BBB is
a functional barrier that acts to facilitate the influx and eﬄux of metabolic substrates
and products. It regulates ion balance and protects from potentially harmful circulating
molecules [17].
The physical basis of the BBB is a complex of cells, termed the neurovascular
unit, comprising endothelial cells, astrocytes, pericytes, neurons, and extracellular
matrix around the vessels; the neurovascular unit is also responsible for mediating
some of the CBF regulation described above, such as neurovascular coupling, on the
microvascular level. Segregation of blood from brain extracellular fluid (ECF) is achieved
through the presence of adherens junctions and tight junctions. The former refer to the
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structures between adjacent endothelial cells within the capillary bed, across which
scant diffusion/transport of substrate occurs. Tight junctions are formed at the point
where circumferential endothelial cells ‘complete the circle’ and an endothelial cell’s
membrane apposes itself; this is depicted schematically in figure 1.4a. These tight
junctions are made impermeable to polar molecules by the presence of proteins such
as occludin [17].
Traversal of the BBB can occur by a number of mechanisms, summarised in figure
1.4b. Whilst the vasoactive product of metabolism CO2, being lipophilic, can diffuse
freely across the BBB, other small charged molecules – including glucose, lactate,
pyruvate, H+ ions and bicarbonate ion (HCO3
–), must undergo active or facilitated
transport through endothelial cells and astrocytes in order to reach the brain ECF.
Glucose enters brain ECF through facilitated diffusion through glucose transporter
(GLUT)-1 channels, and lactate-pyruvate can undergo bidirectional flux through the
monocarboxylate transporter 1 (MCT-1) channel [18].
function to occur. Hugh Davson argued (Davson and
Spaziani, 1959) that if the slow passage of certain ma-
terials from the circulation into the brain were simply
due to the necessity of penetrating parenchymal cells
rather than a barrier at the level of the capillary endo-
thelium or its basement membrane, then these materi-
als would equilibrate at a similarly slow rate from a
Ringer solution into excised brain tissue where the vas-
culature was no longer interposed. Furthermore, these
materials would equilibrate quickly into excised skeletal
muscle under the same conditions due to the presence of
an ample extracellular space. In testing this hypothesis
with iodide, p-aminohippurate, and sucrose, it was
found that this was not the case. Penetration into the
brain following peripheral injection occurred at “barely
measurable rates by contrast with their penetration into
skeletal muscle” (Davson and Spaziani, 1959). However,
when excised cerebral hemispheres were incubated in
Ringer solution containing these substances, equilibra-
tion occurred at a rate and magnitude comparable to
that of skeletal muscle, indicating an extracellular space
in the brain similar to that in muscle (14–22%) that is
blocked in vivo by a barrier to diffusion from the vascu-
lature (Davson and Spaziani, 1959). Further support for
this idea was obtained in an elegant study by Hoffman
and Olszewski (1961), in which it was shown that so-
dium fluorescein diffused from the area postrema—a
region of the brain that lacks BBB properties—into sur-
rounding tissues. Since fluorescein was not confined to
the “barrier-less” region of the brain, it was concluded
that the barrier must be due to special properties of the
vascular system rather than a lack of extracellular space
in the brain.
Another controversy was whether the anatomical
structure forming the BBB was the capillary endothe-
lium itself, the astrocytic processes that ensheathe the
capillaries, or the basal lamina (with which the astro-
cyte end-feet are continuous). The close apposition of
astrocytic processes to capillaries as well as the large
percentage of the capillary surface covered by these pro-
cesses certainly seemed to indicate that astrocytes were
involved in the anatomical barrier, if not its sole constit-
uent. Indeed, a number of experimental findings sup-
ported this idea as well (reviewed in de Robertis and
Gerschenfeld, 1961). However, EM studies by Reese and
Karnovsky (1967) at a resolution of 100,000! that could
distinguish between the capillary lumen and the space
between the end-feet/basal lamina and outer wall of the
capillary demonstrated that horseradish peroxidase ad-
ministered via the vasculature did not pass the lumen.
Furthermore, the presence of epithelial-like “tight junc-
tions” (TJ) was reported in the interendothelial cleft.
Thus, it was proposed that the capillary lumen bridged
by TJ formed a continuous, impermeable membrane
that constituted the primary anatomical substrate of
the BBB (Reese and Karnovsky, 1967). Later studies
showed that horseradish peroxidase injected into the
brain could diffuse through the "20-nm gaps between
astrocyte end-feet to the abluminal surface of the endo-
thelium, indicating that astrocytes do not significantly
cont ibute to the physical barrier (Brightman and
Reese, 1969).
C. Anatomical Description
Although the concept of the BBB has continued to be
refined over the past few decades, the current under-
standing of its basic structure is built on the general
framework established by the work of Reese, Karnovsky,
and Brightman in the late 1960s. Specifically, the BBB
exists primarily as a selective diffusion barrier at the
level of the cerebral microvascular endothelium, charac-
terized by the presence of tight cell-cell junctions and a
lack of fenestrations. Figure 1 shows a schematic cross-
sectional representation of a typical cerebral capillary.
The circumference of the capillary lumen is enclosed by
a single endothelial cell. Anatomically, the endothelial
cells of the BBB are distinguished from those in the
periphery by increased mitochondrial content (Olden-
dorf et al., 1977), a lack of fenestrations (Fenstermacher
et al., 1988), minimal pinocytotic activity (Sedlakova t
al., 1999), and the presence of TJ (Kniesel and Wolburg,
2000). Attached at irregular intervals to the abluminal
membrane of the endothelium are pericytes, often di-
vided into granular and filamentous subtypes (Tagami
et al., 1990). Pericytes and endothelial cells are en-
sheathed by the basal lamina, a membrane 30 to 40-nm
thick composed of col gen type IV, heparin sulfate pro-
teoglycans, laminin, fibronectin, and other extracellular
matrix proteins (Farkas and Luiten, 2001). The basal
FIG. 1. Schematic cross-sectional representation of a cerebral capil-
lary. The circumference of the capillary lumen is completely surrounded
by a single endothelial cell (EC), the apposing membranes of which are
connected by TJ. Pericytes (PC) are attached to the abluminal surface of
the EC, and these two cell types are surrounded by the basal lamina (BL),
which is contiguous with the plasma membranes of astrocyte (AC) end-
feet and ECs.
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(a) Schematic depiction of the BBB. From [17].
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The brain endothelial transporters that supply the 
brain with nutrients include the GLUT1 glucose carrier, 
several amino acid carriers (including LAT1, L-system 
for large neutral amino acids), and transporters for 
nucleosides, nucleobases and many other substances10. 
Several organic anion and cation transporters identified 
in other tissues and the choroid plexus are also prov-
ing to be expressed on the brain endothelium. Where 
compounds need to be moved against a concentration 
gradient, the energy may come from ATP (as in the ABC 
family of transporters, including P-glycoprotein (Pgp) 
and multidrug resistance-related proteins, MRPs), or 
the Na+ gradient created by operation of the abluminal 
Na+,K+-ATPase. Some transporters (for example, GLUT1 
and LAT1) are bidirectional, moving substrates down 
the concentration gradient, and can be present on both 
luminal and abluminal membranes, or predominantly 
on one. Quantification of GLUT1 expression on luminal 
and abluminal endothelial membranes is complicated by 
the fact that some antibodies do not recognize the trans-
porter when the C-terminal is masked, as it may be in 
the luminal membrane23. Among the efflux transporters, 
Pgp is concentrated on the luminal membrane24, whereas 
the Na+-dependent transporters are generally abluminal, 
specialized for moving solutes out of the brain25,26. They 
include several Na+-dependent glutamate transporters 
(excitatory amino acid transporters 1–3; EAAT1–3)27, 
which move glutamate out of the brain against the large 
opposing concentration gradient (<1 µM in ISF compared 
with ~100 µM in plasma) (FIG. 2). The clear apical–basal 
polarity of brain endothelial cells noted above is hence 
reflected in their polarized transport function20,28.
Induction of BBB properties
What causes the endothelium of blood vessels growing into 
the brain during development to become so specialized? 
It has been clear from the earliest histological studies that 
brain capillaries are surrounded by or closely associated 
with several cell types, including the perivascular endfeet 
of astrocytic glia, pericytes, microglia and neuronal proc-
esses (FIG. 2). In the larger vessels (arterioles, arteries and 
veins), smooth muscle forms a continuous layer, replacing 
pericytes1. Neuronal cell bodies are typically no more than 
~10 µm from the nearest capillary6. These close cell–cell 
associations, particularly of astrocytes and brain capil-
laries, led to the suggestion that they could mediate the 
induction of the specific features of the barrier phenotype 
in the capillary endothelium of the brain29.
Figure 3 | Pathways across the blood–brain barrier. A schematic diagram of the endothelial cells that form the blood–
brain barrier (BBB) and their associations with the perivascular endfeet of astrocytes. The main routes for molecular 
traffic across the BBB are shown. a | Normally, the tight junctions severely restrict penetration of water-soluble 
compounds, including polar drugs. b | However, the large surface area of the lipid membranes of the endothelium offers 
an effective diffusive route for lipid-soluble agents. c | The endothelium contains transport proteins (carriers) for glucose, 
amino acids, purine bases, nucleosides, choline and other substances. Some transporters are energy-dependent (for 
example, P-glycoprotein) and act as efflux transporters. AZT, azidothymidine. d | Certain proteins, such as insulin and 
transferrin, are taken up by specific receptor-mediated endocytosis and transcytosis. e | Native plasma proteins such as 
albumin are poorly transported, but cationization can increase their uptake by adsorptive-mediated endocytosis and 
transcytosis. Drug delivery across the brain endothelium depends on making use of pathways b–e; most CNS drugs enter 
via route b. Modified, with permission, from REF. 8  (1996) Elsevier Science.
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(b) Transport across the BBB. From [19].
Figure 1.4 – Schematic depiction of blood–brain barfrier structure and transport routes across it. AC –
astrocyte; BL – basal lamina; EC – endothelial cell; PC – pericyte; TJ – tight junction.
1.3 CELLULAR RESP I RAT ION
Cellular respiration is the process by which cellular energy generation (considered, for
the purposes of this thesis, to be synonymous with ATP sy thesis) occurs. The preceding
section describes the deliv ry of metabolic sub t ate to brain parenchymal ECF. H re,
we consider the steps in neuronal and gli l cellular energ g neration, t rting from
substrate that situated in the ECF.
After the facilitated transp rt of glucose (via GLUT-1 to astrocytic cytosol and GLUT-3
in to neuronal cytosol), the process of cellular respiration takes place in two stages. The
first stage is glycolysis, which takes place in the cytosol, and yields the intermediate
metabolite pyruvate. The second stage of cellular respiration depends on the presence
of oxygen – i. e. whether metabolism is aerobic or anaerobic. In the presence of
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oxygen, aerobic respiration occurs within the mitochondria. This process, termed
oxidative phosphorylation, depends on the generation of a proton gradient across the
inner membrane of the mitochondrion, which is then harnessed to phosphorylate
adenosine 5’-diphosphate (ADP), in the reverse of the reaction shown in Equation
1.1. In the absence of oxygen, pyruvate undergoes anaerobic fermentation to yield the
monocarboxyl acid lactate [3].
1.3.1 Glycolysis
The process of glycolysis, summarised in Equation 1.4, takes place in multiple stages and
acts to convert a single glucose molecule in to two pyruvate molecules, also resulting
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Figure 1.5 – Schematic summary of cerebral aerobic respiration. Adapted from [20].
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Figure 1.6 – Stages in classical model of glycolysis. Modified from [22].
in the phosphorylation of two molecules of ADP to yield ATP and the oxidation of two
molecules of nicotinamide adenine dinucleotide hydride (NADH), and is given by the
equation
C6H12O6 + 2 ADP
+2 Pi + 2 NAD
+
−−→ 2 CH3COCOOH+ 2 ATP+ 2 NADH+ 2 H+.
(1.4)
The individual steps of glycolysis are illustrated in figure 1.6. Of these stages, a crucial
regulatory step is that of phosphorylation of phosphofructose by phosphofructokinase-1
(PFK-1), the third stage in the pathway. Counterintuitively (ATP is a substrate and ADP
is a product of the PFK-1-catalysed reaction), ATP acts as an allosteric inhibitor and
ADP as a facilitating co-factor of the reaction. Thus the rate of glycolysis, and so the
rate of pyruvate generation, is directly coupled to intracellular ATP levels [21].
1.3.2 Anaerobic fermentation
The pyruvate generated by glycolysis can meet two fates, depending on the presence or
absence of adequate mitochondrial oxygen. In the presence of adequate mitochondrial
oxygenation (and absence of any other disordered mitochondrial function), adequate
intracellular ATP levels prevent pyruvate accumulation by the PFK-1 coupling described
above. In the absence of adequate mitochondrial oxygen, ATP levels fall with a concom-
mitant rise in cytosolic NADH and flavin adenine dinucleotide hydride (FADH2) levels
(as mitochondrial oxidative phosphorylation fails to consume the reduced coenzymes).
These conditions combine to drive the reaction catalysed by lactate dehydrogenase
(LDH) towards lactate (i. e. to the right), as given by the equation
CH3COCOOH+NADH+H
+ LDH−−⇀↽ − CH3CHOHCOOH+NAD+. (1.5)
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Lactate is clasically described as a metabolically inactive waste product of anaerobic
metabolism [23]. However, there is an increasing body of work suggesting that lactate,
far from being a toxic and metabolically inactive by-product of anaerobic metabolism,
is in fact closely involved with aerobic metabolism under normal resting conditions in
brain tissue.
In the brain, a growing body of evidence points to lactate as a key intermediary
in normal metabolism with potential neuroprotective effects [24]. Lines of evidence
suggesting this include that:
• astrocytes are a major source of lactate production, in particular in response to
glutamate, the primary excitatory neurotransmitter in the central nervous system
[25];
• lactate may be a preferred fuel for neurons, in particular after traumatic or hypoxic
brain injury [24];
• brain tissue can rely on lactate produced elsewhere in the body [26].
The astrocyte–neurone lactate shuttle hypothesis (ANLSH) unifies a number of
these findings to yield an integrated model of the role of lactate in brain energy
metabolism [27]. Central to the hypothesis is that the primary site of aerobic glycolysis
is within astrocytes, and that the end-product of glycolysis, lactate, is shuttled to neuronal
mitochondria by mono-carboxylate transporters, where they are converted back to
pyruvate and undergo oxidation in the TCA cycle. A more radical hypothesis, where
lactate does not only act as an additional energy substrate during times of metabolic
distress, but is actually the primary substrate for the TCA cycle in health and pathology,
has also been posited [28,29].
Whilst there are compelling arguments in favour of both the ANLSH and Schurr’s
obligatory fermentation hypothesis, the crucial underlying premise in both theories is
that lactate is a normal intermediary in cerebral energy generation in both healthy and
pathological states.
1.3.3 Aerobic metabolism
PYRUVATE DECARBOXYLAT ION Regardless of the role of lactate as a metabolic
substrate, the fact remains that it is readily converted to pyruvate by various isoforms of
lactate dehydrogenase (LDH). In the mitochondrial matrix, this pyruvate is bound to
coenzyme A (CoA) as it is irreversibly converted to acetyl coenzyme A (ac-CoA) by the
pyruvate dehydrogenase complex (PDHC), as given by the equation
CH3CHOHCOOH+NAD
+ + CoA PDHC−−−→ Ac-CoA+NADH+H+. (1.6)
This reaction takes place under strict regulation to couple acetyl CoA generation to the
availability of ATP and nicotinamide adenine dinucleotide (NAD+). Ac-CoA is used in
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several different pathways, including the generation of fatty acids, steroids and ketone
bodies. With respect to energy generation in the brain, it is complete oxidation of
ac-CoA through the tricarboxylic acid (TCA) cycle which is of crucial importance [23].
TR ICABOXYL IC AC ID CYCLE The TCA cycle involves the complete oxidation of
ac-CoA in order to yield reduced coenzymes (predominantly NADH) to fuel oxidative
phosphorylation and the generation of ATP. Ac-CoA can be generated from many
sources, but in the brain the main supply is derived from pyruvate; in alternative
circumstances such as those seen during prolonged starvation, ac-CoA can also be
derived from ketone bodies generated in the liver.
The TCA cycle consists of a cyclic series of reactions which take place within the
mitochondrial matrix. The cycle itself begins with the acetylation of oxaloacetate
followed by a series of eight reactions, of which three are oxidation reaction which
yield the reduced coenzymes NADH or FADH2. The net reaction of one cycle of the
TCA cycle is shown in Figure 1.7 and given by the equation
Ac-CoA+ 3 NAD+ + FAD+GDP+ Pi
−−→ CoA+ 3 CO2 + 3 NADH+ FADH2 +GTP+ 3 H+.
(1.7)
Aside from the production of the reduced coenzymes FADH2 and NADH, the TCA
cycle is also responsible for the generation of guanosine triphosphate (GTP), an ATP-like
phosphorylated nucleotide which can be hydrolyzed like ATP for energy [7,23].
MITOCHONDR IAL OX IDAT IVE PHOSPHORYLAT ION Thus far, the oxida-
tion of one molecule of glucose has been responsible for the generation of 10 molecules
of NADH, 2 molecules of FADH2, 2 molecules of GTP and 2 molecules of ATP, all ‘car-
rier molecules’ which contain energy released by glucose oxidation. However, whilst
the reduced coenzymes NADH and FADH2 are able to supply the energy to facilitate a
minority of cellular processes, ATP is by far the predominant carrier molecule used in
cellular metabolism.
Oxidative phosphorylation is the process by which the reduced coenzymes are
oxidised, and the free energy harnessed to phosphorylate ADP, in the reverse of
Equation 1.1. This process is carried out by a collection of four protein complexes (I-IV)
embedded within the inner mitochondrial membrane, termed the electron transport
chain. Complexes I, III and IV are responsible for the sequential oxidation of NADH and
FADH2, harnessing the resultant free energy to pump protons against their concentration
from the mitochondrial matrix in to the intermembrane space. In doing so, they generate
a proton motive force. This is harnessed by ATP synthase (also known as complex
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Figure 1.7 – Stages in TCA cycle. Modified from [30].
V), which allows protons to flow along their electrochemical gradient, utilizing the
liberated free energy to phosphorylate ADP [31], given by the equation
NADH+ 12 O2 +H
+ −−→ NAD+ +H2O. (1.8)
Thus, the oxidation of NAD, as shown in Equation 1.8 releases the free energy required
for the generation of ATP, in the reverse of the process depicted in Equation 1.1. The
components of the chain and a schematic diagram of its function are shown in Table
1.1 and Figure 1.8.
CY TOCHROME c OXIDASE Cytochrome c oxidase (CCO) is the final electron
acceptor in the electron transport chain. It is considered here in more detail as it is a
key subject of study of this thesis.
Cytochrome c oxidases of the aa3 variety are found in a multitude of organisms
encompassing all cellular phylogenetic kingdoms. Although the variants cytochrome c
oxidase (CCO) comprising 3, 4 and 13 subunits have been described, the metabolic
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Figure 1.8 – Schematic depiction of electron transport chain. From [32]
functions of CCO are performed by three core subunits (I, II and III), which are well-
conserved across species. Subunit I is the best conserved subunit and contains two
haem groups – one haem a and one haem a3 in mammalian mitochondrial forms –
and a copper atom, copper B (CuB ). Subunit II contains a binuclear copper centre,
copper A (CuA) [33].
CCO carries out two main metabolic functions within mitochondria: the translocation
of one proton from the mitochondrial matrix in to the intermembrane space, and
reduction of oxygen. The latter processoccurs by the binding of two protons (from the
matrix side of the membrane), two electrons to half a dioxygen molecule, as given by
the equation
1
2 O2 + 2 H
+ + 2 e− CCO−−→ H2O. (1.9)
The CuA centre of subunit II is the likely binding site of cytochrome c. The electron
is then transferred to the haem a3–CuB complex via haem a. The electron is then
passed from CuB to oxygen, which is then bound to a proton to yield water. The precise
mechanism by which two protons – one as a charged particle, one as a substrate to
yield water – are transferred across the mitochondrial inner membrane are unclear.
However, it is apparent that the transfer of an electron to haem A causes the uptake of a
proton from an unidentified ‘pump site’ and the subsequent transfer of that electron to
the haem a3–CuB complex leads to the release of the proton in to the intermembrane
space [33–35]. The key catalytic centre, and a major regulatory site, is the haem a3-CuB
core. The iron contained within haem a3 cycles between +2, +3 and +4 oxidation
states, with the pH on each side of the mitochondrial membrane as well as the supply
of electrons (in the form of reduced NADH and FADH2) acting to regulate the rate
of reaction via effects on the haem a3-CuB core. Meanwhile, the copper ion in CuB
alternates between the +1 and +2 oxidation state. Aside from the two roles of oxygen
reduction and proton translocation, there is an increasing body of evidence suggesting
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COMPONENT NOTES
Complex I
NADH:ubiquinone oxidoreductase.
Oxidises NADH and translocates one proton across mitochon-
drial membrane.
Complex II
Succinate:ubiquinone reductase.
Participates in electron transport but does not translocate protons
across mitochondrial membrane. Participates in TCA and transfers
electrons from complex I to coenzyme Q.
Complex III
Cytochrome bc1
Delivers electrons from coenzyme Q to cytochrome c. translo-
cates one proton across mitochondrial membrane.
Complex IV
Cytochrome c oxidase
Oxidises cytochrome c and translocates one proton proton across
mitochondrial membrane and oxidises half dioxygen molecule
per cycle.
Coenzyme Q
Ubiquinone
Small coenzyme able to diffuse along mitochondrial membrane.
Acts as electron shuttle between Complexes II & III.
Cytochrome c Membrane-anchored protein that acts as electron carrier betweencomplexes III & IV.
Table 1.1 – Components of electron transport chain
that CCO in has a role in the inactivation of NO·. NO· is a substance that has a multitude
of physiological and pathological roles. In health, NO· acts as an intercellular and
second messenger, and contributes to the control of cerebral vascular tone; it also
acts as a neurotransmitter. Following brain injury, overproduction of NO· can trigger
deleterious cascades [36]. The interaction between NO· and CCO is complex, and
depends on the oxidation state of the CuB subunit; NO· can also bind the haem a3
subunit of CCO, and in doing so inhibit the flow of electrons through CCO [37]. These
complex interactions may also form the basis of the characteristic cerebral vasodilation
observed during hypoxia [16,38].
1.4 CONCLUS ION
This chapter has described the process of cellular respiration, by which ATP is generated
from the primary metabolic substrates glucose and oxygen as well as the stages in
and regulation of supply of these substrates to neural tissue. The description of these
physiological processes is not exhaustive; the level of detail in which they are discussed
is tailored to its relevance to the remainder of the thesis. Having established how these
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processes occur in health, the next chapter describes their malfunction following acute
brain injury.
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ACUTE BRA IN IN JURY
This chapter describes the epidemiology, pathophysiology and tenets of clinical man-
agement of ABI. Whilst the diseases that comprise this grouping – subarachnoid haem-
orrhage (SAH), traumatic brain injury (TBI), ischaemic stroke and intracerebral haem-
orrhage (ICH) – are distinct pathological entities, there are significant commonalities
in their pathophysiology, and thus their clinical management. Thus, while the clinical
studies in this thesis focus primarily on patients with SAH and TBI, the focused review
in this chapter draws on evidence from all subtypes of ABI, with particular reference to
the pivotal role of cerebral cellular hypoxia-ischaemia (CH-I) in the pathophysiology of
ABI and the clinical monitoring modalities and strategies used to detect and prevent it.
2.1 DEF IN I T IONS & EP IDEM IOLOGY
2.1.1 Traumatic brain injury
TBI is common, with an incidence of 229/100,000 people/year in England, which is
consistent with the European average of 235/100,000 in Europe but markedly lower
than the incidence of 579/100,000 observed in the USA [1–3]. TBI comprises 1.4%
of Emergency Department attendances in the USA [3], and was found to account for
3.4% of attendances in the Emergency Department in one western English district
general hospital [4]. Ninety percent of TBI is classified as ‘mild’ [2]; the data regarding
such injuries are complex and controversial, but in general, mild TBI is associated with
negligible mortality and carries a good prognosis for recovery, although the period of
recovery and rehabilitation incurs significant personal and societal cost. The remaining
moderate and severe TBI – typically defined by an admission Glasgow Coma Score
(GCS) of 9–12 and 3–8, respectively – exacts a more apparent heavy toll on both the
individual and society: a mortality rate of 40% has been observed in both British and
pan-European multicentre studies following severe TBI [5,6]. Furthermore, disability is
common amongst TBI survivors: TBI is the leading cause of injury-related long-term
disability, with up to 60% of survivors suffering from impairments leading to limitations
in cognition, major activity, and recreation [7,8]. The patients described in the clinical
studies of this thesis are patients who require admission to a neurocritical care unit
(NCCU) with invasive intracranial monitoring, and thus have invariably suffered from
severe TBI.
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2.1.2 Subarachnoid haemorrhage
SAH is a form of stroke characterised by haemorrhage in to the subarachnoid space,
the cerebrospinal fluid (CSF) space between the arachnoid and pial membranes of the
meninges. SAH has an incidence of 9/100,000 people/year and a female preponderance
[9]. A poor outcome (death or severe disability) is seen in 20–30% of patients suffering
SAH [10,11]. SAH occurs in a relatively young population (albeit somewhat higher than
that of TBI); as a result, the loss of productive life years in the general population is the
same for SAH as it is from ischaemic stroke, even though ischaemic stroke is as much
as 50 times higher in incidence [9,12–14].
Whilst traumatic SAH can be observed as a feature of TBI (where it is a feature of a
high energy impact and associated with poor outcome [15]), spontaneous SAH can
be attributed to the rupture of an intracranial aneurysm in over 85% of cases [13].
A number of grading scales exist for aneurysmal subarachnoid haemorrhage (aSAH),
which aim to prognosticate based variously on clinical features, radiological features
and combinations of the two, although none has proved definitely superior to the others
[16]. The patients described in the clinical portions of this thesis, like those with TBI,
are patients who require admission to a NCCU with invasive intracranial monitoring,
and thus fall at the ‘poor-grade’ end of classification spectra, regardless of scale used.
2.2 PATHOPHYS IOLOGY OF ACUTE BRA IN IN JURY
Pathophysiological processes contributing to ABI are widely considered in terms of
primary and secondary injury processes. The term primary injury has historically
referred to that cellular death and dysfunction which occurs at the ictus of injury and
is “instantaneous and irreversible” [17], whereas the term secondary injury referred to
potentially avoidable, delayed cell death occurring as a result of subsequent insults to
tissue rendered susceptible to injury as a consequence of pathophysiological cascades
set in motion at ictus. This framework has gained currency in a number brain pathologies,
including TBI, SAH, ICH and ischaemic stroke, as well as extracranial diseases such
as spinal cord injury [18–22]. However, it is increasingly recognised that primary
injuries evolve in the hours following ictus, and the cascades that lead to cell death
may be modifiable. Thus, whilst the terms ‘primary’ and ‘secondary’ injury are still
widely employed in the literature, there is an overlap in their timescales – depicted
schematically in Figure 2.1 – and so a more precise way of distinguishing the two
types of injury may be on the basis of time course, where primary injury occurs in the
immediate aftermath of ictus, and secondary injury processes exert their effects over
the following days [17]; some authors underline this point by referring to primary brain
injury as ‘early brain injury’ [23].
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INTRODUCTION
The 1975 paper ‘Patients with Head Injury who Talk and Die’1
illustrated quite dramatically the distinction between primary injury,
sustained at the moment of impact and secondary injury due to
events which have their effects later. In 1975 primary impact injury
was generally considered to be instantaneous and irreversible.
However, since then it has become clear that the effects of the
impact are not all instantaneous. In fact a substantial component of
cell death resulting from the primary brain injury may begin hours
later (Fig. 1). Furthermore and most importantly these continuing
effects of the impact are not all irreversible. It is possible in experi-
mental models to halt the progression of the primary injury itself.
Thus brain injury is now seen as a process beginning with an
impact rather than a single event which may then be followed by
secondary complications. The injury also initiates processes which
may lead, if properly understood, to repair and regeneration.
The injury process may be considered in four overlapping
phases:2
1. Primary injury 
2. Evolution of the primary injury
3. Secondary or additional injury
4. Recovery.
This review will describe some current insights into the early
events after head injury, illustrated by research undertaken by the
Adelaide Head Injury Group, a multidisciplinary group comprising
departments of the University of Adelaide, Royal Adelaide Hospital
and Institute of Medical and Veterinary Science. The Group encom-
passes research interests within each of the four phases of brain
injury; the Road Accident Research Unit into the interface between
mechanical force and brain injury; and clinical neuropsychologists
into the relation between injury patterns and outcome. 
Two main lines of research into the early phase of injury have
been undertaken:
1. Clinical studies which aim to identify the nature of the injury
through bedside monitoring
2. Laboratory studies into the primary injury and its evolution.
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Fig. 1 A current model of the effects of impact on the brain envisages three
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Figure 2.1 – Schematic depiction of the time-courses of primary and secondary injury, from [17].
Following both TBI and SAH, an enormous array of interacting processes conspire
to cause cell death and dysfunction; a complete review of these processes and their
interactions is beyond the scope of this thesis. However, the aggressive avoidance of
secondary injury has seen a concomita t improvement in o tcomes following ABI in the
last two decades, and forms a central tenet to contemporary critical care management
of these diseases [24]. In order to aid in understanding of these tenets (described in
Section 2.3 below), the most important primary and secondary injury processes are
considered here.
2.2.1 Mechanisms of primary/early brain injury
TRAUMAT IC BRA IN IN JURY In TBI, injury is a result of the impartation of kin-
etic injury to the tissue of the brain as a consequence of blunt, or more rarely penetrating,
trauma. Intracranial contents have heterogeneous density and viscoelastic properties;
consequently the acceleration/deceleration forces at impact result in a complex pattern
of tensile, compressive and shearing strains [25]. On a macroscopic level, damage res-
ulting from these strains includes the formation of haematomas (both intraparenchymal
and extracerebral), focal cerebral contusions and widespread disruption of white matter
tracts by shearing forces with diffuse swelling, which is termed diffuse axonal injury
(DAI).
On a cellular level, these macroscopic events lead to cellular death through direct
cellular disruption, resulting in membrane microporation, loss of cellular ion homeo-
stasis (which, as discussed in Section 1.1.1, is crucial to cellular survival), and changes
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in protein conformation. Furthermore, acute critical ischaemia – discussed below – can
occur shortly after injury ictus, as a result of locally raised intraparenchymal pressure
(for example, in peri-contusional tissue) and focal microvascular disruption by injury
[26].
SUBARACHNOID HAEMORRHAGE Primary injury in aSAH is related to the
immediate effects of aneurysm rupture. Rupture and the subsequent extravasation
of blood, with consequent ‘mass effect’, results in the rapid development of severe
intracranial hypertension – intracranial pressure (ICP) can reach the level of diastolic
arterial pressure within one minute – with concomitant cerebral circulatory arrest [27].
Thus, global acute ischaemia is the predominant primary injury process that occurs in
subarachnoid haemorrhage. In addition to this acute ischaemic insult, there may be
direct tissue damage as a consequence of intraparenchymal haemorrhage associated
with aneurysm rupture [13].
Following ABI ictus, cells that survive these insults do not simply return to normal
function; rather, the effect of these primary insults is to put in motion a series of
pathophysiological cascades that render neural tissue vulnerable to further damage by
secondary injury processes.
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(intracerebral and extracerebral), and diﬀ use swelling 
(fi gure 1). At the cellular level, early neurotrauma events 
(which can occur minutes to hours after initial injury) 
include microporation of membranes, leaky ion 
channels, and stearic conformational changes in 
proteins. At higher shear rates, blood vessels can be 
torn, causing (micro)haemorrhages. 
DAI is characterised by multiple small lesions in 
white-matter tracts. Patients with DAI are usually in 
profound coma as a result of the injury, do not manifest 
high ICP, and often have a poor outcome. Focal cerebral 
contusions are the most common traumatic lesion, are 
more frequent in older patients, and usually arise from 
contact impact. Traumatic intracranial haematomas 
occur in 25–35% of patients with severe TBI and in 
5–10% of moderate injuries.
In static crush injuries and focal blows, much of the 
energy is absorbed by the skull; thus, brain damage 
might remain superfi cial, often with a depressed skull 
fracture. Blast injuries have been identifi ed as a novel 
entity within TBI.30,31 The pathological mechanism is 
much less understood, but the injuries are characterised 
by severe early brain swelling, subarachnoid 
haemorrhage, and often prominent vasospasm.32,33 
Outcome of severe blast injuries, even with aggressive 
management, is still unknown, but has been encouraging 
after debridement of wounds and aggressive control of 
ICP, including decompressive surgery.
Ischaemic brain damage is often superimposed on 
the primary damage (fi gure 1), and can be widespread 
or, more commonly, perilesional. Impaired cerebral 
perfusion and oxygenation, excitotoxic injury, and focal 
microvascular occlusion can be contributing factors.34,35
Secondary damage
Each type of head injury might initiate diﬀ erent 
pathophysiological mechanisms, with variable extent 
and duration (fi gure 1). These mechanisms (acting 
concurrently and often with synergising eﬀ ects) and 
the intensity of systemic insults determine the extent of 
secondary brain damage. Secondary processes develop 
over hours and days, and include neurotransmitter 
release, free-radical generation, calcium-mediated 
damage, gene activation, mitochondrial dysfunction, 
and infl ammatory responses.
Glutamate and other excitatory neurotransmitters 
exacerbate ion-channel leakage, worsen astrocytic 
swelling, and contribute to brain swelling and raised 
ICP. Neurotransmitter release continues for many days 
after TBI in human beings, paralleling the course of 
high ICP, and, with free-radical and calcium-mediated 
damage, is a major cause of early necrotic cell death. 
Early gene activation and release of proapoptotic 
molecules (eg, caspases) induce apoptotic neuronal 
loss. A third potential cause of cell death, autophagy, 
might also play an important part.36,37
Infl ammatory response is an important component 
of TBI, particularly around contusions and 
(micro)haemorrhages. The maximum response occurs 
within a few days, but cytokines are released from 
microglia, astrocytes, and polymorphonuclear cells 
within hours after TBI, leading to opening of the blood–
brain barrier, complement-mediated activation of cell 
death, and the triggering of apoptosis. Although the 
infl ammatory response can be deleterious in excess, it 
is necessary in order to clean up cellular debris after 
injury, and infl ammatory signals might also trigger 
Inflammation
Receptor-mediated damage
Oxidative damage
Calcium-mediated damage 
0
Diffuse axonal 
injury Co
nt
rib
ut
io
n 
to
 se
co
nd
ar
y d
am
ag
e (
%
)
90
80
70
60
50
40
30
20
10
100
SDH DAIContusion
Systemic insults
Swelling
Haematoma
Contusion
Hypoxia/ischemia
ICP ↑
CPP ↓
BA
Figure 1: Components of TBI and importance of diff erent pathophysiological mechanisms
(A) The diff erent components of TBI with ischaemic damage are superimposed on the primary types of injury (haematoma, contusion, and diff use axonal injury). 
Systemic insults and brain swelling contribute to ischaemic damage, which might in turn cause more swelling. (B) The relative importance of diff erent 
pathophysiological mechanisms in various types of TBI. CPP=cerebral perfusion pressure. ICP=intracranial perssure. SDH=acute subdural haematoma. DAI=diff use 
axonal injury. Adapted from Graham et al,29 with permission from Hodder Arnold.
Figure 2.2 – A – interplay between primary injury processes and mechanism resul ing development of
secondary ischaemia; B – predominant contributing factors that lead to secondary cell death following
different forms of traumatic brain injury. From [26].
2.2.2 Processes of secondary brain injury
Primary injuries in both TBI and SAH set in motion a series of concurrent cascades
which can conspire to cause cell death beyond that incurred during th primary injury,
and thus lead to further mortality and morbidity following ABI. Although the nature
of the primary insult varies in different forms of ABI, there are substantial similarities
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Figure 2.3 – Schematic diagram illustrating principal secondary injury processes. The diagram is not
comprehensive, but rather serves to expose the interconnected, recursive nature of secondary injury
processes. Cellular hypoxia is a pivotal event that links all secondary injury processes, either directly or
indirectly.
between processes of secondary injury that ensue. The mechanisms of secondary injury
are described here in more detail, with particular reference to the role of CH-I.
In the 1970s, Miller observed that systemic hypotension and hypoxia had a deleterious
effect on functional outcome following TBI [28,29]; these studies – whose findings
have been widely replicated subsequently – were the earliest indications of the central
role that CH-I plays in the pathophysiology of secondary brain injury. Following SAH,
the epidemiological outcome data linking systemic hypoxia and hypotension to poor
outcome, whilst still congruent, are more sparse [30]; cerebral ischaemia is, however,
recognised as the major cause of poor outcome [13,31–37]. Several studies have used
invasive and non-invasive bedside monitoring techniques, as well as neuroradiological
techniques, to confirm both the occurrence of CH-I and its association with poor
outcome following ABI (discussed below in Section 2.3.1).
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CELLULAR HYPOX IA - I SCHAEM IA Defining CH-I is a non-trivial task. Whilst
CH-I can be defined as the state that occurs when CBF and O2 delivery are inadequate
for the continuation of normal cellular and neuronal function, these functions are diverse
and vary in their requirements for O2 and metabolic substrate. Consequently, CH-I does
not simply occur as an ‘on/off’ phenomenon when CBF falls below a certain threshold;
rather, there are a variety of thresholds for CH-I, which correspond to the physiological
functions that are disrupted. Data from ischaemic stroke identifies CBF thresholds
for CH-I: below 50 ml.100g−1.min−1, clinical evidence of functional impairment
manifests, with corresponding electrophysiological changes, impaired protein synthesis
and selective cell loss; below 20 ml.100g−1.min−1, membrane stability is impaired
and permanent infarction occurs [38,39].
However, it is unclear the degree to which these thresholds can be applied to the
already-injured brain. For example, reduction in (CMRO)isarecognisedsequelaof TBIandSAH [40,
41]; inthiscontext, reductionsinCBFmaybepathological , thusresultinginCH− I , butmayalternativelybetheeffectofintactneurovascularcouplinginresponsetoreducedCMRO.Conversely , impairedneurovascularcoupling−
−consequenttoABI −−maycausereducedCBFinthepresenceofnormalCMRO [42,43], andthesituationisfurthercomplicatedbytheuseof CMRO−
loweringanaestheticagentsasamainstayoftheNCCUmanagementof ABI .Thesefactorscombinedmeanthatflowthresholdsalonearelikelyinadequatefortheidentificationofclinically −
relevantischaemia, andthereisthusaneedformoresophisticatedmeasuresofinadequatesupplyofmetabolicsubstratetocerebraltissue.
CATEGORY OF CH I CAUSE EXAMPLE
Decreased O2
delivery –
extracranial cause
Systemic hypoxia/hypotension.
Can be direct consequence of brain injury (e. g. myocardial
dysfunction, neurogenic pulmonary oedema followingeither TBI or
SAH), indirectly related to brain injury (e. g. haemorrhagic shock in
polytrauma associated with TBI) or unrelated/iatrogenic(e. g.
pneumonia, venous thromboembolism).
Decreased O2
delivery – intracranial
cause
Raised ICP causing decreased CPP
Brain herniation causing large vessel occlusion
Cerebral vasospasm
Impaired CA causing hypoperfusion
Impaired substrate diffusion due to inflammation/oedema
Increased demand for
metabolic substrate
Seizures
Cortical spreading depression
Excitatory amino acid release
Metabolic failure Mitochondrial dysfunction/decoupling
Table 2.1 – Categorised causes of cerebral hypoxia-ischaemia
Systemic hypotension/hypoxia can occur in concert with neurological injury – for ex-
ample, neurogenic myocardial dysfunction and pulmonary oedema are both recognised
as complications of TBI and SAH, and cardiorespiratory injury or haemorrhagic shock
can result from extracranial injury occurring simultaneously to TBI [44–50]. However,
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factors resulting in CH-I are diverse and not limited to systemic hypoxia/hypotension;
CH-I can occur as a result of:
• the reduction of cellular O2 and metabolic substrate delivery below critical
thresholds;
• an increase in cellular O2 and metabolic substrate requirements because of
secondary injury processes such as excitotoxicity;
• an inability to utilise O2 and metabolic substrate on account of mitochondrial
and metabolic dysfunction – i. e. functional CH-I;
Systemic hypoxia and hypotension can cause CH-I by overcoming the homeostatic
mechanisms described in Section 1.2.1, but CH-I can also occur as a result of disordered
CA in the absence of hypoxia/hypotension. Failure of cerebrovascular autoregulation
can occur following ABI [51–54], and is associated with poor outcome. A special case
of dysautoregulation is cerebral vasospasm, which has the potential to cause delayed
cerebral ischaemia (DCI) following SAH. This well-recognised but poorly-understood
complication of SAH is discussed separately below. Vasospasm is also increasingly
recognised as a complication TBI sustained by blast injuries [55]. Regardless of the
cause, CH-I results in the initiation of cascades that can lead to cell death and thus
poor outcome. Important processes leading to CH-I are considered here.
INTRACRAN IAL HYPERTENS ION Inadequate cerebral perfusion can also be
the result of intracranial hypertension, which is a key secondary injury process in both
SAH and TBI. The role of intracranial hypertension in the brain injury pathogenesis
is well-understood as ICP is frequently monitored following ABI (see Section 2.3.1
below).
A key concept in the consideration of ICP in both health and disease is the Monro-
Kellie doctrine. This states that the skull is a fixed spacewhich contains non-compressible
contents (brain parenchyma, arterial and venous blood and CSF). The expansion of any
of these compartments, or the introduction of new contents – in the form of a mass
lesion such as a haematoma – can only occur with a resulting compression of the other
compartments. The collapse of cerebral venous sinuses and caudal displacement CSF
provide limited buffering capacity maintaining ICP at its normal physiological level
of 7–15 mmHg, but once this is exhausted, any increase in cerebral content volume
results in raised ICP. Intracranial hypertension can result in two serious consequences:
reduced cerebral perfusion and brain herniation.
The measurement of ICP allows the determination of CPP, which is defined as the
difference between mean arterial pressure (MAP) and ICP, as given by the equation
CPP−MAP−ICP. (2.1)
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CPP represents the pressure gradient that exists across the cerebrovascular bed and is
thus a crucial component in determination of CBF and cerebral O2 delivery [56] and
the measurement of CPP forms a cornerstone in the critical care management of TBI.
Aside from causing reduced delivery as a result of decreased CPP, intracranial
hypertension can also contribute to secondary brain injury by causing brain herniation
[57].
The intracranial vault is incompletely divided in to several compartments: the two
cerebral hemispheres are separated by the falx cerebri, and from the cerebellum and
brainstem by the tentorium cerebelli. The falx and tentorium are semi-rigid infoldings
of the dura mater, one of the meningeal membranes that envelopes the surface of the
brain. Pressure gradients from localised mass lesions can cause herniation of cerebral
contents and associated vasculature from one compartment to another, leading to
shearing strain on brain parenchyma and occlusion of large vessels. Well-recognised
patterns of herniation include:
• trans-falcine hernation, where the herniation of the cingulate cortex may be
associated with the herniation of an ACA, with subsequent ischaemia in that
vascular territory;
• uncal herniation, where the medial temporal lobe herniates downwards across
the tentorium with potential pressure exerted on the midbrain and pons;
• tonsillar herniation – also termed “coning” – where the cerebellar tonsils are
displaced downwards through the foramen magnum in the base of the skull, with
pressure exerted on the brainstem. This is almost inevitably a fatal occurrence.
Thus, through brain herniation and reduced cerebral perfusion, intracranial hyperten-
sion plays a central role in the pathogenesis of secondary brain injury. It also plays a
‘feedback’ role in reinforcing pathological cascades, as processes that increase cerebral
metabolic demand, through intact neurovascular coupling, can increase cerebral blood
volume (CBV) and thus ICP.
DELAYED CEREBRAL I SCHAEM IA AND VASOSPASM delayed cerebral isch-
aemia (DCI) is a complex and poorly-understood process that is the predominant cause
of death and disability following aSAH [10,58,59]. Although a comprehensive review
is beyond the scope of this thesis, its high incidence and potentially devastating effects
on outcome mandate a more detailed consideration of its pathophysiology.
The first problem encountered in considering DCI is a heterogeneity of nomenclature,
with terms such as vasospasm, delayed ischaemic neurological deficit and delayed
cerebral ischaemia used seemingly interchangeably. This problem is further complicated
by the absence of clear, standardised criteria for the diagnosis of DCI [60]. For the
purposes of this thesis, nomenclature proposed by recent consensus guidance from the
Neurocritical Care Society is used:
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• delayed cerebral ischaemia (DCI) refers to any neurological deterioration that is
presumed to be ischaemia-related and cannot be attributed to any other cause;
• delayed neurological deficit (DND) is a clinical neurological deterioration fol-
lowing SAH that can be attributed to a cause other than re-bleeding, and may be
attributed to a wide variety of aetiologies, both extracranial and intracranial; DCI
and hydrocephalus are particulary important intracranial causes;
• vasospasm describes arterial narrowing, demonstrated either radiologically or by
ultrasonography [61].
Whilst arterial vasospasm has historically been considered the predominant aetiolo-
gical factor in DCI (with the result that the term ‘vasospasm’ is colloquially used to
refer to the clinical diagnosis of DCI), recent discoveries have refuted this assumption.
In fact, macrovascular vasospasm has been exposed as only one of many factors that
contributes to DCI [33]. There is clearly some link between ischaemia and outcome fol-
lowing DCI – for example the administration of nimodipine, the only treatment shown
to improve DCI-related outcome following SAH, results in a co-incident reduction in
the incidence of poor outcome and radiologically-defined infarction [10]. However, the
relationship between clinically-defined DCI, vasospasm observed on digital subtraction
angiography (DSA), other measures of vasospasm and ischaemia (such as elevated TCD
flow velocities and elevated cerebral microdialysate ischaemic markers, see below) is
complex and unclear: patients can show angiographic, TCD, xenon computed tomo-
graphy (CT) perfusion, positron emission tomography (PET) or microdialysate evidence
of ‘vasospasm’ in the absence of any clinical deficit, or vice versa [62–65]. Furthermore,
recent trials of drugs have shown significant reductions in the radiological occurrence of
vasospasm without any associated improvement in clinical outcome [66] and more than
a quarter of infarcts occur outside areas of angiographically-defined vasospasm [67]; in
subsidiary analyses, cerebral infarction has been shown to contribute to poor outcome,
but a significant portion of this contribution could be attributed to non-vasospastic
processes [68].
DCI, then, is an early complication of aSAH that results in cerebral ischaemia and is
associated with evidence of large vessel vasospasm and invasive markers of ischaemia,
but not exclusively so. Many other aetiological factors have been associated with
DCI: these include microcirculatory vasospasm, microembolism, increased ICP, BBB
dysfunction, cortical spreading depression and perihaemorrhagic ischaemia [33]. Whilst
these pathophysiological processes are all discussed below in the context of CH-I, what
is unclear is how SAH precisely initiates the cascades that leads to their contribution to
DCI and impaired outcome.
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2.2.3 Mitochondrial dysfunction
Under ischaemic conditions, ATP production is the result of anaerobic fermentation,
rather than mitochondiral oxidative phosphorylation (see section 1.3.3). However,
beyond this expected, substrate-dependent reduction in mitochondrial function, CH-I
results in further mitochondrial damage that amplifies cellular bio-energetic failure, ap-
optotic and necrotic cascades [69]. Mitochondrial dysfunction is considered separately
from other processes causing cell death (section 2.2.4 below) not only because of its
central importance in the pathogenesis of secondary brain injury, but also because of
its role in generating conditions of functional ischaemia – that is, the failure of cellular
energy generation in the presence of normal cellular oxygen delivery.
Following ABI, mitochondrial injury and dysfunction takes many forms. Structural
damage, is observed as mitochondrial swelling and loss of cristal membranes [70,71];
such changes are heterogeneously observed in the brain following experimental TBI
[72].
From a pathophysiological perspective, the functional impairment of mitochondria
following ABI is of more interest. Although many of the injurious processes that occur
following CH-I result in a increase in cellular energy requirements, the ability of
mitochondria to generate adequate ATP in order to meet these demands is, perversely,
reduced.
The intracellular influx of calcium ions (Ca2+) that occurs as a result of excito-
toxicity results in Ca2+ accumulation within the mitochondrial matrix; this leads to
mitochondrial depolarisation and a consequent inability to continue normal oxidative
phosphorylation, and leads to the generation of reactive oxygen species (ROS) [69].
Furthermore, intramitochondrial Ca2+ accumulation can lead to the opening of the mi-
tochondrial transition pore, an elaborate and poorly understood complex that results in
decoupling of oxidative phosphorylation and is the harbinger of cellular apoptosis [73].
Decoupling also occurs as a result of expression of mitochondrial uncoupling protein
UCP-2, which may conversely protect against cell death by reducing the formation of
ROS [74].
2.2.4 Other processes causing cell death
The reduction of CBF and O2 delivery below critical thresholds puts in motion a set
of cascades results in cell death by a variety of mechanisms; these mechanisms –
summarised in Figure 2.3 – are considered here.
Under ischaemic conditions, cells must rely on anaerobic respiration to generate
ATP. As discussed in Sections 1.3.2 and 1.3.3 , the amount of ATP yielded per glucose
molecule by anaerobic respiration is an order of magnitude less than that yielded
by aerobic respiration. In severely ischaemic conditions, this leads to an inability to
maintain the resting membrane potential (see Section 1.1.1), with subsequent cell
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membrane breakdown and tissue necrosis [75]. However, ischaemic insults that do not
reach the threshold for triggering membrane instability still lead to cell death, by the
mechanisms described below.
EXC I TOTOX IC I T Y A consequence of sub-lethal membrane depolarisation is the
release of excitatory amino acids(EAAs) from presynaptic terminals, particularly glutam-
ate, the primary excitatory neurotransmitter in the CNS. The active re-uptake of released
EAAs from the synaptic space requires further energy, but the more deleterious effects
of the widespread release of large amounts of glutamate are the result of the postsyn-
aptic activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and
N-methyl-D-aspartate (NMDA) receptors channels. The activation of these receptors
results in an influx of cations, with many injurious effects. Water passively follows
the cations, giving rise to intracellular (“cytotoxic”) oedema [76]. Ca2+, the universal
second messenger [77], floods in to cells, leading to indiscriminate activation of down-
stream Ca2+-dependent enzymes. Activation of calpain and caspase proteases initiates
apoptotic cascades [78–80]; wholesale activation of other proteases and phospholipases
occurs, leading to the lysis of proteins and phospholipids critical to cell structure and
survival [81]. Furthermore, the disordered intracellular ionic homeostasis contributes
to mitochondrial dysfunction (see below), increases cellular ATP consumption as mem-
brane ion pumps attempt to re-establish homeostasis, and can lead to propagation
of depolarisation, as organised pathological neuronal discharge – i. e. seizures – or
the more poorly understood process of cortical spreading depression [82,83]. These
processes can, as a result of intact neurovascular coupling, be accompanied by large
increases in CBF, which can propagate a deleterious cycle of intracranial hypertension
and further ischaemia.
IN F LAMMAT ION There is a wealth of experimental evidence, although only lim-
ited clinical evidence, that the inflammatory response that accompanies ABI predisposes
to, causes and exacerbates injury. Whilst the inflammatory response to brain injury may
have some neuroprotective effects, for example the development of ischaemic tolerance
and promotion of tissue repair [84], inflammation can also cause cell death as result
of oxidative stress, increased BBB permeability leading to oedema and intracranial
hypertension, and induction of apoptosis [84–86].
OX IDAT IVE STRE S S Oxidative stress refers to the cytotoxic effects of ROS. Through
both direct and indirect oxidation, peroxidation and nitration of deoxyribonucleic acid
(DNA), protein and lipid, ROS are able to cause widespread cellular damage [87,88].
Three important processes generating ROS are as disordered mitochondrial metabol-
ism, induction NO· generation by raised cytosolic Ca2+ levels and inflammation (see
below).
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In health, mitochondria generate ROS as a result of ‘leakage’ of electrons from the
electron transport chain, whereby molecular oxygen is instead oxidised to yield superox-
ide (O2·). Under ischaemic conditions, factors such as raised intramitochondrial Ca2+
levels and mitochondrial decoupling/dysfunction conspire to increase this production
[88–90].
NO· is an intriguing molecule; whilst a ROS, it is also a key mediator of cerebrovas-
cular regulation, being involved in the mediation of several vasodilatory processes [91],
including hypoxic vasodilation [92,93]. Dysregulation of NO· synthesis is a key compon-
ent of disordered CA and DCI following SAH [94,95] and TBI [96]. Furthermore, NO·
regulates oxidative phosphorylation through CCO inhibition [97,98]. The effects of NO·
on CCO activity are complex and incompletely understood, but interactions between
NO· and the CuB and haem a3result in either inhibition of CCO activity or reduction
of NO· to yield to non-reactive nitrite (NO2–) [99]; furthermore, these interactions may
have spectral significance when using NIRS to measure CCO concentrations.
APOPTOS I S Apoptosis – programmed cell death – is a key cause of cell death
following ABI and has been proposed as a therapeutic target [100].
Several of the secondary injury processes described above initiate apoptosis. Cas-
pase activation occurs as a result mitochondrial lysis, opening of the mitochondrial
transition pore and translocation of cytochrome c in to the cytosol [101–103]. ROS act
as ‘signalling’ molecules, inducing apoptosis by a number of pathways, including by
inhibition of DNA repair enzymes [104]. Apoptosis is extrinsically induced through
activation of cell membrane ‘death receptors’ such as the TNF-R (tumour necrosis factor
receptor) [84].
After both severe traumatic brain injury (sTBI) and aSAH, evidence for the importance
of apoptosis is gleaned primarily from experimental models rather than clinical studies.
Following experimental SAH, apoptosis has been implicated as both a key process in
the early phase following injury [23] and as a part of DCI [60]. Following experimental
TBI, increasing injury severity is associated with an increase in the proportion of cell
death caused by necrosis rather than apoptosis [105]. Indeed, it has been suggested that
there is a continuum between apoptosis and necrosis, with increasing injury severity
predisposing to the latter [106].
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The NCCU management of ABI is a vast subject beset with controversy and widely
differing approaches to clinical management. This section is not intended to be a
comprehensive review of the clinical management of ABI; recent consensus guidelines
for the management of TBI [107,108] and SAH [61,109] collate the evidence for
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nearly all aspects of clinical management of ABI, from feeding to invasive intracranial
monitoring to prophylaxis against thromboembolism. Rather, having established the
pivotal role of CH-I in the pathophysiology of ABI, the aim of this section of the thesis
is to review strategies for the identification, prevention and correction of CH-I after ABI.
As discussed in Section 2.2.2, cascades leading to cell death are initiated by re-
ductions in cellular O2 delivery, increases in cellular O2 utilisation and reductions
in the ability to utilise the O2 that is delivered. Attempts to treat ABI by targeting the
individual injury processes have proved, on the whole, unsuccessful. Examples of failed
therapeutic strategies include attempts to prevent excitotoxicity through the use of
NMDA antagonists [110–112]; the use of anti-inflammatory glucocorticoids in TBI
[113], and the use of anti-oxidant drugs to prevent oxidative stress from ROS [110].
Attempting to attenuate mitochondrial dysfunction forms another therapeutic avenue;
ciclosporin has been used in this regard, but is in early stages of human testing, with
safety and dose-finding studies complete, but Phase II clinical trials awaited [114,115].
Following aSAH, trials aimed at the prevention of DCI have also proven disappointing,
with only nimodipine being of proven benefit [10,116]; it has been suggested that an
overemphasis on vasospasm, rather than other causes of secondary brain injury, has
hampered attempts to improve outcome following aSAH [117].
In the face of these failures, the approach to neurocritical care management advocated
by consensus guidelines is predicated on the prevention of CH-I by the maintenance of
appropriate systemic physiological conditions like ABP and PaO2, the identification of
CH-I by specific cerebral monitoring, and the correction of CH-I by employing clinical
manoeuvres to reduce cerebral O2 utilisation and increase cerebral O2 delivery.
The epidemiological studies outlined in Section 2.2.2 establish the importance
of maintaining systemic parameters such as ABP and PaO2 at physiological levels
following ABI. However, in some clinical scenarios – e. g. in the case of concomitant
cardiopulmonary pathology – it is impossible to do, and thus desirable to establish
whether a lower threshold of cerebral oxygen delivery (DO2) is adequate for the
prevention of CH-I and secondary brain injury. Conversely, in some situations, the
maintenance of normal physiological levels of parameters such as ABP and PaO2 is
inadequate for the prevention of CH-I and secondary brain injury. In these situations, it
is necessary to monitor the brain for CH-I.
2.3.1 Detection of CH-I: Cerebral monitoring
In addition to standard systemic monitoring – invasive ABP, arterial blood gases (ABGs),
electrocardiography, inspired/expired gas partial pressures and pulse oximetry – a
defining characteristic of neurocritical care is the use of bedside monitoring techniques
to minimise secondary injury. Not considered here are the wealth of imaging techniques
that are able to characterise cerebral structure, haemodynamics and metabolism with
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great spatial resolution [118], but require the transfer of patients to remote radiology
suites and are thus inappropriate for the minute-to-minute monitoring of critically-ill
patients.
MODAL I T Y ADVANTAGES D I SADVANTAGES
ICP
Relatively inexpensive Single RCT shows no superiority to
imaging + clinical examination
Well-established and advocated by
consensus guidelines
Not a direct marker of ischaemia – only
measures surrogates and epiphenomena
Continuous
PbrO2
Familiar physiological concept Likely to represent oxygen delivery, but
not necessarily utilisation
Proven prognostic value No RCT evidence to support utility
Focal Invasive & unable to monitor for remote
insults
Continuous
Microdialysis
Able to measure parameters of
physiological and biochemical
importance
Cumbersome
Focal Invasive & unable to monitor for remote
insults
Intermittent
TCD
Measurement of CBF Relative changes only
Non-invasive, non-ionising Operator dependent, unable to monitor
in 10% of cases
Continuous Sensitivity to movement artefact makes
ambulatory monitoring difficult
Table 2.2 – Monitoring modalities, their advantages and limitations
INTRACRAN IAL PRE S SURE Following ABI, ICP is frequently measured. Follow-
ing sTBI, ICP-monitoring is generally accepted as ‘a relatively low-risk, high-yield and
value for money intervention’ [119]; this evidence has been extrapolated to patients
with ICH [120]. Following SAH the role of ICP-monitoring is less well defined [109,121].
ICP can be easily monitored by an implanted intracranial microtransducer catheter or
by ventriculostomy , with a relatively low complication rate [119]. The rationale behind
ICPmonitoring is based on three hypotheses: that uncontrolled intracranial hypertension
leads to brain herniation, that intracranial hypertension itself is an epiphenomenon
indicating ongoing secondary brain injury, and that therapy aimed at the maintenance
of adequate CPP – which depends on ICP measurement – can avoid cerebral ischaemia.
The relationship between intracranial hypertension and poor outcome has been
established for over three decades [122], yet the data regarding the clinical benefit of
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ICP monitoring following TBI are mixed: studies can be found to support the hypothesis
that ICP monitoring is associated with improved, unchanged, or poorer patient survival
(e. g. [123–126]. While a large systematic review of 98 studies with a total of >41,000
patients suggests that the use of treatment regimens incorporating ICP monitoring
is associated with a reduction in mortality and poor outcome [127], the only RCT
evaluating the utility of ICP- and CPP-based management strategies has showed no
improvement in a composite outcome of survival and functional recovery [128]. This
trial, however, does not refute the notion that ICP-monitoring is a useful exercise, as
post-hoc analyses revealed a significant reduction in the required treatment intensity in
the ICP-monitored patients [128].
Whilst complex analysis of the measured ICP signal can be used to identify wave-
forms associated with poor outcome, it is also possible to derive indices describing
pathophysiological perturbations in CA and cerebral compliance [51,119,129–131].
However, even such analyses do not explain the consistent finding that many patients
with intracranial hypertension go on to achieve a good outcome, whilst many patients
without intracranial hypertension fail to do so. There must, therefore, be aspects of
secondary brain injury that are inadequately reflected in changes in ICP after ABI, and
that adequate CPP is an insufficient measure of cerebral perfusion. These realisations
that have prompted investigation in to alternative monitoring modalities.
CEREBRAL BLOOD FLOW Despite the difficulty in establishing absolute CBF
thresholds for the definition of CH-I (see Section 2.2.2 above), the ability to monitor
CBF in order to identify and prevent secondary brain injury remains an attractive
prospect. However, while imaging techniques such as single photon emission computed
tomography (SPECT), PET and Xenon-enhanced CT imaging can provide snapshots
of CBF (SPECT and PET in absolute terms, Xenon-enhanced CT in relative terms), the
ability to monitor CBF continuously at the bedside has proved more difficult. Whilst it
is possible to estimate or approximate relative changes in CBF indirectly through other
monitoring modalities such as jugular venous haemoglobin saturation (SjvO2), NIRS or
invasive PbrO2 monitoring, the two main modalities that can be used to directly estimate
CBF at the bedside are TCD and invasive measurement of CBF by the placement of
a proprietary catheter based on thermal diffusion [132,133]. The latter, the Hemedex
Bowman Perfusion Monitor® has not found widespread clinical use, so only TCD is
considered here in more detail.
TCD is a non-invasive sonographic technique that, in common with all ultrasound
Doppler measures, is based on the use of a pulsed-Doppler ultrasonic beam. Ultrasound
waves from a combined emitter/transducer are transmitted through a ‘window’ in the
skull. The foramen magnum window is used to insonate the posterior circulation and
the orbital (i. e. trans-occular) window is used to insonate the ACAs. However, it is the
temporal window, an area found 2cm above by a line drawn from the tragus to the
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lateral canthus of the eye that is most frequently used [132]; insonating through this
window it is possible to measure flow velocity in the terminal carotid, anterior cerebral,
middle cerebral and posterior communicating arteries. The MCA is the most frequently
insonated vessel, chiefly as it is the easiest to insonate via the temporal window, and
is clinically important, carrying 50-60% of blood from its ipsilateral internal carotid
[134].
Normal values for TCD-measured middle cerebral artery flow velocity (VMCA) vary
between 35-90 cm.s−1, with a high level of intra- and inter-subject variation; this is
ascribed to variability in MCA diameter and angle of insonation, rather representing
differences in CBF . Following ABI, the use of TCD has been described in a number
of scenarios, but the identification of DCI/vasospasm following aSAH is the single
scenario where it has found greatest utility. Elevated VMCA values (of above 120–140
cm.s−1) are a specific, but not entirely sensitive marker of vasospasm when compared
to DSA, and rapid increases in VMCA are associated with outcome. However, the
interpretation of VMCA values is difficult, and multifactorial, depending on a number of
factors including PaCO2, blood haemoglobin levels and levels of sedation, in addition
to the issue of large intra/intersubject variability described above [132]. Consequently,
it is difficult to interpret single ‘spot readings’ of VMCA, but ambulatory TCD recording
of VMCA can characterise changes in CBF during the length of recording.
BRA IN OXYGENAT ION The central role of CH-I in the pathophysiology of sec-
ondary brain injury underpins the rationale for monitoring brain oxygenation. Two
recognised techniques use for the identification of brain tissue hypoxia are jugular
venous oximetry and PbrO2 measurement [135]; another method of brain oximetry,
NIRS, is discussed in detail in Chapter 3.
Jugular venous oximetry is an invasive procedure that measures SjvO2, achieved
through the retrograde catheterisation of the dominant internal jugular vein, and sub-
sequent continuous measurement of SjvO2 by fibre optic oximetry [136]. SjvO2 reflects,
the global balance between cerebral oxygen utilisation and delivery [137]. Following
TBI, the occurrence of jugular venous desaturation is associated with poor outcome
[138] and whilst it has been proposed that SjvO2 monitoring may be useful in guid-
ing therapy [136], difficulty in establishing ischaemic thresholds, insensitivity to focal
ischaemia and poor reliability have mitigated against its more widespread adoption
[139,140].
Conversely, PbrO2 monitoring is a means of focal monitoring of cerebral oxygen-
ation that is finding increasingly widespread clinical utility. The LiCox® (Integra Life
Sciences, Plainsboro, NJ) system for PbrO2 measurement is the commercially available
clinical apparatus in most widespread use for the measurement of PbrO2 currently.
LiCox catheters consist of a Clarke-type electrode [141] that are inserted in to brain
parenchyma at craniotomy, via a burr hole or via a “bolt” fixation device. Measurement
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in healthy animals has revealed normal PbrO2 values between 29–42 mmHg, while
human measurements acquired during neurosurgery and from ‘normal-appearing’ brain
following TBI have revealed values between 37–48 mmHg [135].
Various thresholds for the identification of brain tissue hypoxia (BTH) have been
proposed. Following TBI, observational studies have linked PbrO2 values of <5 mmHg
with poor outcome following TBI [142], while one study used regression analysis have
associated a higher risk of death with the amount of time spent with PbrO2 <20 mmHg,
or the occurrence of <6 mmHg at any point [143]. Another study suggested various time-
hypoxia thresholds that were associated with a higher (>50%) mortality rate, varying
from <5 mmHg x 30 minutes to 10–15 mmHg x 4 hours [144]. Whilst a number of
studies have described the use of PbrO2 monitoring after SAH, none has proposed a
threshold for BTH [145–148]. A recent systematic review identified four cohort studies
– using a mixture of historical and non-randomised, prospective controls – that suggest
that the PbrO2-guided therapy is associated with improved outcome following TBI,
when compared to CPP-guided therapy alone [149]; an RCT is currently recruiting to
further test this hypothesis [150].
One mixed blessing of PbrO2 monitoring, however, is its focal nature. Following both
TBI and SAH, patterns of ischaemia are heterogenous; data from cerebral microdialysis
(CMD) studies confirms that remote ischaemia can go undetected by focal measure-
ments carried out via an invasive catheter [151]; this heterogeneity is also observed
in imaging studies [152]. The invasive nature of PbrO2 monitoring necessarily limits
the number of sites that can be measured, and thus while focal measurements can
identify ischaemia that would go unnoticed by global measures, remote insults can go
unnoticed [137]. Furthermore, it is unclear whether PbrO2 monitoring adequately rep-
resents disorders of oxygen utilisation, as CBF has been shown to be the predominant
determinant of PbrO2 after ABI [147].
BRA IN T I S SUE B IOCHEM I STRY Microdialysis (MD) relies on the principle of
dialysis to produce a simulacrum of tissue extracellular fluid. The process, depicted in
Figure 2.4, relies on a catheter lined with a semi-permeable membrane – the MD probe
– which is implanted within brain tissue at craniotomy via a burr hole or skull bolt and
continually infused with isotonic fluid – termed perfusate. Small molecules within the
brain ECF undergo recovery – that is, they diffuse across the probe membrane – and
the resulting fluid (dialysate) is collected for analysis either at the bedside or frozen for
subsequent analysis [153].
The ability to measure the concentration of any molecule that will diffuse across the
MD membrane has led to the suggestion that the MD probe is a “universal biosensor”
[154]. However, three main groups of molecule are frequently measured after ABI:
markers of oxidative metabolism (glucose, lactate and pyruvate), cell membrane damage
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Figure 2.4 – Schematic representation of microdialysis apparatus. A - pump driving perfusate infusion; B -
microdialysis catheter, to be implanted within cerebral parenchyma; C - microvial containing dialysate,
collected for measurement of relevant D - bedside analyser.
(glycerol) and excitotoxicity (glutamate); only the first group of molecules is considered
in more detail here.
Glucose, lactate and pyruvate play a central role in cellular metabolism – discussed
in Section 1.3 – and CH-I is reflected by changes in their concentrations. However, as
discussed in Section 1.3.2, lactate concentrations can rise in the absence of CH-I. As a
consequence, the lactate:pyruvate ratio (LPR) is used as a measure of cellular energy
state, as the LPR reflects the balance between (oxidised) NAD+ and (reduced) NADH
in the mitochondrial matrix [155], as given in the equation
[NAD][H+]
[NAD]
− [Lactate]
[Pyruvate]
x KLDH. (2.2)
Frontal lobe measurement in patients undergoing surgery on posterior fossa lesions
reveals a normal LPR to be <25 [156]. Following aSAH, LPR thresholds of 20–40 have
been suggested for the identification of CH-I, based on correlation with patient clinical
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state [157]. The prognostic value of microdialysis is well established: elevated LPR
is associated with poor outcome following both TBI [158,159] and aSAH [160–162].
Microdialysis can also provide insights in to the pathophysiology of ABI: one combined
PET-microdialysis study in patients following aSAH revealed clinically relevant meta-
bolic derangements with CBF above the classical threshold of 20 ml.100g−1.min−1,
highlighting the inadequacy of simple flow-based ischaemic thresholds; other studies
have shown signs of metabolic crises in the absence of PET-defined ischaemia [163]
and independently of CPP [164], both underlining the fact that an inability to utilise
delivered substrate is a key feature of ABI.
As in invasive PbrO2 monitoring, the position of microdialysis catheter placement is
of great importance: placement in normal (as opposed to injured) tissue creates the risk
of insensitivity to ischaemia [151]. Furthermore, the interpretation of microdialysate
chemistry at the bedside is complex: the clinician is presented with a multitude of
biochemical variables and a systematic approach to their interpretation is necessary
[154]. However, even when utilising such an approach, current commercial micro-
dialysis apparatus allows a minimum sampling period of 15 minutes, a significantly
lower temporal resolution than the other modalities described above. Furthermore,
there have been no prospective studies to suggest that clinical management paradigms
based on microdialysis are associated with improved outcome. Thus, whilst micro-
dialysis can provide important insights in to the pathophysiology of ABI and be a
useful marker of cerebral ischaemia, it has not gained widespread clinical acceptance,
despite a consensus meeting in 2002 suggesting that its adoption – and in particular,
the measurement of LPR – in patients with aSAH and TBI who require ICP monitoring
[165].
2.4 CONCLUS ION
Following ABI, there are a multitude of injury processes that conspire to cause cell
death, all interlinked in a sometimes recursive fashion; cerebral ischaemia results as a
consequence of reductions of substrate delivery below critical thresholds, and yet these
thresholds are difficult to define; metabolic dysfunction results functional ischaemia in
the presence of otherwise adequate substrate delivery. The ideal clinical management
strategies following ABI are unclear: a multitude of monitoring modalities exist and
several have proven prognostic value, yet none has been proven to improve outcome.
It is against this backdrop that we consider a further monitoring modality: near infrared
spectroscopy.
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3
NEAR INFRARED SPECTROSCOPY
3.1 INTRODUCT ION
The previous chapter established the central role of CH-I in the pathophysiology of This chapter draws
heavily on a review
article published in
Anesthesia and
Analgesia [1].
ABI, and underlined the role of monitoring for CH-I in its management. Yet despite
the existence of a plethora of monitoring modalities to identify CH-I, the limitations of
existing monitors mean that time-critical windows to prevent or minimise permanent
ischaemic neurological injury may pass silently.
NIRS is a non-invasive optical technique that has the potential to address many of
the shortcomings inherent to other cerebral monitoring modalities and is the technique
that forms the basis of the experimental studies in this thesis. Although it has been over
three decades since its first description, the clinical adoption of NIRS has been limited.
There is a wealth of data describing the application of NIRS in neonates, where invasive
brain monitoring is not possible [2,3], and NIRS is also widely used in non-brain tissue
[4] and during functional brain imaging [5,6]. Whilst there is a burgeoning body of
clinical data describing the use of NIRS in the healthy adult brain, data describing its
use following ABI are limited.
The aim of this chapter is to review the principles of cerebral NIRS, and its utility
and limitations as a monitor of CH-I following ABI. Having considered the limitations
of commercially available NIRS apparatus, this is followed by a description of the
hybrid optical spectrometer (pHOS), the specialised NIRS apparatus that is used for the
experimental studies described in this thesis.
3.2 PR INC I P L E S OF N IRS
This section will not exhaustively review the physical principles underlying the clinical
use of NIRS – these are comprehensively reviewed elsewhere [7,8] – but rather aims
to highlight the capabilities and limitations of, as well as the assumptions underlying
different NIRS-based approaches to brain monitoring.
The NIRS technique was first described in 1977 by Franz Jöbsis [9], who made two
key observations regarding near infrared (NIR) light. First, light in the NIR spectrum
(700-950nm) can traverse biological tissue because of the relative transparency of tissue
to light in this wavelength range and, second, several biological molecules, termed
chromophores, have distinct absorption spectra in the NIR . From a clinical perspective,
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oxyhaemoglobin and deoxyhaemoglobin are the most commonly measured chromo-
phores, although CCO may prove clinically more important [10] and was in fact the
target of Jöbsis’s initial investigations.
NIRS is based on the transmission and absorption of NIR light as it passes through
tissue and there are basic features common to all NIRS devices [8]. Light is generated at
specific wavelengths, typically by light-emitting diodes and usually detected by silicon
photodiodes [11] . Alternative methods of light detection include photomultiplier tubes
in older devices, and CCD, similar to those used in consumer digital cameras, in
broadband systems (see Section 3.4 below). The emitting and detecting fibre optics
are often referred to as the optodes. Many systems incorporate two or more channels –
i. e. optodes and associated detectors capable monitoring of multiple tissue regions of
interest simultaneously [12].
3.2.1 Light absorption, scattering and the Beer-Lambert Law
ABSORPT ION In an idealised situation – shown in Figure 3.1a – where the only
cause of light attenuation between a source and its detector is its absorption by chro-
mophores, the attenuation of light which, at a given wavelength, is described by the
Beer-Lambert Law (BLL), as given by the equations
A = log10
(
I
I0
)
(3.1)
A = ε.c .d . (3.2)
Rearranging to calculate c :
c =
A
ε.d
. (3.3)
This states that, at a given wavelength, attenuation A (which is calculated from
emitted light intensity I0 and measured light intensity I , as shown in Equation 3.1) Conventions vary as
to whether base-10 or
natural logarithms are
used in the definition
of attenuation (as
well as the absorption
and scattering
coefficients,
described below)
is dependent to three variables: chromophore concentration c , the source-detector
distance d , and the extinction coefficient of the chromophore ε, which describes
the absorptive properties of a chromophore at a given wavelength (Equation 3.2). In
this hypothetical situation, chromophore concentration can be accurately calculated
using the measured degree of light attenuation by the chromophore in association
with knowledge of the source-detector separation and relevant absorption coefficient
(Equation 3.3).
The extinction coefficient ε is a constant defined empirically a priori for each chro-
mophore across a desired wavelength range. For a solution containing only a single
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(a) The idealized situation where light attenuation is
described by the BLL;
Scattering losses G
d
(b) Transmission spectroscopy, utilising the
modified Beer-Lambert Law (mBLL);
d
(c) Reflectance spectroscopy, also using the
mBLL.
Figure 3.1 – Schematic depictions of light transport and differential spectroscopy.
chromophore, the is given as the product of the extinction coefficient and the mean
optical pathlength:
µa = ε.c . loge 10. (3.4)
The effect of absorption by multiple chromophores is additive, and thus for a solution
containing multiple chromophores, is defined as:
µa = (εa.ca + εb.cb + εc .cc + · · ·+ εn.cn). loge 10, (3.5)
where εa and ca are the extinction coefficient and concentration of chromophore a
and so on [13], and the scaling factor loge 10 included as optical absorption coefficient
(µa) is defined in natural logarithms. The absorption spectra of several important
chromophores are shown in Section 3.2.4 below.
SCATTER ING Biological tissue poses a much more complex optical situation than
the ideal set out above. Although chromophore concentration is still directly related to
light absorption, it is light scattering that is the major contributor to attenuation in most
biological tissue, including the adult head [14]. Scattering is quantified by means of
optical scattering coefficient (µs ), which is analogous to µa, but describes the degree
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of attenuation attributable to scattering losses. Where scattering is anisotropic, it can
approximately be described using the reduced optical scattering coefficient (µ′s ), which
incorporates the anisotropy of such scattering:
µ′s = µs .(1− g), (3.6)
where g is the mean cosine of the scattering angle.
Scattering gives rise to two important consequences. First, not all emitted light
reaches the detector because some of it is scattered away from the detector, giving rise
to scattering losses (see Figure 3.1b). Second, some of the light that reaches the detector
will have been scattered multiple times and therefore the optical pathlength is greater
in distance than the direct source-detector separation. This increase in pathlength is
quantified as the differential pathlength factor (DPF), defined as:
DPF =
Mean Optical Pathlength
d
, (3.7)
so
Mean Optical Pathlength = d .DPF . (3.8)
The mBLL incorporates DPF to account for the effect of lengthened pathlength. The
DPF must be defined a priori, and published values are available for a range of adult
human tissues including for the head [15]. Scattering losses (G ), by definition, cannot be
quantified. However, by assuming that scattering losses are constant, differential spec-
troscopy can be used to derive changes in chromophore concentration from attenuation,
cancelling out constant G . The mBLL is thus given by the equation
A = ε.c .d .DPF +G . (3.9)
Assuming scattering losses G are constant:
∆A = ∆c .ε.d .DPF
∆c =
∆A
ε.d .DPF
(3.10)
In the adult head scattering attenuates NIR light to such an extent that it cannot
traverse the whole head so reflectance spectroscopy (Figure 3.1c), where the light
source and detector are placed on adjacent areas of the head, must be used.
3.2.2 NIRS techniques
All NIRS techniques rely on a measure of optical attenuation, which is the total loss of
light due to absorption and scattering. However, chromophore concentrations (which
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are the physiologically- and clinically-relevant measures that we wish to know) require
knowledge of solely the absorption spectrum of tissue, which is then used to construct
a series of simultaneous equations based on equation 3.2. Thus one of the major
challenges of NIRS is to derive optical absorption from measured optical attenuation.
Several approaches are employed to do so, either by directly measuring optical scattering
or accounting for its effects. It should be noted that multi-distance spectroscopy forms
the basis of most commercially available clinical devices, in part because of the ability
to generate a tissue oxygen saturation (TOS) – a measure that is clinically intuitive –
and the majority of other methodologies are used predominantly in a research setting.
DI F F ERENT IAL SP ECTROSCOPY Differential spectroscopy relies on the mBLL
described above and depicted in Figures 3.1b and 3.1c. It is the simplest form of in
vivo NIRS, although it is now rarely used in adult clinical practice . This technique
assumes that light scattering remains constant during the measurement period and that
measured changes in attenuation are due only to changes in absorption. Therefore only
changes in chromophore concentration from an arbitrary baseline point (i.e. trends)
can be measured. The scale of these changes is dependent on the (a priori defined)
DPF.
MULT I -DI STANCE SPECTROSCOPY This technique, also known as spatially-
resolved spectroscopy (SRS), is a technique commonly used in commercial NIRS
devices. An array of closely-spaced detectors is used to measure light attenuation as a
function of source-detector separation, as depicted in Figure 3.2a.
Commercial devices vary in the algorithm they use to derive the absorption coefficient
from multi-distance spectrometers. For example, the INVOS devices (Somanetics®, Troy,
MI) apply proprietary algorithms that are not published for scrutiny. The term ‘cerebral
oximeter’ has been coined to describe several commercially available devices, as most
report a TOS or equivalent – the nomenclature varies between devices – where
TOS =
[HbO2]
[HbO2] + [HHb]
. (3.11)
One widely-used approach to SRS is the use of the Boltzmann diffusion approx-
imation; algorithms based on this model (which considers the transport of photons
through a highly-scattering medium as analogous to the diffusion of a particle in a
liquid medium) are used in the Hamamatsu NIRO devices (Hamamatsu Photonics KK,
Hamamatsu City, Japan), as well as the pHOS (described below in section 3.4). The
diffusion approximation states that:
µa.µ
′
s ≈
1
3
(
δA
δd
− 2
d
)2
. (3.12)
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The wavelength dependence of scattering (defined a priori [16]) is then used to calculate
the spectral shape, but not the absolute value, of µa. These values are then used to
calculate absolute chromophore concentrations, albeit modified by an unknown scaling
factor [17]. However, when calculating tissue oxygenation index (TOI, the term coined
by Hamamatsu to describe the TOS-equivalent reported by their devices), this scaling
factor is cancelled by division.
The use of the diffusion approximation for SRS is subject to certain underlying
assumptions [18,19]. These include:
• the tissue being monitored is homogenous in its optical properties and ‘semi-
infinite’– that is, an infinite medium bound by a flat plane;
• optical scattering is much greater in magnitude than absorption (µ′sµa) – a
situation that is true of most biological tissue
• scattering is nearly isotropic (i. e. g ≈ 1);
• the source-detector separation is much greater than the diffusion length (d 
1/µ′s )
Whilst the use of SRS serves theoretically to increase the intracranial (or depth-)
specificity of NIRS measurements, there is still empirical evidence to suggest a persistent
contribution of extracranial haemoglobin concentration changes to TOS measurements
[20,21].
FREQUENCY-RESOLVED SPECTROSCOPY Frequency-resolved (or domain) spec-
troscopy modulates the intensity of light at a known radiofrequency and measures
the phase-shift and degree of light attenuation directly (Figure 3.2b). Models of light
transport – such as the diffusion approximation detailed above – are then used to derive
absolute values of µa and µ′s and therefore absolute chromophore concentration [22].
T IME -RESOLVED SPECTROSCOPY Time-resolved spectroscopy (TRS) uses an
ultra-short pulse of light, typically a few picoseconds in duration, emitted by a laser.
A histogram of the number of photons detected and their arrival time to the detector
is constructed (Figure 3.2c). This is called the temporal point spread function (TPSF)
and is interpreted with the aid of a model of light transport (for example, the diffusion
approximation shown in Equation 3.12, but solved in the time domain) to calculate
absolute values of µa and µ′s , and thereby absolute chromophore concentration [23,24].
There is a relative paucity of TRS-based devices available for use outside of the research
arena, but TRS-based techniques may soon overtake ‘continuous-wave’ techniques
such as those three mentioned above [24].
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Figure 3.2 – Schematic depictions of spatially-, frequency-, and time-resolved spectroscopy.
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3.2.3 Spectral resolution
The accurate derivation of chromophore concentration is tightly linked to thewavelengths
of light chosen and optical absorption at one wavelength for each chromophore of
interest must be known. The wavelengths of NIR light used in commercial devices
are usually selected to be sensitive to haemoglobin and therefore generally utilise
wavelengths between 700nm and 850nm where the absorption spectra of oxyhaemo-
globin and deoxyhaemoglobin are maximally separated and absorption by water is
relatively low (see Figures 3.3 and 3.5) [13]. Many commercial NIRS systems employ
two wavelengths, limiting their use to measurement of two chromophores, namely
oxyhaemoglobin and deoxyhaemoglobin [8]. The addition of more wavelengths brings
improved accuracy and can be achieved through the use of additional laser diodes that
emit light at discrete wavelengths, or by using broadband spectroscopy (BBS) systems
which utilise a ‘white’ light source emitting a continuous spectrum of light within the
NIR range. The use of multiple wavelengths is of particular importance when measuring
CCO [25]; although it is possible to resolve CCO concentration using fewer wavelengths,
the selection of these is of paramount importance. However, the task of deciding which
wavelengths to use is non-trivial and requires the use of complex algorithms [26].
3.2.4 Chromophores
Several chromophores possess characteristic spectra within the NIR range. These include
oxyhaemoglobin, deoxyhaemoglobin and the oxidised and reduced forms of CCO, but
also lipids, water and melanin.
WATER , MELAN IN AND L I P ID The human body comprises approximately 70%
water by weight, although individual tissue compartments vary from ∼12% water in
the case of cortical bone to >99% in the cerebrospinal fluid spaces in the brain [27].
Water is also a weak absorber in the ‘near’ NIR range, but its strongest absorption is
above 1500nm, and in practice this absorption limits photon penetration in this range
(see Figure 3.3). Water concentration can be calculated – i. e. cerebral oedema can be
quantified – by resolving for its spectrum [28]. Alternatively, if the water concentration
is known or assumed a priori, the second differential of the water spectrum can be
used to estimate pathlength and thus DPF [29].
Melanin is a strong Rayleigh scatterer within the ultraviolet (UV) spectrum, and this
is necessary for its primary biological role of protection of cell nuclear material from
damage by UV light. Melanin is also a weak absorber within the NIR range. As melanin
levels are relatively constant, it is not necessary to account for melanin during differential
spectroscopy in most clinical settings. However, the presence of melanin may require
consideration when using other absolute quantification methods. Furthermore, the
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Figure 3.3 – Absorption spectra of water; data from [30,31].
absorptive properties of melanin allow the use of NIRS for the detection of melanin-
producing tumours i. e. melanomas [32].
Lipid also possesses a characteristic absorption spectrum within the NIR range (Figure
3.4). However, like melanin, lipid concentration is relatively constant and is not oxygen-
dependent, and so it need not be considered for differential spectroscopy, but may be
important when using absolute quantification methods. The spectral characteristics of
lipid are exploited in the estimation of regional adiposity [4], and also finds utility in
the industrial use of NIRS to estimate food lipid and fat content.
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Figure 3.4 – Absorption spectrum of lipid; data from [33].
HAEMOGLOB IN The measurement of haemoglobin (either in its individual forms
as oxyhaemoglobin or deoxyhaemoglobin, or as a TOS-like measure) forms the basis of
virtually all clinical NIRS studies. Haemoglobin’s biological role as oxygen transporter
(discussed in Chapter 1.2) is predicated on the binding of oxygen to one of the four
iron-containing haeme centres in haemoglobin [34,35]. Just as the oxidation state of
haemoglobin causes changes in its absorption spectrum in the visible range (giving rise
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Figure 3.5 – NIR absorption spectra of oxy- and deoxy-haemoglobin. Data from [25,36].
oxygenated blood), haemoglobin’s absorption in the NIR range varies with oxidation
(Figure 3.5). The measurement of oxyhaemoglobin concentration ([HbO2]) and de-
oxyhaemoglobin concentration ([HHb]) and derived quantities using the various NIRS
techniques described above has reached a relatively mature stage, and many haemoglo-
bin measures and indices are derived using NIRS. Two frequently-encountered measures
derived using differential spectroscopy are the total haemoglobin concentration ([HbT])
and the haemoglobin difference concentration ([HbDiff]), defined as:
[HbT] = [HbO2]+ [HHb] (3.13)
and
[HbDiff] = [HbO2]− [HHb]. (3.14)
Other haemoglobin measures frequently encountered are the TOS-equivalents (see
above) and total haemoglobin index (THI) – a normalised ratio that is an SRS-derived
analogue of [HbT] [13].
CY TOCHROME c OXIDASE Although the measurement of CCO concentration
with NIRS was Jöbsis’s goal when he first described NIRS [9], subsequent decades have
seen an emphasis on the measurement of the haemoglobin species in both clinical and
non-clinical NIRS applications [4,8,11,37,38]. The measurement of CCO concentration,
however, poses a much greater challenge.
Themultiple redox cores of CCO (see section 1.3.3) result in it possessing an oxidation-
dependent absorption spectrum within both the visible and NIR ranges (Figure 3.6)
– a trait it shares with haemoglobin. However, CCO differs from haemoglobin in
two important ways: first, while the individual oxidised and reduced haemoglobin
spectra can reliably be measured using whole blood in vitro, the purification and
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provided by Dr James Moody (Plymouth University) to the Biomedical Optics Research Laboratory, UCL.
preparation of CCO raises concerns regarding the veracity of in vitro spectra [39]. The abbreviation
oxCCO is reserved for
oxidised-reduced
CCO, measured by
resolving for the
difference spectrum;
the oxidised form is
always referred to in
full.
Second, CCO concentrations are constant, so it is possible to measure the in vivo
difference spectrum [i. e. the spectrum of oxidised-reduced cytochrome c oxidase
(oxCCO), shown in Figure 3.7]. Thus, it is the in vivo CCO difference spectrum that
is used to resolve for cytochrome in most NIRS studies. The predominant spectral
feature of the CCO difference spectrum within the NIR range is the broad peak seen
at 830nm. It is generally accepted that the major contributor to this peak is the CuB
core [41]. While haemoglobin and CCO have similar absorption, ceteris paribus, CCO
exists in significantly lower concentrations, meaning that that even in conditions of
complete anoxia, the absorption signal from CCO is an order of magnitude lower than
that from haemoglobin species [39]. The total concentration of CCO within the adult
human brain is unknown (it is difficult to measure directly), but it has been suggested
that the adult rat CCO concentration – 5.5µM – to be the upper limit of adult human
brain concentration [42]. The diminutive size of the CCO absorption signal increases
the potential for scattering losses and pathlength changes to confound the accurate
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Figure 3.7 – Difference spectrum of CCO measured in vivo, based on data from [40].
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measurement of CCO changes, although the use of BBS can mitigate somewhat against
these confounders [25]. Further difficulties arise in the interpretation of the physiological
and clinical relevance of measured CCO oxidation changes. While NIRS can be used to
measure the oxidation of the CuB core of CCO, the relationship between CuB oxidation
and electron flux through the enzyme, discussed in Chapter 1.3.3 is complex. These
challenges combined have resulted in a relative paucity of NIRS-derived data describing
the behaviour of CCO.
3.3 CL IN ICAL USE OF N IRS
There has been interest in using NIRS to detect CH-I since its first description, but the
relatively wide use of the technology in the research setting has not been matched
by clinical applications [8]. There are many reasons for this, including limitations
inherent to the technique, ambiguity regarding what is actually measured, deficiencies
in algorithms, difficult translation of instruments designed for research use to the bedside
and data that are not reproducible and specific enough for clinical decision-making.
3.3.1 Cardiac surgery and carotid endartectomy
Two clinical scenarios where there is evidence to support the use of NIRS for the
identification of CH-I are during carotid endarterectomy (CEA) and cardiac surgery.
Following CEA, the decision of whether or not to place an intracarotid shunt during
cross-clamping is of key importance: if placed unnecessarily (i. e. when collateral
circulation is adequate to perfuse the brain despite cross-clamping), it exposes the
patient to the risk of carotid vascular injury; conversely, omission of a shunt in the
presence of inadequate collateral circulation can lead to ischaemic brain injury [43].
A number of studies have demonstrated broad equivalence between NIRS and
alternative modalities such as TCD, and somatosensory evoked potential measurement
to identify CH-I during carotid cross-clamping, but a key difficulty is in the identification
of the ‘ischaemic threshold’ below which shunting should take place. Using a variety
of apparatus, TOS threshold values vary between 11-20 percentage point reductions
in TOS; an absolute TOS threshold of 59% has also been suggested [44–48]. This
ambiguity serves to highlight the inadequacy of purely haemoglobin-based measures
in the identification of CH-I, but the relative ease-of-use, temporal resolution and lack
of operator-dependence makes NIRS an attractive monitoring option in this context [1].
In the case of cardiac surgery, NIRS-guided ‘brain-protection’ protocols aimed at
optimising cerebral DO2 during cardiopulmonary bypass (CPB) have generated great
interest, in the hope that they may aid in the prevention of stroke, which occurs in 1-3%
of patients, and longstanding postoperative cognitive dysfunction, which occurs in more
than 50% of patients [49,50]. Whilst the use of protocol based on the maintenance
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of normal TOS has not been shown to improve neurological outcome, it is associated
with reduced non-neurological morbidity [51,52]. Post-hoc analyses suggest that there
may exist a ‘time-viability’ threshold for clinically significant ischaemia, where both
the depth and duration of reductions in TOS are of prognostic importance [1].
In summary, there is prospective evidence supporting the use of cerebral NIRS
monitoring – in the form of cerebral oximeters – to improve non-neurological outcome
following CPB, the evidence linking reductions in TOS to poor neurological outcome
are limited to retrospective and post-hoc analyses. As with CEA, the question must be
asked: could this ambiguity be resolved through the use of NIRS to monitormetabolism
in addition to haemodynamics and oxygenation?
This was precisely the question posed by the Tamura group, who used NIRS apparatus
and associated ‘Sapporo’ algorithm based largely on the mBLL and designed and
validated for the measurement of oxCCO (reviewed in [53]). In an observational study
of 66 patients undergoing thoracic arch surgery with CPB, Kakihana and colleagues
identified three patterns of oxCCO change in response to CPB (Figure 3.8). Although the
algorithm is unable to quantify changes in oxCCO (as it does not correct for pathlength,
and thus expresses changes in arbitrary units), the investigators reported a significant
association between reductions in concentration of oxidised-reduced cytochrome c
oxidase ([oxCCO]) and poor neurological outcome: a transient reduction (‘Type B’)
was associated with an 5.7-fold increase and a persistent reduction (‘Type C’) was
associated with a staggering 33.3-fold increase in the occurrence of poor neurological
outcome – which was not prospectively defined, but encompassed a range from the
occurrence of seizures to coma [54]. Although criticisms have been levelled on the
integrity of chromophore changes derived using the Sapporo algorithm [25], this paper
is the one of only two studies that associates CCO oxidation status to clinical outcome
in man. The other was an observational study of 41 adult patients undergoing cardiac
surgery (with bypass), who underwent cerebral NIRS monitoring with a NIRO-500
(Hamamatsu Photonics KK, Hamamatsu City, Japan) device, which reports changes
in [oxCCO] using a mBLL-based algorithm. Three patients suffered from a temporary
delerium, which resolved within three days; the observed median reduction in [oxCCO]
during bypass was as much as 5.5µM greater in these patients than those who did
not suffer any neuropsychological sequelae [55]. However, it should be noted that this
algorithm, too, has been shown to overestimate the magnitude of [oxCCO] changes [25],
a notion corroborated by the fact that an oxCCO reduction of 5.5µM would suggest
reduction of the entire enzyme pool.
3.3.2 Acute brain injury
ABI presents a more complicated challenge, where CH-I caused by reductions in
cerebral substrate delivery in concert with increases in cerebral metabolic demand
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Figure 3.8 – Patterns of oxCCO change seen during cardiopulmonary bypass (schematic on left, actual
recordings on right). Reduction in oxCCO (labelled ∆[cyt. ox]) in B type and C type patterns is was
associated with poor outcome. Modified from [54].
and mitochondrial dysfunction, leading to an inability to use delivered substrate (see
Chapter 2.2). There has been limited investigation of the utility of NIRS in this area,
and no outcome studies. Investigations in the adult neurocritical care population have
been solely observational and serve to highlight two key difficulties in investigating
NIRS-derived variables in this context: the definition of ischaemic thresholds in an
injured brain with acutely disordered haemodynamic and metabolic function, and the
lack of a gold standard against which to compare NIRS-derived measures [10]. Factors
such as the presence of intracranial haematoma, cerebral oedema and subarachnoid
blood present further challenges since they may invalidate some of the assumptions
upon which NIRS algorithms are based. In fact, this has been utilised to advantage in
studies using NIRS to identify intracranial haematomas [56] and cerebral oedema [28].
One small observational study of 18 patients with TBI identified an association
between increasing length of time with regional oxygen saturation (rsO2, the TOS-
equivalent reported by INVOS oximeters) values of <60% and mortality, intracranial
hypertension and compromised CPP [57]. A more recent study compared PbrO2 with
regional oxygen saturation (rsO2) in 22 patients over a 16-hour period following severe
TBI [58]. An rsO2 <60% was moderately accurate for the prediction of ‘severe’ brain
hypoxia (PbrO2 < 12 mmHg) but poor at detecting ‘moderate’ hypoxia (PbrO2 12-
15 mmHg) with sensitivities and specificities of 73% and 86%, and 62% and 49%
respectively. The authors conclude that rsO2 is an inadequate substitute for PbrO2 for
routine monitoring of cerebral oxygenation and, whilst this is reasonable, it fails to
consider the different physiological variables and brain regions being monitored by the
two techniques.
There has been recent interest in using NIRS to monitor cortical changes during
cerebral vasospasm after aSAH. In one study of 32 patients undergoing coil embolisation,
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the rate-of-decline of rsO2 (measured using an INVOS oximeter) was 3.5%.min−1
greater in patients who developed vasospasm during the procedure than in those
who did not [59]. Yokose and colleagues used TRS (TRS-20, Hamamatsu Photonics)
to demonstrate that vasospasm could be predicted with 100% sensitivity and 85.7%
specificity in 14 predominantly poor-grade aSAH patients, and that a threshold of a
3.9–6.4% decline in cortical oxygen saturation was optimal for the identification of
ischaemia [60]. In this study, the reliability of repeated NIRS measurements over time
was ensured by the use of CT image-guidance to position the NIRS optodes. This novel
approach allowed consistent measurement of the same cortical area on consecutive
days. The introduction of time-resolved devices to the clinical setting brings the prospect
of the measurement of multiple chromophore concentrations in absolute terms at the
bedside.
Impairment of CA renders the brain more susceptible to ischaemic insults and is thus
associated with poor outcome after brain injury (see Chapter 2.2.2). NIRS has recently
been used to monitor CA in a variety of clinical settings and, although the therapeutic
value of monitoring and managing CA is not clear, this has become an area of intense
investigation. In a study of 40 patients with severe TBI, Zweifel and colleagues identified
a statistically significant correlation between total haemoglobin reactivity index (THx),
a measure of CA based on the moving correlation between THI and arterial blood
pressure and pressure reactivity index (PRx), an outcome-validated index of pressure
reactivity derived from invasive ICP and arterial blood pressure [61]. The same group
also demonstrated a correlation between a TOS-derived measure of CA and Mx, a
TCD-based index derived from middle cerebral artery blood flow velocity, in a group of
27 patients following poor-grade SAH [62]. It is suggested that NIRS-derived measures
of CA may be able to guide optimisation of cerebral haemodynamics, including cerebral
perfusion pressure, although evidence of its clinical utility is currently sparse.
As with CEA and CPB, measurement of CCO oxidation state may provide additional
information about metabolic failure and aid in the determination of ischaemic thresholds
following brain injury [10]. Using a customised BBS system based on the UCLn algorithm
[25], Tisdall and colleagues found that changes in CCO oxidation correlated with
measures of cerebral DO2 in healthy volunteers [63] and subsequently demonstrated
an increase in CCO oxidation during normobaric hyperoxia (NBH) in a pilot study of
eight patients following TBI [64]. However, as discussed in Section 1.3.3, relationship
between CCO oxidation status andmetabolic activity is complex, and these complexities
combine with the potential confounding effects of scattering and pathlength changes
[25] to render the interpretation of observed oxCCO changes very difficult. These
difficulties may be addressed by the development of mathematical models of brain
haemodynamics and metabolism allows in silico derivation of signals which can be
compared to measured signals and thereby facilitate their interpretation [65,66].
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3.4 THE HYBR ID OPT ICAL SP ECTROMETER
The pHOS is the NIRS apparatus that is used for the experiments described in this thesis.
It combines two components: an multidistance broadband spectrometer (MDBBS)
and an multidistance frequency domain spectrometer (MDFD) spectrometer. By using
these two components, either singly or in concert, it should be possible to investigate,
simultaneously, changes in chromophore concentration – in particular changes in
oxCCO – as well glean information on factors which may confound the accurate
measurement of these chromophore changes. Furthermore, whilst absorption is clearly
a biomarker in disease (as it is directly dependent on chromophore concentration), it
has also been suggested that scattering may be clinically-relevant biomarker in brain
injury [67].
3.4.1 MDFD instrumentation & technique
A detailed derivation of the physical and mathematical basis of the MDFD technique is
reported by Fantini [18,19] and Hueber [68]; its basic principles are outlined here. The
MDFD spectrometer is based on the commercially-available OxyPlexTS™ spectrometer,
(ISS Inc, Champaign, IL, USA), but has been modified with LED emitting light at four
wavelengths: 690, 750, 790 and 850nm; these are amplitude-modulated at 110MHz.
The instrument measures the average light intensity (DC), average wave amplitude (AC)
and phase (θ) of the modulated intensity at source-detector separations of 3 and 3.5cm.
Using linear regression, the slope (i. e. the change with respect to distance) of each
of these variables is calculated. The Boltzmann diffusion approximation (discussed in
Section 3.2.2 above) is then used to construct a system of simultaneous equations that
relates these six variables (DC amplitude, AC amplitude, phase shift, DC slope, AC
slope, phase shift slope) to the µa and µ′s .
The MDFD undergoes a calibration procedure against a tissue-like phantom of known
µa and µ′s at the four wavelengths; this is required to account for the fact that the eight
different sources (four wavelengths at two source-detector separations) emit light with
variable intensity and phase. The original (unmodified) apparatus has been validated
using tissue-like optical phantoms [18,19] and for tissue oximetry in adult human
muscle [19]; as a tissue oximeter it has found widespread use in a variety of pre-clinical
and clinical scenarios that are not considered here. The modified apparatus used for the
studies described in this thesis has been validated using tissue-like optical phantoms
[69,70], and its use described in use for the measurement of absolute µ′s in the healthy
adult head during a Valsalva manoeuvre and during functional activation [71–73]. This
measurement of µ′s is especially notable as changes in µ′s have been proposed as cause
of spuriously-observed changes in [oxCCO] [42].
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Figure 3.9 – Schematic representation of MDBBS. a-light source; b-source fibre; c-detector fibre bundle, with
four detector optodes; d-charge-coupled device (CCD); e-diffraction slit and large-aperture lens; f-diffraction
grating; g-large aperture lens.
3.4.2 MDBBS instrumentation & technique
The MDBBS component of the pHOS has been described in more detail elsewhere
[69,74], it is represented diagramatically in Figure 3.9.
A 50w halogen light source is used with a short-pass filter (to minimise heat effects).
The detector assembly comprises four detectors, placed 20/25/30/35mm from the
source optical fibre. Detector fibres pass to the lens spectrograph, which is based on
large aperture (f/1.2) lenses, a 50x50mm diffusion grating (300 groves per mm, blazed at
1000nm) and a 12.3x12.3mm, 512x512 pixel water-cooled CCD (Pixis 512, Princeton
Instruments, Trenton NJ, USA). The spectrometer is calibrated against a mercury-argon
laser to ensure accurate wavelength calibration and a spectral resolution of at least
5nm.
The MDBBS thus measures optical attenuation between 512-1024nm at four source-
detector separations. These attenuation spectra can be used to measure changes in
chromophore concentration using the UCLn algorithm – a broadband algorithm based
upon the mBLL [25]– at four distances, potentially measuring chromophore changes in
four different tissue layers simultaneously. Alternatively, by combining the four distances
to measure the slope of attenuation, broadband SRS can be performed.
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3.4.3 Combined use of MDBBS & MDFD
In addition to use in isolation, as described above, the two componenents of the pHOS
can be used in concert, using novel algorithms. One example of such an algorithm is
the use of DPF, derived from the MDFD using the diffusion approximation [71], which
states that:
DPF =
√
3µ′s
2
√
µa
(3.15)
By measuring the DPF in real time and substituting it in to the mBLL (equation 3.10,
or its equivalent using the broadband UCLn algorithm). This methodology has been
adopted in NIRS studies of functional activation [72,73] and changes in haemoglobin
concentrations during a Valsalva manoeuvre [71].
Another novel combined use of the two components of the pHOS is through the
use of absolute values of µa and µ′s , derived from the MDFD, to accurately scale the
value of µa derived from multidistance measurements (see Section 3.2.2), providing
the absolute values of µa across a wide range of wavelengths and thus, potentially,
absolute chromophore concentration. This method has been proven in principle, but
not validated [75].
3.5 CONCLUS ION
Despite a large and ever-increasing number of commercial devices designed for, and
clinical studies describing the use of NIRS as a monitor of CH-I, the data from the
literature – largely reporting TOS-equivalents – have been largely disappointing. These
introductory chapters have made the case for a bedside monitor of not only cerebral
haemodynamics and DO2 but of metabolism, on the basis of normal physiology, the
pathophysiology of ABI and the clinical data describing the use of NIRS. There is some
evidence that oxCCO may fulfil this role, but there are physiological and spectroscopic
hurdles to the interpretation of this complex signal. The pHOS is a sophisticated custom-
built NIRS apparatus that is designed to clear these hurdles – or at least assess their
influence and pertinence. In the next part of this thesis concerns a clinical experimental
study describing the use of the pHOS in healthy volunteers and patients with ABI.
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Part II
EXPER IMENTAL STUD I ES
4
CYTOCHROME C OXIDASE DURING MANIPULATION OF CEREBRAL
OXYGEN DELIVERY IN HEALTHY VOLUNTEERS
This chapter describes the use of the hybrid optical spectrometer (pHOS) in a cohort of This chapter draws
heavily on a paper
published in
NeuroImage [1].
healthy volunteers. We manipulated cerebral oxygen delivery (cDO2) by controlling
the volunteers’ gas mix and minute volume. The pHOS was used in a single-channel,
four-distance configuration to measure changes in oxyhaemoglobin concentration
([HbO2]), deoxyhaemoglobin concentration ([HHb]) and concentration of oxidised-
reduced cytochrome c oxidase ([oxCCO]) at four source-detector separations, and also
to perform spatially-resolved spectroscopy (SRS) to measure tissue oxygen saturation
(TOS). We describe the changes in these chromophores and explore the anatomical
and physiological basis of the observed [oxCCO] changes.
4.1 INTRODUCT ION
TOS and its proprietary equivalents are frequently described as potential targets for
brain monitoring in clinical contexts, yet the evidence to support such use is limited to
a handful of specific clinical scenarios (as described in Section 3.3 and [2]). Whilst the
concept behind TOS – that proportion of tissue haemoglobin that is oxidised – is simple,
interpretation of this measure in the context of acute brain injury (ABI) is complex. Brain
injury entails a number of interlinking pathophysiological cascades that may serve to
limit the utility of TOS-like measures because differing pathophysiological perturba-
tions may result in the same change in TOS. This results in difficulty deconvoluting
the underlying contributing processes and thus appropriate clinical interventions [3].
Furthermore, haemoglobin from extra-cranial tissues makes a significant contribution
to near infrared spectroscopy (NIRS)-derived haemoglobin measures [4–6]. The use of
SRS-derived measures like TOS decreases this extracranial contribution [7,8], but lack
of ‘depth-specificity’ remains a significant concern [9].
The measurement of changes in cytochrome c oxidase (CCO) oxidation state – as the
NIRS-measured [oxCCO] – is thus an attractive alternative prospect for the detection
and avoidance of secondary brain injury. It has been suggested that [oxCCO] is a
‘brain-specific’ signal because the higher mitochondrial number in brain compared to
extracranial tissue gives rise to a higher CCO concentration in the former [3,10,11],
but this postulate has never been proven experimentally. Before moving to clinical
studies measuring [oxCCO] in patients with ABI, we sought to address specific concerns
82
4.1 INTRODUCT ION 83
regarding the veracity and robustness of the [oxCCO] signal [12]. Specifically, we wished
to establish whether [oxCCO] is a more brain-specific signal than the concentration
of haemoglobin species, by using the multidetector broadband array of the pHOS to
measure simultaneously at multiple source-detector separations. We also sought to
establish whether changes in optical scattering or differential pathlength factor (DPF)
could be potentially confounding the accurate measurement of CCO oxidation in vivo.
Because reductions in cDO2 are a key aspect of ABI pathophysiology, we sought to
investigate the CCO response across a wide range of cDO2 – ideally wider than one
would encounter during clinical practice, for example during significant ischaemia,
hypoxia or large changes in cerebral blood flow (CBF). Reduction in cDO2, however,
carries significant risks in patients with ABI; incrementing cDO2 by means of inducing
increases in CBF carries the risk of concomitantly increasing cerebral blood volume
(CBV), thus increasing intracranial pressure (ICP) in patients who are liable to have de-
creased cerebral compliance and thus potentially inducing secondary injury. Increasing
cDO2 by means of normobaric hyperoxia (NBH), however, carries no such risk and
thus forms the basis of the experiment described in Chapter 5.
The aims of this study were to investigate the utility of measurement of CCO oxidation
status, measured with NIRS as ∆[oxCCO]. In particular, we wish to confirm the veracity
of the measurements and the ‘brain-specificity’ of the ∆[oxCCO] measure. Furthermore,
we wish to investigate whether measurement of ∆[oxCCO] has any additional benefit
over the measurement of more commonly-used NIRS chromophores, both as a result of
brain-specificity and its physiological basis. The experiment thus aims to systematically
investigate the NIRS measured haemoglobin and CCO redox responses to isovolaemic
and hypo- and hypervolaemic manipulations in cDO2.
The hypotheses were that:
• changes in chromophore concentration in response to hypoxia, hyperoxia, hypo-
capnia and hypercapnia would be consistent with basic physiological principles
and with those previously reported in the literature;
• CCO concentration changes would show a greater depth-specificity than haemo-
globin species concentration. This would manifest as:
– a greater magnitude of CCO oxidation changes observed in longer source-
detector separations and
– no difference in haemoglobin species concentration between the different
source-detector separations.
• Optical scattering would show no change during the course of the cDO2 manip-
ulations.
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Figure 1. Schematic of the modified sequential
gas delivery circuit
The manifold attached to the non-vented mask is
separated into inspiratory and expiratory limbs using
one-way low resistance valves. The two limbs are
connected via a bypass limb with a one-way cross-over
valve that has an opening pressure greater than that of
the other two valves. During exhalation, all of the
exhaled gas is directed through the expiratory limb into
the atmosphere, with the last portion of the exhaled
breath trapped in the expiratory reservoir. At the same
time, Gas 1 (G1) collects in the inspiratory reservoir. At
the beginning of inhalation, G1 is drawn from the Gas
1 inlet and the inspiratory reservoir. If minute ventilation
exceeds the flow of G1 during inhalation, G1 in the
reservoir is depleted and the reservoir collapses. The
negative pressure in the inspiratory limb causes the
cross-over valve to open and the balance of the breath
is then made up of Gas 2 from the expiratory reservoir.
to subject’s minute ventilation (V˙E) (Fig. 2, stage A).
If V˙G1 is then reduced further, the cross-over valve will
open and the balance of inspiration will be composed
of G2. However, with small reductions in V˙G1 below the
subject’s V˙E, FETCO2 does not rise despite rebreathing of the
exhaled gas (Somogyi et al. 2005) (see stylized capnograph
tracing in Fig. 2, stage B). This apparent contradiction
can be explained by referring to a simple lung model
consisting of anatomical dead space (VDAN) in series with
alveolar space. Since G2 is only inspired after all of G1
has entered the lung, G2 is initially distributed exclusively
to VDAN and therefore has a negligible effect on alveolar
gas exchange. In fact, FETCO2 remains constant until V˙G1
is reduced sufficiently below V˙E to diminish the fresh
gas delivered to the alveoli, i.e. until V˙A is decreased. In
this circumstance, the reduction of G1 is compensated
by an increase in G2 (Fig. 2, stage D). Thus, the V˙G1 at
which FETCO2 starts to increase corresponds to the subject’s
V˙A (V˙E – VDAN) as illustrated in Fig. 2, stage C. At such
a V˙G1 , all of VDAN is filled with G2 (Fig. 2, stage C)
and any further reduction in V˙G1 effectively reduces V˙A,
causing a corresponding increase in FETCO2 (Fig. 2, stage
D).We conclude that the following rule applies to the SGD
circuit:
Rule 1:Whenever V˙G1 is less than or equal to V˙A (or V˙A is
greater than or equal to V˙G1), then V˙G1 determines V˙A.
Concept of ‘neutral gas’
When V˙G1 is less than or equal to V˙A, VDAN is filled with
previously expired gas, so that the gas in the expired gas
reservoir will have a composition that differs from that
of a subject breathing room air with a V˙G1 greater than
V˙A. Instead of being filled with a ‘mixed expired gas’
consisting of a combination of alveolar gas and G1 from
VDAN it is filled only with mixed alveolar gas, because the
gas in VDAN is previously expired gas. Mixed alveolar gas
is, by definition, fairly well equilibrated with pulmonary
capillary blood (West, 1990) and reflects average arterial
blood gas partial pressures as long as there are negligible
effects from alveolar dead space ventilation and shunt.
Thereforemixed alveolar gas re-entering the alveolar space
from VDAN during inspiration, increases lung volume
but does not affect the FACO2 and alveolar fractional
Figure 2. Changes in end-tidal partial pressure of CO2 (PETCO2 ,❡) in response to progressive decrease in the flow of Gas 1 (V˙G1 )
Also shown in the figure is the stylized raw capnograph tracing
(continuous line). At the top of the figure, the observed results are
explained with a lung model consisting of anatomical dead space
(VDAN) in series with alveolar volume (VA). If V˙G1 exceeds minute
ventilation (V˙E), then the lung is only filled with Gas 1 (G1). When, on
average, the inspiratory reservoir of the SGD circuit collapses at the
end of each inspiration, V˙G1 equals V˙E (stage A). If V˙G1 is less than V˙E,
Gas 2 (G2) starts to enter the lungs via a bypass conduit of the SGD
circuit. This is confirmed by a characteristic rebreathing ‘shoulder’ at
the end of the inspiratory portion of the raw CO2 tracing. G2 remains
trapped in VDAN (stage B), however, and therefore has no effect on
PETCO2 . PETCO2 only starts to increase when G2 starts to enter alveoli
(stage D). The V˙G1 when PETCO2 values start to increase corresponds to
the alveolar ventilation (V˙A). At this point, all of VDAN is occupied by
G2 (stage C).
C⃝ 2007 The Authors. Journal compilation C⃝ 2007 The Physiological Society
Figure 4.1 – Schematic diagram of sequential gas delivery circuit used for the hypoxia, hyperoxia and
hypercapnia challenges (from [13]).
4.2 METHODS
This study was approved by the Joint Research Ethics Committee of the National Hospital
for Neurology & Neurosurgery and Institute of Neurology. All subjects provided written
infor ed onsent.
4.2.1 Physiological challenges
Cerebral oxygen delivery was manipulated by four separate physiological challenges:
hypoxia, hyperoxi , hypocapnia and hypercapnia. Before each challenge, a 5-minute
period of baseline recording, inhaling room air, was carried out. A sequential gas
delivery circuit, shown in Figure 4.1 was constructed and used for the hypoxia, hyperoxia
and hyp rcapnia challenges [13], and throughout these challenges, the overall gas
flow rate titrated to maintain the desired end tidal CO2 (etCO2) (i. e. constant in the
hypoxia/hyperoxia studies and increased, as described bel w, during the hypercapnia
st dies).
HYPOX IA Hypoxia was induced through th d livery of a hypoxic mix, achieved
thr ugh the addition of nitrogen to room air. Following the initial 5-minute ‘baseline’
period of recording, a mix with an inspired fraction of oxygen (FiO2) of 8% was
introduced – the ‘induction’ period, where the FiO2 was titrated to achieve a reduction
in pulse haemoglobin oxygen saturation (SpO2) to 80%. Once this desired level of
hypoxia was achieved, SpO2 was maintained at 80% for a period of 5 minutes –
the ‘plateau’ period. Following this, the inspired gas was returned to room air – the
‘recovery’ period, which ended when the end tidal O2 (etO2) had returned to baseline
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values. A further 5 minutes of baseline recording was then carried out to complete the
return-to-baseline period.
HYPEROX IA After the initial 5-minute baseline period of recording, hyperoxia was
induced by increasing the FiO2 to >90%. This was maintained for 5 minutes – the
‘challenge’ period – before returning the inspired gas to room air. The period between
this re-introduction of room air inspiration to the normalisation of etO2 to baseline
levels was the recovery period, which was followed by a further 5 minutes of baseline
recording.
HYPERCAPN IA The hypercapnia protocol was analogous to that used for hyperoxia
in timing, with the inspired gas mix comprising an FiO2 of 21% with the addition of 8%
carbon dioxide (CO2) for the challenge period, titrated to achieve an etCO2 increase
of ∼2kPa and the recovery period considered complete when etCO2 had returned to
baseline values.
HYPOCAPN IA The sequential gas delivery circuit was not used for the hypocapnia
studies; rather, the subjects were given a mouthpiece incorporating the etCO2 and
etO2 sensors/sidestreams and were breathing room air. Following the 5-minute baseline
recording, subjects were instructed to hyperventilate to achieve an etCO2 reduction of
∼2kPa, which was maintained for 5 minutes.
4.2.2 NIRS monitoring
Instrumentation
The pHOS (described previously [14,15] and Section 3.4) comprises multidistance
broadband spectrometer (MDBBS) and multidistance frequency domain spectrometer
(MDFD) components. The MDBBS component was used to measure chromophore
concentration and TOS; all four distances (20, 25, 30 and 35mm) of MDBBS component
were used. The MDFD component was used to measure optical absorption coefficient
(µa) and reduced optical scattering coefficient (µ′s ). The pHOS optode – shown in Figure
4.2 – was applied in the mid-pupillary line on the forehead, high enough to avoid the
expected position of the frontal sinus using elastic bandages, with extra light-shielding
applied if the initial reflectance spectrum showed signs of external light contamination.
The sampling period of the pHOS was 3.2 seconds - comprising a 2 second window for
MDBBS data acquisition and 1.2 seconds for MDFD acquisition, shown schematically
in Figure 4.3. MDBBS exposure adjusted to achieve a photon count of 6-65,000 photons
per sample) and MDFD collected four samples in a 1.2 second period and with mean
of these four samples recorded as the MDFD reading for this period. The processing
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Figure 4.2 – Schematic diagram showing hybrid system optode, incorporating two MDFD light sources with
a single detector (top half) and single MDBBS light source with four detectors (bottom half).
MDBBS 
sample x 1
MDFD spectrometer 
sample x 4
2 seconds 1.2 seconds
1 cycle
Figure 4.3 – pHOS sampling period with sequential MDBBS and MDFD acquisition.
of NIRS data to derive chromophore concentration was performed in Matlab (version
R2010b, MathWorks, Natick MA).
NIRS algorithms
FREQUENCY DOMA IN SPECTROSCOPY The MDFD component was used to
measure the µa and µ′s using the technique described in Section 3.4.1; µa and µ′s were
derived from the measured average wave amplitude (AC) amplitude and phase shift
[16–18]. We report µ′s and DPF measured at 790nm and 850nm, as these were the
wavelengths that lie within the resolving wavelength used for broadband spectroscopy
(see below).
DI F F ERENT IAL SP ECTROSCOPY The modified Beer-Lambert Law (mBLL) was
used to derive ∆[HbO2], ∆[HHb] and ∆[oxCCO] using the UCLn algorithm (described
previously [15,19] and Sections 3.2.1 and 3.2.2), incorporating a correction for the
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wavelength dependence of DPF [20] and resolving over the wavelength range 780-
900nm. Chromophore concentration changes were calculated individually for each
source-detector separation. For the proximal two detectors (20 and 25mm), the DPF
was assumed to be 6.26 [21]. For the distal two detectors (30 and 35mm), an individual-
specific DPF was calculated from the mean DPF as measured with the MDFD during the
first minute of recording, as previously described [22,23]. After ∆[HbO2] and ∆[HHb]
were derived, changes in ∆haemoglobin difference concentration ([HbDiff]) and ∆total
haemoglobin concentration ([HbT]) were calculated as described in Equations 3.14
and 3.13.
SPAT IAL LY RE SOLVED SPECTROSCOPY TOS was calculated using the SRS
methodology [24]. Using the measurements of light attenuation (A) across the four
source-detector separations (d ), linear regression was performed to yield an attenuation
slope (δA/δd ). This was repeated for every wavelength (λ) across the range 740-900nm
for each time point. The diffusion approximation was then used to derive a relative µa
spectrum as given by the equation
kµa(λ) =
1
3(1− hλ)
(
ln10.
δA(λ)
δp
− 2
ρ
)2
. (4.1)
where (1−hλ) is a correction factor for the wavelength dependency of optical scattering
[25] and ρ is the mean source-detector separation. A 70% water concentration was
assumed, and the consequent spectrum was subtracted from the kµa(λ) spectrum; this
spectrum was used to derive the relative concentrations of [HbO2] and [HHb], and the
TOS then derived as described in Equation 3.11.
FURTHER PROCESS ING All concentrations calculated using the mBLL as well
as the TOS were processed with a linear detrend to remove baseline drifts and subject
to a low-pass filter with a 5th order Butterworth filter with a cut-off frequency of 0.08
Hz as previously described [22,26].
4.2.3 Other physiological monitoring
Other physiological monitoring comprised SpO2 measurement, using beat-to-beat pulse
oximetry (modified Oxypleth, NovaMetrix, MA); continuous non-invasive arterial blood
pressure (PortaPres, Finapres Medical Systems, The Netherlands); heart rate monitoring,
using electrocardiography (IntelliVue MP50, Philips Healthcare, The Netherlands);
inspired/expired oxygen partial pressure (IntelliVue Anaesthetic Gas Module, Philips
Healthcare); etCO2 measurement by capnography (CO2SMO, NovaMetrix) and middle
cerebral artery flow velocity (VMCA) measurement, using transcranial Doppler (TCD)
ultrasonography ipsilateral to the pHOS optode (DWL Doppler Box, Compumedics,
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Germany). Data from the IntelliVue monitors was collected using Trendface (Ixellence,
Wildau, Germany) at 125hz. Capnography and blood pressure waveforms and SpO2
connected via analogue interface and analogue-to-digital convertor (ADC) to the TCD
software (QL, Compumedics, Germany) and oversampled at 50hz.
4.2.4 Derivation of other brain metabolic indices
Changes in estimated cerebral oxygen delivery (ecDO2) were calculated from the
measured VMCA and SpO2. CDO2, in units of ml/100g tissue/minute can be calculated
as follows:
cDO2 = CBF× (Haemoglobin-bound O2 + dissolved O2)
= CBF× (1.39× [Hb]× SpO2 + 0.0025× pO2). (4.2)
where CBF is in ml/100g tissue/minute, 1.39 is the oxygen carrying-capacity of haemo-
globin in ml/g, [Hb] is the concentration of haemoglobin in g/dL, 0.0025 is the solubility
of oxygen in blood in ml/kPa/dL and partial pressure of oxygen (pO2) is in kPa. Assum-
ing constant TCD insonation angle and middle cerebral artery (MCA) artery diameter,
VMCA correlates with CBF [27], and ignoring dissolved fraction of O2, which is small in
comparison to the haemoglobin-bound component, changes ecDO2 can be estimated
as:
∆ecDO2 ≈ ∆VMCA×∆SpO2. (4.3)
ecDO2 was calculated in this fashion for the hypoxia, hypocapnia and hypercapnia
challenges. It was not calculated during the hyperoxia challenge as the increase in
cDO2 achieved during hyperoxia is typically as a result of an increase in water-dissolved
O2, assuming – as it is in health – that haemoglobin is at full or near-full saturation.
An estimation of (CMRO)wasalsoderivedinasimilarfashion, usingaNIRS− approximationoftheKety −
Schmidt/Fickequation[28] :
∆Relative CMRO =
VMCA
VMCA0
.
(
SpO2 − TOS
SpO20 − TOS0
)
, (4.4)
where VMCA, SpO2 and TOS for any given timepoint are compared to their respective
baseline values, VMCA0, SpO20 and TOS0.
4.2.5 Further processing and epoch selection
All further processing was carried out in MatLab (version R210b, MathWorks, Natick
MA). Synchronisation between the various systems was achieved by means of a constant
potential output by the MDFD component of the pHOS, which was recorded by the
4.2 METHODS 89
75
80
85
90
95
100 ~ 5 min of 80% SpO2
 1   2   3   4   5      6         7        8         9     10 11 12 13 14 15 16  17
0 120 240 360 480 600 720 840 960 1080
Time ( s)
Sp
O
2 
(%
)
Figure 4.4 – Illustrative example of epoch selection during hypoxia challenge in a single volunteer.
TCD software via ADC and Trendface via a modified pressure monitor interfaced with
the IntelliVue monitor. After synchronisation of all measured signals, the measured
oxygen (O2) and CO2 partial pressure waveforms were processed by selecting the mean
of the maximum and minimum 5% of readings to yield the inspired and end-tidal gas
partial pressures. The TCD-measured velocity envelope, SpO2, heart rate and arterial
blood pressure were all averaged over 3.2-second periods to coincide with the sampling
period of the pHOS and the resulting data synchronised with the NIRS data yielded
from the pHOS, resulting in a single combined dataset for each subject.
Each subject varied in their physiological responses to the individual challenges. In
order to allow averaging across subjects despite this, for each challenge in each subject,
the recorded data were split in to 17 epochs on the basis of the observed (systemic)
physiological response to the challenge.
For the hyperoxia, hypercapnia and hypocapnia challenges, the beginning and end
of the challenge periods were identified from the corresponding inspired or end-tidal
gas partial pressures. This challenge period was split in to 8 epochs of equal length
(termed Epochs 2–9); Epoch 1 was defined as the time period immediately preceding
the commencement of the challenge; Epochs 10–17 were defined as those epochs
immediately following the completion of the challenge period. All epochs were of equal
length, that length being defined in the initial split of the challenge period. Examples
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Figure 4.5 – Illustrative example of epoch selection during hyperoxia challenge in a single volunteer.
4.2 METHODS 90
0 120 240 360 480 600 720 840 960 1080
Time ( s)
5
6
7
8
9
~ 5 min of 6% CO2
1   2   3   4   5   6   7   8   9  10 11 12  13 14 15 16 17
Et
C
O
2 
(k
Pa
)
Figure 4.6 – Illustrative example of epoch selection during hypercapnia challenge in single volunteer.
illustrating this process in individual subjects’ datasets are shown in Figures 4.5, 4.6
and 4.7.
The hypoxia challenge differed from the others in that it contained an induction
phase – that is, the time between the commencement of hypoxic gas mix inhalation
and reduction of SpO2 to 80% – which varied in length from individual to individual;
this mandated a different approach to epoch selection. First, the onset of the induction
period and end of the plateau period were identified by inspection of the measured
FiO2. The onset of the plateau period was identified from the measured SpO2. The
induction and plateau period were then each split in to 4 epochs of equal length
(termed Epochs 2–5 for induction and Epochs 6–9 for plateau). The period following
the plateau was split in to eight epochs (Epochs 10–17), each the same in length as
Epochs 2–5. An illustrative example of this process as carried out in an experimental
subject is shown in Figure 4.4.
In each of epochs in each of the challenges, representative NIRS and systemic
physiological data were derived by averaging the values final 9× 3.2s.
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Figure 4.7 – Illustrative example of epoch selection during hypocapnia challenge in single volunteer.
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Figure 4.8 – Photograph of volunteer with all monitoring in situ (reproduced with permission of subject).
4.2.6 Statistical analysis
Statistical analysis was carried out in SPSS (PASW Statistics for Windows, version 18.0,
SPSS Inc, Chicago, IL) and R [29]. Normality was assessed through the use of Q-Q plots.
For each of the four challenges, two sets of comparisons were made.
First a comparison of group means (for each measured variable) between the baseline
epoch (Epoch 1) and each subsequent epoch in the challenge protocol was performed.
This was achieved by first using repeated measures analysis of variance (ANOVA) with a
Greenhouse-Geisser correction for sphericity. If this showed a significant change, post-
hoc tests with Bonferroni corrections were used to calculate the statistical significance
of the observed mean changes in Epochs 2–17 compared to baseline Epoch 1.
Second, a comparison was made between the mBLL-derived chromophore concen-
tration changes between the four source-detector separations at each time point. A
repeated-measures ANOVA with Greenhouse-Geisser correction was again used to de-
termine whether there was a significant difference between the varying source-detector
separations; if this showed statistically significant variation, then post hoc tests with
Bonferroni corrections were used determine the statistical significance of changes when
compared to the neighbouring detectors.
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Unless otherwise stated, all data are expressed as mean±standard error of mean
(SEM). Statistical significance was inferred at p<0.05.
4.3 RESULTS
Each challenge was completed in 15 subjects (22 subjects took part in total, but not
all completed every challenge). Demographic data is shown in Table 4.1. With regard
to statistical significance, p-values reported in the text below are those derived from
the repeated-measures ANOVA; where statistical significance is indicated in Figures
4.9–4.16, these were derived from the post-hoc testing comparing either individual
Epochs to the baseline Epoch, or adjacent detectors during the same epoch. We were
unable to resolve SRS-derived chromophore measures for 3 volunteers in hypoxia and
hypocapnia studies, and for 2 volunteers in the hyperoxia and hypercapnia studies –
the TOS figures quoted are thus for 12 and 13 volunteers, respectively.
4.3.1 Hypoxia
PHYS IOLOG ICAL VAR IABL E S Reduction of FiO2 resulted in a reduction in
SpO2 to 80 ± 1.3 % (p<0.001) by the end of the challenge period. Changes in physiolo-
gical variables are shown in Table 4.2 and Figure 4.9. Statistically significant increases
in heart rate and VMCA were also seen (both p<0.001), as was a statistically significant
reduction in etCO2 (p<0.01). Baseline VMCA was 61.6±3.5 cm.s−1.
Of note, throughout the experiments, the baseline SpO2 was approximately 97.5%,
rather than the 99-100% that would be expected for a set of healthy volunteers. We
ascribe this to an equipment-related error pertaining to the interfacing between the
pulse oximeter, which outputted an analogue signal which required re-digitisation
for recording. This discrepancy was noted during the experiments, but after several
volunteers had already completed the experiments, and a decision taken to continue
without applying an extra scaling factor to all experiments to correct for this.
CHROMOPHORE CONCENTRAT ION Figure 4.9 shows changes in [oxCCO],
[HbT] and [HbDiff] during hypoxia and recovery at the 35mm source-detector separa-
tion. Reductions in [oxCCO] and [HbDiff] were seen, accompanied by an increase in
[HbT] (p<0.001 for all). Changes for each source-detector combination are shown in
Figure 4.13. The direction of change was consistent – i. e. a reduction in mean [oxCCO]
and [HbDiff] and increase in [HbT] – was seen in each Epoch of the challenge period
for each of the source-detector separations. A statistically significant difference in mean
[oxCCO] between one detector and its neighbour was observed in 10/30 post-hoc
comparisons between a detector and its neighbour during the induction or challenge
Epochs; such a change was observed in 12/30 comparisons in the case of [HbDiff] and
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only 1/30 in the case of [HbT]. A significant reduction in TOS was seen (p<0.001), as
shown in Figure 4.17a.
VASOVAGAL SYNCOPE One subject suffered from a vasovagal syncope during
the hypoxia challenge. He was excluded from the group for analysis, but the findings
from his study are discussed below in Section 4.4.6.
4.3.2 Hyperoxia
PHYS IOLOG ICAL VAR IABL E S Increase in FiO2 resulted in an increase in mean
etO2 from 14.3 ± to 89.2 ± 1.4 kPa (p<0.001) with a corresponding increase in
SpO2 (p<0.01). Changes in measured physiological variables are shown in Table 4.2
and Figure 4.10. Statistically significant reductions in etCO2 (p<0.01) and heart rate
(p<0.05) were also seen. No statistically significant change was observed in VMCA,
with a baseline flow of 60.7±3.1 cm.s−1.
CHROMOPHORE CONCENTRAT ION Figure 4.10 shows changes in chromo-
phore concentration at the 35mm source-detector separation; the changes observed
were the inverse of those seen during hypoxia, with increases in [oxCCO] and [HbDiff]
and a reduction in [HbT] (all p<0.001). Changes for each source-detector combination
are shown in Figure 4.14. As was the case with the hypoxic challenge, there was a
consistent direction of change was consistent, with an increase in mean [oxCCO] and
[HbDiff] and reduction in mean [HbT] seen for each of the source-detector separations
during the induction and challenge Epochs of the study. A statistically significant dif-
ference in mean [oxCCO] between one detector and its neighbour was observed in
8/30 post-hoc comparisons between a detector and its neighbour during the induction
or challenge Epoch, but only in 3/30 comparisons in the case of [HbDiff] and no
significant difference was seen between detectors in for [HbT]. A significant increase in
TOS was seen (p<0.05), as shown in Figure 4.17b.
4.3.3 Hypocapnia
PHYS IOLOG ICAL VAR IABL E S Changes in measured physiological variables are
shown in Table 4.2 and Figure 4.11. Hyperventilation resulted in a reduction in etCO2
from 5.3 ± 0.2 to 3.0 ± 0.1 kPa, with a corresponding reduction in VMCA by 30 ±
2.3% from a baseline flow rate of 56.6±4.1 cm.s−1; both changes were statistically
significant (p<0.001). A statistically significant increase in heart rate was also seen. An
increase in mean arterial pressure (MAP) was observed (p<0.05), although post-hoc
testing revealed no change during the challenge period, but there was a statistically
significant increase observed in a single Epoch during the recovery period. Heart rate
showed a significant increase (p<0.001).
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Figure 4.9 – Physiological variables and chromophore concentration with 35mm detector during hypoxia
challenge. All figures are mean with error bars showing SEM. * - statistically significant (p<0.05) difference
when compared to baseline Epoch (Epoch 1).
4.3 RESULTS 95
*
*
*
* * * *
*
*
* * * *
et
O
2 
(k
Pa
)
20
40
60
80
100
Epoch
1 5 9 14
*
*
*
* * * * * *
*
*
et
C
O
2 
(k
Pa
)
5.0
5.2
5.4
5.6
*
*
* *
* *
* * *
* *
*
*
∆
V
M
C
A
 (%
)
−5
0
5
* * * * * * * *
MAP
HR
M
A
P 
(m
m
H
g)
  /
 H
R
 (B
PM
)
70
80
90
*
* * * * * * * *
*
*
*
*
* *
* * * * *
*
* * *
[HbT]
[HbDiff]
H
bD
iff
/H
bT
 (µ
M
)
−2
−1
0
1
2
3
*
* *
* * * * *
*
* *
ox
C
C
O
 (µ
M
)
0
0.1
0.2
0.3
Figure 4.10 – Physiological variables and chromophore concentration with 35mm detector during hyperoxia
challenge. All figures are mean with error bars showing SEM. * - statistically significant (p<0.05) difference
when compared to baseline Epoch (Epoch 1).
4.3 RESULTS 96
CHROMOPHORE CONCENTRAT ION As shown in Figure 4.11, hyperventila-
tion was associated with reductions in concentrations all chromophores (p<0.01 for
[oxCCO] and [HbT]; p<0.05 for [HbDiff]). Changes for each source-detector combina-
tion are shown in Figure 4.15. While the direction of change was consistent – i. e. there
was a reduction in each of the chromophores seen in in each Epoch of the challenge
period for each of the source-detector separations during the induction and challenge
periods. A statistically significant difference in mean oxidised-reduced cytochrome
c oxidase (oxCCO) between one detector and its neighbour was observed in 8/30
post-hoc comparisons between a detector and its neighbour during the induction or
challenge Epochs; this was the case in 13/30 comparisons of [HbT], but with smaller
magnitude changes seen at the most distal (35mm) detector. There was no significant
difference between detectors in [HbDiff] measurements. A significant reduction in TOS
was seen (p<0.05), as shown in Figure 4.17c.
4.3.4 Hypercapnia
PHYS IOLOG ICAL VAR IABL E S The delivery of a hypercapnic mix resulted in an
increase in etCO2 from 5.1 ± 0.1 to 7.7 ± 0.2 kPa, with a corresponding increment
in VMCA by 59.1±6.0% from a baseline flow rate of 60.6±7.6 cm.s−1; both changes
were statistically signficant (p<0.001). Significant increases in MAP (p<0.01) and heart
rate (p<0.05) were also seen, as shown in Table 4.2 and Figure 4.12.
CHROMOPHORE CONCENTRAT ION As shown in Figure 4.12, changes in
chromophore concentration during hypercapnia were the inverse of those seen during
hypocapnia, with reductions in [oxCCO] and [HbDiff] (p<0.001) as well as [HbT]
(p<0.01). Changes for each source-detector combination are shown in Figure 4.16. The
direction of change was consistent with an increase in chromophore concentration
seen in each Epoch of the challenge period for each of the source-detector separations.
Larger increases in [oxCCO] were seen in more distal detectors, whereas [HbT] showed
smaller changes in the more distal detectors; there was no clear pattern with [HbDiff].
A statistically significant difference in mean [oxCCO] between one detector and its
neighbour was observed in 22/30 post-hoc comparisons between a detector and its
neighbour during the induction or challenge Epochs; such a change was observed
in 7/30 comparisons in the case of [HbDiff] and only 2/30 in the case of [HbT]. A
significant increase in TOS was seen (p<0.001), as shown in Figure 4.17d.
4.3.5 Comparison of changes in ecDO2 with estimated CMRO and chromophore
concentration changes
Plots comparing ecDO2 to changes in ∆[HbDiff], ∆[oxCCO], both absolute and
individual-changes in TOS and estimated CMRO are shown in Figures 4.20 and 4.21.
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Figure 4.11 – Physiological variables and chromophore concentration with 35mm detector during
hypocapnia challenge. All figures are mean with error bars showing SEM. * - statistically significant (p<0.05)
difference when compared to baseline Epoch (Epoch 1).
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HYPOX IA HYPEROX IA HYPOCAPN IA HYPERCAPN IA
n 15 15 15 15
Age (years) 30±4 30±4 31±4 30±3
Gender (m:f) 10:5 10:5 9:6 11:4
Table 4.1 – Demographic data for volunteers.
4.3.6 DPF and scattering
Mean baseline values for DPF used for the 30 and 35mm detectors, as well as µ′s for
each experiment, are shown in Table 4.3. There was no change in µ′s for any of the
experiments at any wavelength.
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Figure 4.12 – Physiological variables and chromophore concentration with 35mm detector during
hypercapnia challenge. All figures are mean with error bars showing SEM. * - statistically significant (p<0.05)
difference when compared to baseline Epoch (Epoch 1).
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Figure 4.13 – Chromophore concentration for each detector during hypoxia challenge. All figures are mean,
with SEM error bars shown for the SpO2. The bars placed over the chromophore plots indicate a statistically
significant (p<0.05) difference in chromophore concentration between a detector and its neighbour, where
the dark grey box indicates a difference between the 35-30mm pair, light grey indicates a difference
between the 30-25mm pair and the white box indicates a difference between the 25-20mm pair.
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Figure 4.14 – Chromophore concentration for each detector during hyperoxia challenge. All figures are
mean, with SEM error bars shown for the etO2. Statistically significant differences between detectors are
indicated by the overlying bars as in Figure 4.13.
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Figure 4.15 – Chromophore concentration for each detector during hypocapnia challenge. All figures are
mean, with SEM error bars shown for the etCO2. Statistically significant differences between detectors are
indicated by the overlying bars as in Figure 4.13.
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Figure 4.16 – Chromophore concentration for each detector during hypercapnia challenge. All figures are
mean, with SEM error bars shown for the etCO2. Statistically significant differences between detectors are
indicated by the overlying bars as in Figure 4.13.
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Epoch 1 Epoch 9
H
Y
P
O
X
IA
MAP (mmHg) 84.2 ± 1.6 88.1 ± 4.3
HR (BPM) 72.6 ± 3.4 88.6 ± 4.1 *
SpO2 (%) 97.4 ± 0.6 80.0 ± 1.3 *
etCO2 (kPa) 5.5 ± 0.2 5.2 ± 0.1 *
∆VMCA(%) 0 14.3 ± 3.7 *
H
Y
P
E
R
O
X
IA
MAP (mmHg) 88.7 ± 3.3 88.7 ± 3.3
HR (BPM) 74.2 ± 3.1 70.5 ± 2.5 *
SpO2 (%) 97.2 ± 0.5 98.2 ± 0.6 *
etO2 (kPa) 14.3 ± 0.3 89.2 ± 1.4 *
etCO2 (kPa) 5.5 ± 0.1 5.1 ± 0.1 *
∆VMCA(%) 0 −3.5 ± 2.3
H
Y
P
O
C
A
P
N
IA MAP (mmHg) 91.3 ± 4.7 96.8 ± 7.2
HR (BPM) 75.3 ± 2.3 91.0 ± 2.2 *
SpO2 (%) 97.4 ± 0.5 97.3 ± 1.1
etCO2 (kPa) 5.3 ± 0.2 3.0 ± 0.1 *
∆VMCA(%) 0 −30.0 ± 2.3
H
Y
P
E
R
C
A
P
N
IA MAP (mmHg) 90.2 ± 4.3 105.6 ± 4.2 *
HR (BPM) 72.5 ± 3.0 81.5 ± 3.4 *
SpO2 (%) 97.7 ± 0.5 97.4 ± 0.5
etCO2 (kPa) 5.3 ± 0.1 7.7 ± 0.2 *
∆VMCA(%) 0 59.1 ± 6.0 *
Table 4.2 – Changes, expressed as mean ± SEM, in physiological variables for volunteers at baseline (Epoch
1) and at the end of each challenge (Epoch 9).
HYPOX IA HYPEROX IA HYPOCAPN IA HYPERCAPN IA
DPF 7.45± 1.19 6.98± 1.04 6.93± 0.97 7.17± 0.96
µ′s (cm−1) 8.98± 0.37 8.91± 0.43 9.26± 0.41 8.87± 0.41
Table 4.3 – DPF used and µ′s at baseline (i. e. Epoch 1).
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Epoch 1 Epoch 9
H
Y
P
O
X
IA
∆[HbDiff] (µM) 0 −7.50± 0.52*
∆[HbT] (µM) 0 3.10± 0.50*
∆[oxCCO] (µM) 0 −0.55± 0.09*
TOS (%) 69.6 ± 2.5 61.6 ± 1.9 *
∆TOS (%) 0 −8.0 ± 2.0 *
H
Y
P
E
R
O
X
IA
∆[HbDiff] (µM) 0 2.29± 0.33*
∆[HbT] (µM) 0 −1.54± 0.23*
∆[oxCCO] (µM) 0 0.24± 0.05*
TOS (%) 64.5 ± 3.5 66.9 ± 4.2
∆TOS (%) 0 2.4 ± 1.1 *
H
Y
P
O
C
A
P
N
IA
∆[HbDiff] (µM) 0 −1.06± 0.31*
∆[HbT] (µM) 0 −1.13± 0.33*
∆[oxCCO] (µM) 0 −0.27± 0.07*
TOS (%) 64.6 ± 4.2 62.8 ± 3.8
∆TOS (%) 0 −1.8 ± 0.7 *
H
Y
P
E
R
C
A
P
N
IA
∆[HbDiff] (µM) 0 2.86± 0.58*
∆[HbT] (µM) 0 0.92± 0.42*
∆[oxCCO] (µM) 0 0.58± 0.11*
TOS (%) 64.3 ± 4.1 69.3 ± 3.9
∆TOS (%) 0 5.0 ± 1.2 *
Table 4.4 – Changes, expressed as mean ± SEM, in chromophore concentration and TOS for volunteers at
baseline (Epoch 1) and the end of each challenge (Epoch 9). * - p < 0.05 compared to baseline. Note both
absolute values for TOS and changes from baseline are shown, but statistical comparison only reported for
the latter.
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Figure 4.17 – Mean TOS four each of the four challenges.
4.4 DI SCUSS ION 107
4.4 DI SCUSS ION
We manipulated CBF and ecDO2 in 15 healthy volunteers whilst measuring chro-
mophore concentration at 4 source-detector separations and TOS. Analysis of the
relationships between change in chromophore concentration, source-detector separ-
ations and changes in ecDO2 – summarised in Table 4.5 discussed in detail below
– confirms that ∆[oxCCO] is the most ‘brain-specific’ NIRS-derived measure of brain
oxygen delivery. Further qualitative examination suggests that ∆[oxCCO] measurement
more closely reflects changes in ecDO2 and thus may be a superior biomarker of
cellular energy status.
4.4.1 Physiological changes induced by challenges
All challenges induced the expected changes in measures of systemic oxygenation
and CBF, although some changes in potentially confounding systemic physiological
variables did occur.
The sequential gas delivery circuit did not succeed in completely stabilising etCO2,
and we observed a reduction in etCO2 from 5.5 to 5.2 kPa comparing baseline to
end-of-challenge epochs, likely caused by an increase in minute volume as a result
of hypoxic drive [30]. Despite this, VMCA showed a mean increase of 14.3%, which
could be explained by the occurrence of hypoxic vasodilation [31,32] but also may
have been driven by the increase in heart rate, which increased from 72.6 to 88.6 BPM,
comparing baseline to end-of-challenge epochs. The combined effect of the reduction
in SpO2 and increment in VMCA was to produce a change in ecDO2 to 93.6±2.6%
(mean±SEM) of baseline values.
The increase in etO2 that was observed following hyperoxia, with an increase from
14.3 to 89.2 kPa was associated with modest reductions in HR, VMCA and etCO2.
Hyperventilation induced a reduction in etCO2 from 5.3±0.2 kPa to 3.0±0.1 kPa.
There was an associated increase in HR from 75.3±2.3 to 91.0±2.2 BPM, which we
speculate was caused by the increased work of breathing and reduction in intrathoracic
pressure/preload that hyperventilation entailed. Despite these increments in HR and
MAP, there was an overall reduction in VMCA of 30%; as SpO2 was stable, this
reduction in VMCA was the main cause for the observed reduction in ecDO2 to 69.8%
of baseline values.
The delivery of a hypercapnic mix for the hypercapnia challenge was associated with
an increment in etCO2 from 5.3±0.1 to 7.7±0.2 kPa, inducing an increase in VMCA
by 59.1±6.0% from baseline levels. There were associated increases in HR and BPM,
both well-recognised effects of hypercapnia [33]. As with the hypocapnia challenge,
SpO2 remained unchanged, so the change in ecDO2 mirrored that of VMCA, with an
increase to 158.6% of baseline values.
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Figure 4.18 – Graphs comparing ecDO2 and changes in ∆[HbDiff] at 20 and 35mm; changes in ∆[HbDiff]
shown to same scale
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Figure 4.19 – Graphs comparing ecDO2 and changes in ∆[oxCCO] at 20 and 35mm; changes in ∆[oxCCO]
shown to same scale
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Figure 4.20 – Graphs comparing ecDO2, absolute TOS and changes in TOS
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Figure 4.21 – Graph comparing ecDO2 to estimated CMRO
4.4.2 Changes in UCLn-derived chromophore concentration at 35mm
Chromophore changes at the 35mm source-detector separation ought to be the most
reflective of true changes in brain chromophore concentration, as discussed below;
we consider these first. The changes observed in haemoglobin measures at 35mm
were consistent with those expected by basic physiological principles outlined in
Chapter 1. Hypocapnia was associated with a reduction [HbT], hypercapnia conversely
associated with increase, consistent with the vasodilatory effect of carbon dioxide and
consistent with the observed changes in VMCA. In both these challenges, changes in
[HbDiff] mirrored those in [HbT], which would be consistent an increase in CBV caused
by vasodilation. Hypoxia was associated with an increase in [HbT] and hyperoxia a
decrease. In the case of the hypoxia challenge, the reduction in arterial oxygenation
was enough to cause a reduction in [HbDiff], with the converse being true during
the hyperoxia challenge. In summary: the direction of group mean changes in [HbT]
mirrored CBF, and group mean changes in [HbDiff] mirrored those in cDO2 measures.
The pattern of [oxCCO] changes at 35mm similarly mirrored changes in ecDO2.
The pattern of chromophore change is entirely concordant with those previously
reported in the literature [10,34]. There were differences in magnitude of chromophore
change – in a hypoxia study Tisdall and colleagues [10] found different median changes
in [HbDiff] and [oxCCO] compared to this study; they reported [HbDiff] changes of -
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12.7µM compared to our change of -7.5µM and [oxCCO] changes of -0.24µM compared
to our finding of -0.55µM. Tachtsidis and colleagues investigated the effects of hyperoxia
and hypercapnia on haemoglobin and CCO oxidation/concentration [34]. They found
hyperoxia resulted in larger [HbDiff] changes (+4.6µM) but larger changes in [HbT]
and [oxCCO] (-1.3µM and +0.09µM, respectively) compared to our study. They also
found that hypercapnia resulted in much larger changes in [HbDiff] and [HbT] (+7.4µM
and +2.6µM, respectively), although oxCCO changes were smaller (+0.25µM). The
hyperoxia/hypercapnia paradigms used by Tachtsidis et al. were broadly comparable
to those used in our current study, although surprisingly, we achieved a significantly
higher increase in VMCA (+59.1% in our study, compared to +14.9%).
One explanation for the differences in magnitude of chromophore is that the previous
studies have used the second differential of water for calculation of DPF. During the
hypoxia studies carried out by Tisdall et al. (reported in his MD Thesis [35] but not in
the literature), the use of second water differential gave rise to a pathlength of 12.5cm,
equating to a DPF of 3.6. This compares to a DPF of between 6.93 and 7.46 in our study;
this might explain some of the significantly smaller chromophore concentration changes
in our study (see Equation 3.10). It is also possible that differences in experimental
paradigm could explain these differences, as our study used a prolonged hypoxic
challenge, whereas Tisdall and colleagues used a brief ‘swing’ with the maximum
hypoxic period only sustained for a few seconds, as opposed to several minutes in our
experiment.
4.4.3 Changes in TOS
The broadband SRS methodology we used to derive TOS is novel, and to our knowledge,
the first use of broadband SRS to measure TOS in the adult human head – although
such methodology has been reported for skin recording [36]. The aim of this study was
not, however, to develop an improved SRS methodology, but rather to concurrently
measure TOS whilst measuring chromophore concentration with the UCLn algorithm
at different source-detector separations, using the same optode array. Comparison with
previous studies using established NIRS apparatus revealed that the baseline values and
changes that we observed in TOS were consistent with those reported in the literature.
Mean baseline values of TOS were approximately 65–70%, depending on experiment,
although there was a high degree of intersubject variability and an overall (individual
subject) baseline range of 55.0–88.6%. Changes in TOS mirrored those in oxygen
delivery (DO2), as shown in Table 4.4 and Figures 4.20a & 4.20b.
Tisdall et al. found similar magnitude TOS changes with a two-distance, 3-wavelength
commercially available apparatus (HamamatsuNIRO-300), findingmedian TOS changes
of -7.0% during hypoxia, +2.3% during hyperoxia, -2.1% during hypocapnia and
+2.6% during hypercapnia – all changes that are markedly similar in magnitude to
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those we report in this study, despite the differences in SRS algorithms, suggesting that
this methodology of broadband SRS TOS measurement is relatively veracious.
One aspect that warrants further investigation is the wavelength range used to derive
chromophore concentration with the SRS methodology. For SRS-derived measures, we
used the wavelength range 740–900nm, whereas for the UCLn-derived chromophore
concentrations, we used the wavelength range 780–900nm. Our original intention
was to use the latter range for both methodologies for the sake of consistency. For the
University College London n-wavelength (UCLn)-derived measures, our intention was
to investigate oxCCO, and we thus wished to include the 830nm peak (as shown in
Figure 3.6), but wished to avoid distortion induced by the prominent 760nm peak of
deoxyhaemoglobin (shown in Figure 3.5). Furthermore, this is consistent with previous
studies we have reported using both this and other broadband spectrometers [10,34,37,
38]. We initially used this wavelength resolution range for broadband SRS, but signals
appeared to have significant levels of noise and some results were physiologically
implausible, including negative absolute concentrations of deoxyhaemoglobin and
subsequently TOS figures in excess of 100%. This prompted us to undertake a systematic
approach to debugging the algorithm; when analysis was repeated using the wavelength
range 740-900nm, far more plausible figures resulted. It is possible that the extra
noise induced by the use of 4 separate detectors is the cause for these physiologically
impossible figures, and perhaps the use of the broader wavelength resolution range has
allowed for an improved signal-to-noise ratio and thus more realistic results. We have
previously compared the use of the 740-900nm and 780-900nm wavelength resolution
ranges when using differential (i. e. UCLn) spectroscopy and found no significant
differences between the two methods [15]. Systematic investigation of this aspect of
the broadband SRS algorithm is required to affirm its robustness.
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OBSERVED CHANGE IN :
SYSTEM IC
PHYS IOLOGY
CBF ecDO2 ∆[oxCCO] ∆[HBDI F F] & ∆[HBT] TOS
HYPOX IA SpO2 ↓ to 80.0%;
HR ↑; BP↔
VMCA ↑ by
14.3%
↓ to 93.6%
baseline level
↓ with larger
reduction with
longer
source-detector
separation
[HbDiff] ↓, [HbT] ↑. Larger changes with
longer source-detector separation for
[HbDiff] but not [HbT]
Absolute ↓ 8%
HYPEROX IA etO2 and SpO2 ↑
; etCO2 ↓; HR ↓
↔ Unable to
determine
↑, with larger
increases with
longer
source-detector
separation
[HbDiff] ↑ & [HbT] ↓; no any clear
association between source-detector
separation & magnitude
Absolute ↑ 2.4%
HYPOCAPN IA etCO2 ↓ to 3.0
kPa; BP & HR ↑
VMCA ↓ by 30% ↓ to 69.8%
baseline level
↓ with larger ↓
with longer
source-detector
separations
∆[HbDiff] and ∆[HbT] ↓; significantly larger
changes with longer source-detector
separation for ∆[HbT] but not ∆[HbDiff]
Absolute ↓ 2.3%
HYPERCAPN IA etCO2 ↑ from 5.1
to 7.7 kPa; HR
and MAP ↑
VMCA ↑ by
59.1%
↑ to 158.6%
baseline level
↑, with larger
increases in
longer
source-detector
separations
[HbDiff] and [HbT] ↑; smaller [HbT]
changes at longer source-detector
separations; no clear relationship between
source-detector separation and magnitude
of ∆[HbDiff]
Absolute ↑ 4.5%
Table 4.5 – Summary of observed changes in systemic physiology, CBF, ecDO2 and NIRS parameters during different challenges
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4.4.4 Depth sensitivity and brain-specificity
Longer source-detector separations are associated with an increased partial pathlength
in brain – that is, a larger proportion of backscattered photons will have passed through
brain tissue [39,40] – thus chromophore concentrations derived from longer source-
detector separations reflect changes in brain chromophore concentration to a larger
extent than shorter ones, which reflect skin changes [41]. Despite this, even at longer
source-detector separations, extracranial ‘contamination’ of NIRS signals is an acknow-
ledged issue (as discussed in Chapter 3.2.2 and [2]). Whilst the use of SRS has served
to mitigate this somewhat, extracranial tissues have still been proven to contribute
significantly to changes in TOS [4,42].
A key aim of this experiment was to investigate the difference in observed chromo-
phore concentration change at different source-detector separations in response to the
four experimental challenges. Figures 4.13–4.16 show the response of different chromo-
phores at each source-detector separation in response to each of these challenges. Our
results show changes in ∆[oxCCO] were consistently larger for longer source-detector
separations than changes in ∆[HbDiff] and ∆[HbT].
∆[HbT] showed no difference between detectors for the hyperoxia challenge, and
only a modest difference between detectors for the hypoxia and hypercapnia challenges.
Interestingly, a significantly larger reduction in shorter source-detector separations were
shown during the hypocapnia challenge, perhaps suggesting that the extracranial tissues
have a higher CO2 reactivity than brain (in response to hypocapnia, at least), although
there are no data in the literature supporting this notion.
Changes in [HbDiff] too generally showed larger changes at shorter distances than
longer ones in response to most of the challenges. This was particularly pronounced in
the response to hypoxia, as shown in Figure 4.13. A statistically significant difference
between a detector and its neighbour was also seen for a number of observations in
response to hyperoxia and hypercapnia.
In contrast, ∆[oxCCO] consistently showed larger changes for the longer source-
detector separations than the shorter ones. This was the case for each of the four
experimental challenges. This suggests that ∆[oxCCO] is the most brain-specific of
the UCLn-derived chromophore measures we report. This notion is also supported by
comparison between the 35mm and 20mm source-detector separations when com-
paring chromophore concentration change to changes in ecDO2. Comparing Figures
4.18a & 4.18b the pattern of ∆[HbDiff] response is substantially similar in between the
two source-detector separations, whereas comparing changes in ∆[oxCCO], as shown
in Figures 4.19a & 4.19b, the gradient of the curve of the line of best fit comparing
∆[oxCCO] to changes in ecDO2 is clearly shallower in the 20mm detector than the
35mm detector, which would be consistent with a significantly lower concentration of
CCO within the tissue volume interrogated at 20mm than 35mm.
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∆[oxCCO] ∆[HBDI F F] ∆[HBT]
HYPOX IA 85% 17% 67%
HYPEROX IA 81% 33% 67%
HYPOCAPN IA 93% 63% 8%
HYPERCAPN IA 94% 48% 30%
Table 4.6 – Scores of brain-specificity for each chromophore for each challenge
CCO has previously been suggested a brain-specific chromophore by virtue of its
posited high brain concentration compared to that in extracerebral tissues [3,10–12],
although there are no experimental data proving this notion. This in part because
the direct measurement of tissue CCO concentrations is technically challenging; CCO
activity can bemeasured through biochemical methods [43], but this only allows relative
measurement of enzyme concentration and function. Absolute measurements have
been described in rat brain, using differential spectroscopy with the [oxCCO] spectrum
in the presence of oxidising and reducing agents – Brown et al. found concentrations
of 5.5µM in the adult rat brain [44] – but such measurements have never been carried
out in the adult human brain or other tissue. An extracranial:cerebral concentration
ratio of 1:10 ratio of CCO has been posited [CE Cooper, personal communication],
but this has never been proven experimentally.
In order to clearly summarise the brain-specificity of each chromophore, we contrived
a supplementary score of brain specificity – shown in Table 4.6. This was derived by
individually inspecting each of the 15 datasets for each challenge and identifying the
point of maximum ∆[oxCCO] change. Subsequently, for each of the 60 datasets, we
assigned a score to the ∆[oxCCO], ∆[HbDiff] and ∆[HbT] based on whether a larger
change was seen in the longer detector source-detector pair comparisons. Scores were
summed for each of the challenges, and a final score of brain-specificity was calculated
as a percentage of the maximum possible score. This analysis again corroborates the
higher brain-specificity of ∆[oxCCO]. The higher brain specificity scores of [HbT] for
the hypocapnia and hypercapnia challenges may be reflective of the fact that these
challenges induce larger changes in CBV, whereas the hypoxia and hyperoxia challenges
resulted in larger brain specificity scores for ∆[HbDiff], which is considered to better
reflect changes in arterial oxygenation [2].
It should be note that the methodology used to create this score of brain specificity
uses the point of maximal CCO (as opposed to maximal [HbT] or [HbDiff]) change
as the point of comparison, and there is thus potential for this score to introduce bias
overstating the relative brain specificity of CCO when compared to the haemoglobin
measures.
4.4 DI SCUSS ION 117
4.4.5 Physiological interpretation
We aimed to establish the utility of ∆[oxCCO] as a marker of cerebral energy status. The
physiological plausibility of the changes observed in this study, as well as the reprodu-
cibility of ∆[oxCCO] measurement (i. e. consistency with previously reported literature)
serve to bolster the notion that these measurements are robust and not artefactual. This
notion is further reinforced through the observation that optical scattering, a significant
potential confounder, has shown no significant change during the challenges.
A qualitative examination of our results – in particular, when compared to ecDO2 as
shown in figures 4.18–4.21 – reveals several other features that suggest that ∆[oxCCO]
more closely represents changes in cDO2 than other NIRS-based measures. Comparing
changes in ecDO2 to changes in ∆[HbDiff], there appears to be a relatively linear
relationship between ecDO2 and ∆[HbDiff] for the hypocapnia/hypercapnia challenges,
whereas the the hypoxia challenge leads to a clearly distinct cluster of readings. The
same pattern is apparent on examining the relationship between changes in TOS
and ecDO2, as shown in Figure 4.20b. Examining the equivalent graph showing the
relationship between ecDO2 and ∆[oxCCO], shown in Figure 4.19a, the distinction
between the hypocapnia/hypercapnia challenges and the hypoxia challenges is far less
distinct. Two possible explanations for this are changes in the arterial:venous blood
volume ratio (A:V ratio) and physiological considerations specific to each challenge.
NIRS measures such as [HbDiff] and TOS will, in part, reflect changes in A:V ratio, but
such changes are not necessarily a matter of clinical interest. For example, hypocapnia
induced significant reductions in ecDO2, but only modest reductions in [HbDiff].
Conversely, the reductions in ecDO2 induced by hypoxia were much smaller, but the
reduction in [HbDiff] was much larger. The A:V ratio is typically approximately 1:3 [45],
and some studies of NIRS-measured TOS have suggested that the ratio contributing
to the TOS signal can be as low a 1:6 [46]. Thus, the reductions in arterial [HbO2]
induced by hypocapnic arterial vasoconstriction may be masked by the much larger
venous volume within the head – that is, hypocapnia resulted in a decrease in A:V
ratio. Although one would expect for a reduction in arterial [HbO2] to eventually result
in a reduction in venous [HbO2] (assuming constant CMRO), this analysis is unable to
account for the time it would take for this to occur. The distinction between the hypoxia
and hypocapnia/hypercapnia challenges, whilst still present, is far less apparent for the
relationship ∆[oxCCO], suggesting that oxCCO more closely reflects oxygen delivery.
Nevertheless, despite the fact that the individual data points are far more closely
grouped for the hypoxia and hypocapnia challenges for ∆[oxCCO], they do not overlap
– or rather, the same reduction in ecDO2 resulted in a larger ∆[oxCCO] reduction
during hypoxia challenges than for the hypocapnia challenges. There are potential
physiological explanations for this. For example, increases in pH are known to reduce
the affinity of haemoglobin for oxygen (discussed in Chapter 1.2 and shown in Figure
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1.1). Furthermore, hypocapnia resulted in reduced cDO2 by reducing CBF; as SpO2
remained constant, partial compensation could occur through an increase in oxygen
extraction fraction (OEF), thus attenuating the reduction in cellular and mitochondrial
oxygen delivery. Such a compensation would be less possible during the hypoxia chal-
lenges, where the affinity of haemoglobin for oxygen would be increased as a result of
lower pO2. Increased CO2 is also known to reduce CCO activity in plants [47], although
similar data in mammals do not exist. pH is also known to influence CCO oxidation,
with increases in pH known to induce reduction of CCO [48]; however, predicting the
effect of modulations in either arterial partial pressure of carbon dioxide (PCO2) or pO2
on mitochondrial pH is non-trivial. Mathematical models of cerebral circulation and
metabolism [49–52] have been proposed to aid in the interpretation of these complex
changes [53], and such models have been used to explore the physiological basis of
changes in NIRS signals during hypoxia [51,54], and such models have been used to
look at changes of VMCA and intracranial pressure during changes in arterial PCO2
[55], but no modelled data to explain the changes that we report in this study exist.
The relationship between this estimated CMRO and ecDO2 is shown in Figure 4.21.
However, this was calculated primarily as a contrast to the analysis to be described in
5, as the measurement is likely to be subject to confounding. We estimated CMRO
using a previously described approximation of the Fick equation [28]. The original Fick
equation states that:
CMRO = CBF× AVDO2. (4.5)
where AVDO2 is the arterio-venous oxygen concentration difference [56]. However,
the NIRS approximation uses the difference between SpO2 and TOS to estimate arterio-
venous oxygen concentration difference (AVDO2). As discussed above, changes in
A:V ratio can have a significant effect on TOS, and such changes can occur in the
absence of changes in AVDO2. This notion is bolstered by the fact that CMRO has
previously been shown to be independent of reductions in SpO2 to 70% in a cohort
of healthy volunteers, with the arguably more robust method of CMRO estimating,
by calculating CBF from ultrasound-measured internal carotid artery and vertebral
artery cross sectional areas and velocities, and arterial and jugular venous sampling to
calculate the AVDO2. The changes observed in Figure 4.21 are thus likely affected by
this confounding by changes in A:V ratio. The originators of NIRS-CMRO approximation,
interestingly, do not comment on the importance of ensuring that A:V ratios remain
stable in order to prevent such confounding.
4.4.6 Illustrative case: vasovagal syncope during volunteer hypoxia
This case has been
reported in a case
report in Advances in
Experimental
Medicine and Biology
[57].
During these experiments, one subject suffered from a vasovagal pre-syncope, providing
a further opportunity to demonstrate the relationship between ∆[oxCCO] and cerebral
4.4 DI SCUSS ION 119
∆ecDO2
Vmca
SpO2
ABP
60
70
80
90
100 SpO
2  (%
)
A B C D
B
lo
od
 P
re
ss
ur
e 
(m
m
 H
g)
20
40
60
80
100
V
m
ca
 (c
m
.s
-1
)/e
cD
O
2 
(%
)
40
60
80
100
Time (s)
0 100 200 300 400 500 600 700 800 900 1000 1100
Figure 4.22 – Changes in physiological variables during vasovagal syncope, with data averaging windows
indicated A – baseline; B – hypoxia; C – hypoxia-ischaemia; D – recovery. .
BASE L INE HYPOX IA HYPOX IA - I SCHAEMIA RECOVERY
ABP (mmHg) 85.4 88.9 32.1 83.5
HR (bpm) 78.0 117 41.3 101
VMCA (cm.s−1) 70.4 73.9 34.1 57.8
SPO2 (%) 100 72.6 86.3 99.4
ECDO2 (mmHg) 99.8 75.8 41.5 81.2
∆oxCCO (µM)
3.5cm 0 −0.74 −1.56 −0.13
3.0cm 0 −0.38 −0.62 0.008
2.5cm 0 −0.30 −0.55 0.045
2.0cm 0 −0.14 −0.16 0.23
Table 4.7 – Changes in systemic and cerebral physiology and CCO oxidation before, during and after
vasovagal syncope, with data averaging windows as indicated in Figure 4.22.
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Figure 4.23 – Changes in [HbDiff] and [HbT] during vasovagal syncope.
oxygen delivery during an episode of cerebral ischaemia more severe than one would
usually encounter in clinical practice. The 31 year-old male subject, who had been
screened for pre-existing medical conditions, suffered from vasovagal pre-syncope dur-
ing the hypoxia challenge. Approximately 600s after the commencement of recording,
during the nadir of hypoxia, the subject suffered from sudden onset bradycardia and
hypotension (a typical vasovagal episode[58]), resulting in a reduction in ecDO2 to
41.5% of baseline values. During this time, the subject became briefly unresponsive.
The planned experimental protocol and monitoring was otherwise as described in
Chapter 4.2. The changes in blood pressure, heart rate, VMCA and ecDO2 are shown
in Figure 4.22, with values over the specified data averaging windows shown in Table
4.7.
Individual time courses of [HbDiff]/[HbT] and ∆[oxCCO] are shown in Figures 4.23
and 4.24. The relationship between ecDO2 and ∆[oxCCO] is shown in Figure 4.25.
Whilst hypoxia is a recognised cause of syncope, the occurrence of bradycardia
and hypotension indicate a vasovagal aetiology [58], in this case, provoked by – as
the subject reported – the shock of seeing his reduced SpO2 reading. This vasovagal
response resulted in a profound reduction in cerebral blood flow (evidenced by both
reduced [HbDiff] and VMCA), and this led to a significant reduction in ecDO2.
The other experiments have achieved only modest reductions in ecDO2, leaving
questions unanswered about the relationship between ecDO2 and ∆[oxCCO] [10]. In
particular, it was unclear whether the relationship between ecDO2 and ∆[oxCCO] is
linear, or whether there was a threshold below which rapid reduction occurs. However,
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Figure 4.24 – Changes in [HbDiff] and [HbT] during vasovagal syncope.
∆[oxCCO] = (-2.6) + 0.026*ecDO2
r2 = 0.81, p < 0.001
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Figure 4.25 – Relationship between ecDO2 and ∆[oxCCO] during vasovagal syncope
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our data in Figure 4.25 suggest a linear relationship between ∆[oxCCO] and ecDO2
(r 2 = 0.81, p < 0.001). From this, the extrapolated value of ∆[oxCCO] of -2.6 µM with
zero cerebral oxygen delivery is suggestive of a resting oxidised ecDO2 concentration
of around 2.6 µM. Although no reduction of this size has been reported in humans
– understandably as a reduction in ecDO2 to zero is impractical in humans – these
values are consistent with those reported in animal anoxia models [12,59].
This single case, when considered in conjunction with the results of the larger cohort
of (uncomplicated!) studies, further underlines confidence in the ability to use NIRS to
measure ∆[oxCCO] as a marker of cellular energy status.
4.4.7 Optical scattering
We measured optical scattering at 790nm and found no significant change in optical
scattering for any of the four challenges. The scale of changes in oxCCO are an order
of magnitude lower than those seen in haemoglobin species, and thus the potential
for ‘cross-talk’, whereby changes in optical scattering are misrepresented as changes
in chromophore concentration, is thus a significant concern in the measurement of
∆[oxCCO] [12]. The range of cerebral oxygenation and blood flow during these chal-
lenges lies far outside those routinely encountered in clinical practice, confirming that
∆[oxCCO] will not be confounded by scattering under normal clinical conditions.
4.4.8 Limitations & Future work
Because we did not measure blood haemoglobin concentration, we could not accur-
ately calculate cDO2 and instead had to estimate it; measurement of haemoglobin
concentration would allow the estimation of absolute, rather than relative, cDO2, as
well as allowing for calculation of ecDO2 for the hyperoxia studies.
The major limitation to this study is, however, that the analysis and interpretation
of the data were qualitatively described. The statistical models for interrogating such
a wealth of data are limited; simple linear models would be inappropriate to apply
(due to the repeated measures and non-independence of measurements) and repeated
statistical testing on the same data set re-presented in different convolutions, as has
been performed in this study, runs the risk of inducing type I errors. Rather, a far more
fruitful approach to understanding the physiological basis of the observed changes
is likely to be through physiological rather than statistical analysis, through the use
of mathematical models of cerebral haemodynamics and metabolism as previously
described [49–52,55].
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4.5 CONCLUS ION
This study has shown a clear relationship between ∆[oxCCO] and changes in cDO2
induced through both changes in CBF and arterial oxygenation in a cohort of healthy
volunteers. The results suggest that ∆[oxCCO] is a robust and useful biomarker of
cerebral energy status. In the next chapter, we describe the measurement of changes in
∆[oxCCO] in a cohort of patients with acute brain injury.
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5
EF F ECTS OF NORMOBAR IC HYPEROX IA ON CYTOCHROME C
OXIDASE IN PATIENTS WITH ACUTE BRAIN INJURY
This chapter describes the use of the hybrid optical spectrometer (pHOS) in a cohort This chapter draws
heavily on a paper
published in the
Journal of Cerebral
Blood Flow and
Metabolism [1].
of patients who had suffered from acute brain injury (ABI). The pHOS was used in a
single-channel, single-distance configuration to measure changes in oxyhaemoglobin
concentration ([HbO2]), deoxyhaemoglobin concentration ([HHb]) and concentration
of oxidised-reduced cytochrome c oxidase ([oxCCO]) at 3.5cm, and also four distances
to perform spatially-resolved spectroscopy (SRS) to measure tissue oxygen saturation
(TOS). A multimodal monitoring array was used to measure variables related to cereb-
ral oxygen delivery and metabolism, and the relationship between these variables
and the pHOS-measured ∆[oxCCO] explored in order to better understand the patho-
physiology of ABI and establish the utility of ∆[oxCCO] as a clinical biomarker of
hypoxia/ischaemia.
5.1 INTRODUCT ION
The high metabolic demand of the brain make it critically dependent on oxidative meta-
bolism to generate adequate energy – in the form of adenosine 5‘-triphosphate (ATP) –
to sustain function and survival. As discussed in Chapter 2, there are a wide variety of
primary ABI processes, including trauma, thrombotic/embolic ischaemia, subarachnoid
haemorrhage (SAH) and intracerebral haemorrhage (ICH), but hypoxia/ischaemia is
a central pathogenic process – either as the primary injury or as a secondary injury
process. The consequent lapses in oxygen and substrate supply can result in failure
of cellular energy generation, an event that sets in motion a variety of inflammatory,
excitotoxic, oxidant, apoptotic, and necrotic cascades that lead to cell death and thus
poor functional outcome, as summarised in Figure 2.3 [2–4].
The avoidance of hypoxia/ischaemia is thus critical to the neurocritical care manage-
ment of ABI and, as described in Chapter 2, this requires the use of clinical monitors that
are able to identify hypoxia/ischaemia. Monitors such as transcranial Doppler (TCD)-
based measures of cerebral blood flow (CBF) and brain partial pressure of oxygen
(PbrO2) describe cellular substrate delivery, but mitochondrial dysfunction also plays a
significant role in the pathophysiology of ABI [2,5], with two important consequences:
first, cellular energy failure – that is, an inability to generate sufficient ATP to sustain
normal function and repair – can occur in the presence of adequate substrate delivery
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[6] and second, the leak of electrons from a dysfunctional mitochondrial electron trans-
port chain (ETC) leads to the dual effects of cytotoxic reactive oxygen species (ROS)
generation and decoupling of substrate oxidation from ATP generation [7–10].
For these reasons, the ideal clinical monitor would encompass a measure of oxygen
utilisation as well as delivery, yet, there are no ideal means of identifying impaired oxid-
ativemetabolism following ABI. The (CMRO)canbemeasuredusingpositronemissiontomography (PET )[11], butthistechniquerequirestheuseofunstablerareradionucleotidesandfurthermoreinvolvesthetransferofcritically −
illbrain− injuredpatientstotheradiologysuite−−itselfariskyprocedure; alternatively , relativechangescanbeestimatedusingCBFandoxygenextractionfraction(OEF ), forexamplethroughcombineduseof TCDultrasoundflowmeasurementandmeasurementsofarterio−
venousoxygendifferences [12]or nearinfraredspectroscopy (NIRS)−derivedmeasurementof TOS [13].Microdialysatelactate :
pyruvateratio(LPR)isanothersurrogateofintracellularenergystatus, beinglinkedtointracellular nicotinamideadeninedinucleotidehydride(NADH)levels [14], butitisinvasive, requiringtheplacementofanintraparenchymalcatheter .TheuseofmultimodalneurologicalmonitoringwitharraysofmonitorsincludingPbrO2
and microdialysate LPR has allowed the investigation of the relationship between oxy-
gen (O2) delivery, tissue oxygenation and surrogates of oxidative metabolism following
traumatic brain injury (TBI), SAH and ICH [6,15–18]. The relationship between brain
tissue hypoxia or raised LPR and poor neurological outcome – reviewed in depth in
Chapter 2.3.1 – is well-recognised and while this has led to the widespread adoption of
treatment strategies focused on the maintenance of cerebral substrate delivery [19,20],
the clinical benefit of these strategies is unproven [5].
In this context, the measurement of ∆[oxCCO] is an attractive prospect, for both prac-
tical and physiological reasons. From a practical perspective, NIRS-measured ∆[oxCCO]
has the potential to be a non-invasive, bedside monitor of cellular energy status. Its
noninvasive nature allows for the interrogation of multiple regions of interest. From
a physiological perspective, cytochrome c oxidase (CCO)’s role as the final electron
acceptor in the mitochondrial electron transport chain means that the maintenance of
normal CCO function is central to normal oxidative metabolism, and pathophysiological
first principles dictate that an inability to generate adequate ATP should be reflected in
reduced CCO oxidation, as discussed in previous chapters.
In Chapter 4, we used the pHOS to measure chromophore concentration and TOS
in a variety of challenges manipulating cerebral oxygen delivery in the healthy adult
brain. Our findings confirmed that ∆[oxCCO] was the most brain-specific of modified
Beer-Lambert Law (mBLL)-derived chromophore measures and was superior to TOS as
it was not prone to confounding by changes in arterial:venous ratio. We also found that
optical scattering coefficient (µs ) and differential pathlength factor (DPF) showed no
change during physiological challenges that were more extreme than those that would
routinely be encountered in clinical practice.
The aim of this study was to investigate mitochondrial oxidative metabolism in vivo
following ABI, and in particular investigate the feasibility and veracity of the NIRS-
measured ∆[oxCCO] in patients with ABI. We hypothesised that increasing cerebral
oxygen delivery by means of normobaric hyperoxia (NBH) would elicit an increase in
CCO oxidation and CMRO and a reduction in microdialysate LPR.We also hypothesised
that there would be no significant change in µs that could potentially confound accurate
measurement of ∆[oxCCO].
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Baseline 0.6 FiO2 1.0 FiO2 Post-challenge
Continuous monitoring: ABP, TCD VMCA,  pbrO2 
 Continuous NIRS monitoring: MDBBS and MDFD spectrometers
Microdialysis LPR  measured
Arterial blood gases measured
Figure 5.1 – Schematic representation of NBH protocol and data averaging windows
5.2 METHODS
5.2.1 Study participants and protocol
After approval by the institutional Research Ethics Committee (reference 04/Q0512/67)
and representative consent, recordings were carried out in 16 sedated, mechanically
ventilated patients requiring invasive neuromonitoring as part of the clinical manage-
ment of ABI. Inclusion criteria also included baseline inspired fraction of oxygen (FiO2)
less than 0.5. The patients were subject to the NBH protocol shown in Figure 5.1.
It consisted of a 60-minute epoch of baseline recording followed by two 60-minute
epochs in which FiO2 was increased to 0.6 and then 1.0. In a final 30-minute epoch
FiO2 was returned to baseline values. Patients’ electronic clinical records were reviewed
to ascertain Glasgow Outcome Score (GOS) at 1 year post-study.
5.2.2 Monitored variables
Systemic monitoring included continuous arterial blood pressure (ABP) and intermit-
tent measurement of arterial blood gases (ABGs), including arterial partial pressure
of oxygen (PaO2) and arterial partial pressure of carbon dioxide (PaCO2) and pulse
haemoglobin oxygen saturation (SpO2). Middle cerebral artery flow velocity (VMCA)
was measured ipsilateral to the other cranial monitoring by TCD ultrasonography (DWL
Doppler Box, Compumedics, Singen, Germany). Invasive cerebral monitoring com-
prised PbrO2 (Licox, Integra Neurosciences, Plainsboro, USA) and measurement of
LPR by cerebral microdialysis (M Dialysis AB, Stockholm, Sweden), with catheters
implanted via a cranial access device (Technicam, Newton Abbot UK or Licox IP2,
Integra Neurosciences) or surgically at time of craniotomy. In accordance with con-
sensus guidelines [21], catheters were placed in peri-lesional tissue in patients with
focal TBI or ICH, in the right frontal lobe in patients with diffuse TBI, or tissue thought
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to be at risk of ischaemia from vasospasm in patients with aneurysmal subarachnoid
haemorrhage (aSAH).
5.2.3 NIRS instrumentation and processing
The NIRS apparatus used in this study is described in more detail in Chapter 3.4 and
elsewhere [22]. We previously established in Chapter 4 that the 35mm source-detector
separation is the most brain-specific, and we thus report findings for this distance only.
We used the University College London n-wavelength (UCLn) algorithm to derive
[HbO2], [HHb] and oxidised-reduced cytochrome c oxidase (oxCCO) at the 35mm
distance. The multidistance frequency domain spectrometer (MDFD) component of the
spectrometer was used to derive absolute optical absorption coefficient (µa) and µs at
790nm and these were used to calulate the DPF using the diffusion approximation [23].
We report changes in µs recorded at 790nm, and an individual DPF was calculated for
each patient, based on the µa and µs measured by the MDFD spectrometer during the
initial minute of recording of the baseline epoch.
The TOS – as defined in Equation 3.11 – was calculated using SRS [24]. As in Chapter
4, the wavelength range 740–900nm was used to resolve for [HbO2], [HHb] and water,
combined with scattering values from the MDFD system as previously described [25]
in Chapter 4.2.2.
NIRS data analysis was performed in Matlab 2010b (Mathworks, Natick MA). Differ-
ential concentrations of [HbO2], [HHb] and ∆[oxCCO] were calculated using the UCLn
algorithm [26,27]. Changes in total haemoglobin concentration ([HbT]) and haemoglo-
bin difference concentration ([HbDiff]) were calculated as described in Equations 3.13
and 3.14.
5.2.4 Data processing, epoch selection, averaging
After manual identification and linear interpolation to remove NIRS signal artefacts,
mean values for each monitored variable were calculated for individual epochs for each
patient. The continuously monitored systemic and cerebral variables (including NIRS)
were synchronized and a mean value from a noise-free window, comprising ≥ 50% of
the entire epoch was used for subsequent analysis. For intermittently sampled variables
(i. e. ABGs and microdialysate LPR), the mean of all readings per epoch (minimum 2
per epoch) were used as the summary variable for that epoch.
Relative CMRO was calculated for the post-challenge epoch, as compared to the
baseline epoch – as described in Chapter 4.2.4 and Equation 4.4 [13].
5.2.5 Statistical analysis
We used GLIMMPSE, a validated model for power calculation in linear mixed models
[28] to conduct a sample-size calculation. Assuming a ∆[oxCCO] standard deviation of
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0.2 µM in each epoch, a total of 16 patients would be required in order to provide a
power of 90% in detecting ∆[oxCCO] changes of +0.1, +0.2 and +0.05 µM during
the 0.6 FiO2, FiO2=100% and post-challenge epochs.
Statistical analyses were carried out in R [29]. Parameters of interest were analysed
using a mixed effects model [30], modelling individual subjects as random and epochs
as fixed effects. The significance of the fixed epoch effect for each variable (i. e. the
probability that the variable was the same across all 4 epochs) was then estimated
using the Likelihood Ratio Test (LRT), comparing the mixed effects model to a null
model comprising only random effects. In variables with an epoch effect probability
of <0.05, subsequent pairwise comparison between baseline and subsequent epochs
(0.6 FiO2, 1.0 FiO2, and post-challenge) was performed using Bonferroni-corrected
Wilcoxon signed-rank tests; the Hodges-Lehman estimate was used to calculate the
(pseudo)median and per-epoch 95% confidence intervals; relative changes in CMRO
similarly treated, with only the baseline and post-challenge epochs compared and thus
no Bonferonni correction was necessary.
The associations between ∆[oxCCO] and microdialysate LPR & PbrO2 were similarly
analysed using a mixed effects model, with patients modelled as random effects and
PbrO2 or LPR modelled as fixed effects for their respective analyses. The probability
that the variance of the fixed effects was equal to zero was calculated using the LRT;
the probability that the variance of the random effect was equal to zero was derived
from simulation of the restricted likelihood ratio test (RLRT) [31].
In order to establish whether there was a relationship between baseline hypoxia/is-
chaemia and subsequent changes in LPR, a Spearman correlation was used to assess
the relationship between baseline PbrO2 and LPR and the ∆LPR response to hyperoxia.
All data are expressed as (pseudo)median (95% confidence interval) unless otherwise
stated. Statistical significance was inferred at p < 0.05.
5.3 RESULTS
The full study protocol was completed in 16 patients; technical failure resulted in the
loss of ABP and PbrO2 recordings for one patient – this patient was still included in all
analyses. The demographic data of the 16 patients included in the analysis are shown
in Table 5.1. Baseline levels for the physiological variables are shown in Table 5.2, the
epoch effect for each variable in Table 5.3, and changes in measured variables in Table
5.4 and Figure 5.2.
No change in ∆[HbT] was observed. Hyperoxia caused an increase in ∆[HbDiff] ]
(∆[HbDiff] ] +1.18 µMand+2.17 during the 0.6 FiO2 and 1.0 FiO2 epochs respectively,
both p<0.001) with no significant change observed during the post-challenge epoch.
No significant changes were observed in optical scattering measured at 790nm (epoch
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AGE 46.5 (39.3–51.5)
S EX 6 male, 10 female
PR IMARY D IAGNOS I S TBI 7
SAH 8
ICH 1
T IME TO STUDY (HOURS ) 25.5–45
ADMIS S ION GCS 4–9
OUTCOME GOS 1 6
GOS 4 7
GOS 5 1
Unknown 2
Table 5.1 – Patient demographic and outcome data
VAR IABLE BASE L INE VALUE ( IQR )
FiO2 (%) 0.325 (0.28–0.35)
PaO2 (kPa) 15.7 (12.5–18.0)
PaCO2 (kPa) 4.85 (4.65–4.97)
SpO2 (%) 99 (98–99)
MAP (mmHg) 91.5 (83.2–96.8)
VMCA (cm.s−1) 52.1 (48.7–71.8)
PbrO2 (mmHg) 17.5 (12.0–24.4)
Microdialysate LPR 25.3 (23.5–33.5)
TOS (%) 72.8 (65.5–77.0)
DPF 9.33 (6.75–10.8)
µs (cm−1) 11.1 (6.76–12.4)
Table 5.2 – Values of physiological and optical variabes at baseline.
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VAR IABLE χ2 p
PaO2 171 <0.001
PaCO2 5.63 0.131
SpO2 64.8 <0.001
LPR 9.28 0.026
PbrO2 44.6 <0.001
VMCA 8.31 0.04
∆[HbDiff] 27.0 <0.001
∆[HbT] 4.5 0.21
∆[oxCCO] 15.1 0.002
TOS 22.3 <0.001
µs 1.06 0.787
Table 5.3 – Effect of epoch on specified variable from likelihood ratio test
effect p = 0.786). TOS showed a significant increase during the 0.6 FiO2 and 1.0 FiO2
epochs, with ∆TOS 2.8% and 6.0%, respectively (both p<0.001), with no significant
change observed during the post-challenge epoch.
Hyperoxia was associated with statistically significant increases in PaO2, SpO2 and
PbrO2. There was no change seen in PaCO2 during the study. While a significant overall
epoch effect for VMCA was observed, post hoc testing identified no single epoch as
being different to baseline.
Statistically significant increases in ∆[oxCCO] and reductions in microdialysate LPR
during the NBH challenge were seen. ∆[oxCCO] increased by +0.18 (p<0.01) and
+0.32 (p<0.001) during the 0.6 FiO2 and 1.0 FiO2 epochs respectively. ∆LPR showed
a change of -1.16 (p<0.01) and -3.07 (p<0.01) during the 0.6 FiO2 and 1.0 FiO2 epochs
respectively. These changes persisted in to the post-challenge epoch (∆[oxCCO] +0.22
[p <0.01] and ∆LPR -0.254 [p<0.01]); CMRO was higher in the post-challenge epoch
compared to the baseline epoch [CMRO 107.5% of baseline (95% CI 100.3% - 119.0%,
p = 0.039)]
Scatterplots showing the relationship between ∆[oxCCO] and PbrO2 or LPR are
shown in Figures 5.3 and 5.4, respectively. Comparison between ∆[oxCCO] and PbrO2
revealed both significant fixed effects (χ2 21.4, p < 0.0001) and random effects (RLRT
statistic 21.5, p < 0.0001). Comparison between ∆[oxCCO] and microdialysate LPR
revealed no significant fixed effect (χ2, p = 0.194) and a significant random effect
(RLRT statistic 19.9, p < 0.0001); however, after post-hoc exclusion of a single patient
who had evidence of critical ischaemia in their microdialysate (baseline microdialysate
glucose 0.04mM, LPR 65), a significant association between ∆[oxCCO] and LPR was
observed (χ2 8.72, p = 0.003)
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0.6 FIO2 FIO2=100% POST-CHALLENGE
∆[HbDiff] (µM) 1.18(0.59 – 2.12)
1.13
(1.17 – 4.13)
0.30
(-0.22 – 1.28)
∆[HbT] (µM) -0.13(-0.52 – 0.22)
-0.46
(-1.16 – 0.13)
0.44
(-0.01 – 0.90)
∆[oxCCO] (µM) 0.18(0.08 – 0.47)
0.32
(0.11 – 0.76)
0.22
(0.06 – 0.62)
∆TOS (%) 2.8(1.8 – 5.6)
6.0
(3.4 – 10.9)
3.1
(-2.6 – 2.8)
Relative CMRO (%) — — 107.5(100.3 – 119.0)
∆LPR -1.16(-1.93 – -0.475)
-3.07
(-4.38 – -1.61)
-2.54
(-4.38 – -0.475)
∆PbrO2 (mmHg)
8.44
(5.19 – 12.2)
30.9
(21.6 – 43.4)
2.72
(-1.76 – 9.46)
∆MAP (mmHg) 1.19(-2.32 – 4.92)
1.48
(-3.73 – 8.8)
-0.56
(-7.83 – 7.38)
∆PaCO2 (kPa)
0.15
(0.033 – 0.26)
0.114
(-0.05 – 0.258)
0.203
(-0.1 – 0.425)
∆PaO2 (kPa)
14.1
(11.3 – 17)
38.7
(35 – 42.3)
-1.21
(-1.99 – -0.1)
∆SpO2
1.5
(1.00 – 2.00)
1.5
(1.01 – 2.00)
-0.831
(-1.16 – -0.778)
∆ VMCA (cm.s−1) 2.19(-1.23 – 5.62)
2.64
(-2.09 – 7.47)
5.19
(-0.45 – 11)
µs (cm−1)
5.19
(-0.45 – 11)
-0.0201
(-0.394 – 0.297 )
0.0785
( -0.423 – 0.354 )
Table 5.4 – Changes in measured physiological and optical variables for each epoch. All figures
(pseudo)-median (95% confidence interval from Hodges-Lehman estimate in brackets).
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We have demonstrated an increase in mitochondrial oxidative metabolism – evid-
enced by an increase in ∆[oxCCO] and reduction in microdialysate LPR – in a cohort
of critically-ill brain-injured patients during an NBH challenge. Furthermore, these
changes persisted in to the post-challenge phase of the study, where they were accom-
panied by an increase in relative CMRO in the post-challenge compared the initial
baseline epoch. These findings imply that there is an impairment of cerebral oxidative
metabolism at baseline and that this is partially and persistently reversed by hyperoxia.
The potential mechanisms for these observed changes include impaired substrate avail-
ability – potentially as a result of impaired oxygen diffusion – at baseline, alterations
in NO· metabolism and dysfunction of the mitochondrial electron transport chain,
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Figure 5.2 – Median changes (with error bars signifying 95% confidence intervals) in systemic and cerebral
physiological variables and markers of cerebral aerobic metabolism during NBH from all 16 patients.
all of which are discussed below. Furthermore, we found no significant change in µs
measured at 790nm, suggesting that changes in scattering do not confound the accurate
measurement of ∆[oxCCO].
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Figure 5.3 – Comparison between ∆PbrO2 and ∆[oxCCO] across all (non-baseline) epochs
Our findings of concomitant, congruent changes in brain LPR, CMRO and CCO
oxidation in response to the physiological challenge of hyperoxia on a group level,
as well as our findings of a clear association between ∆PbrO2 and ∆[oxCCO] on an
individual-observation level underline the notion that CCO oxidation is a valid marker
of cerebral oxidative metabolism.
5.4.1 Comparison with previous studies
The hyperoxia-induced changes in PbrO2, LPR and CCO oxidation that we have shown
are consistent with those reported in a previous pilot study [32]. Our results build on
existing work in that they demonstrate not only increased oxygen delivery in response
to hyperoxia but also an increase in aerobic metabolism evidenced by three modalities,
namely reduction in microdialysate LPR, increase in ∆[oxCCO] oxidation and persist-
ent increase in CMRO in a mixed population of patients with severe ABI requiring
neurocritical care.
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Figure 5.4 – Comparison between ∆LPR and ∆[oxCCO] across all (non-baseline) epochs
The literature contains conflicting evidence regarding the effects of hyperoxia on
cerebral pathophysiology following ABI, but with the majority of studies suggesting
no metabolic benefit. These include one that reported a reduction in microdialysate
lactate but not LPR during hyperoxia [33], and another demonstrating no reduction in
LPR [34]. One small PET study also showed no increase in CMRO during hyperoxia,
but this was small and likely underpowered [35] . Furthermore, a study in 83 patients
with severe TBI found that the effect of hyperoxia on PbrO2 was partially correlated
with regional CBF, with a greater relative increase in PbrO2 observed with higher CBF
in the region of interest [36]. In a study combining PET and microdialysis in 11 patients
with TBI, Nortje et al. found that hyperoxia increased CMRO in areas of brain that
showed evidence of ischaemia – that is in areas with already reduced CMRO – but not
in areas of ‘normal’ brain, or in whole-brain studies [37].
The reduction in microdialysate LPR (median reduction -3.07) that we observed
in this study during hyperoxia is small, but consistent with that previously reported
[32,37]. Such reductions in LPR reflect an increased intracellular NADH:NAD+ ratio
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[14], and are likely to represent increased aerobic metabolism [32,38], although LPR
elevatations can reflect mitochondrial dysfunction rather than ischaemia [6] .
The changes that we observed in CCO oxidation are physiologically plausible and,
when compared to measurements taken in different contexts, credible in magnitude.
The total concentration of CCO in the adult human brain is unknown, but has been
found to be approximately 5 µM in rats [39]; on the basis of mitochondrial number and
CMRO, this has been speculated to be the upper limit of adult brain CCO concentration
[40]. In this context, the changes of 0.18–0.32 µM that we have observed are modest,
but plausible, and similar in magnitude to those observed in healthy volunteers during
increments in cerebral oxygen delivery and functional activation [22,25,41,42].
The increase in ∆[oxCCO] during hyperoxia is consistent with an increase in electron
throughput through the enzyme, and thus through the entire mitochondrial electron
transport chain [43–45]. This likely represents increased aerobic metabolism. This
change was dose-dependent, with larger changes observed during the 1.0 FiO2 com-
pared to the 0.6 FiO2 Epoch. The median changes were +0.18µM and +0.32µM
during 0.6 FiO2 and 1.0 FiO2 epochs respectively, and these are comparable to those
previously reported in patients with severe TBI [32] . Interestingly, both microdialysate
LPR and ∆[oxCCO] did not return to baseline values following a return to the initial
baseline FiO2, despite the fact that PbrO2 and PaO2 did, again mirroring the results of
our previous work [32]. Baseline drift is an unlikely explanation for this change, as LPR
is routinely measured over the course of several days within the clinical setting without
any reported concerns of drift in the literature; the other chromophores measured
using the NIRS apparatus showed returned to pre-challenge levels, suggesting that drift
is an unlikely explanation for these observed changes. Furthermore CMRO showed
an increase in the post-challenge when compared to baseline epoch. This raises the
prospect that hyperoxia induces an increase in cerebral oxidative metabolism that
persists beyond the hyperoxic challenge – although our data collection only carried on
for 30 minutes post-challenge and thus the length of time for which this phenomenon
persists is unknown.
5.4.2 Pathophysiological explanations for observed changes
In health, robust methods of CMROmeasurement have shown CMRO to be independent
of moderate modulations cerebral oxygen delivery, but following ABI, a range of disturb-
ances to oxygen transport and its utilisation may complicate the relationship between
PbrO2 and metabolism. Ischaemia is classically described as a situation in which there
is insufficient blood-borne substrate delivery. Studied with PET, a characteristic com-
bination of increased OEF, reduced CBF and depressed CMRO is well-recognised
following ABI [46]. However, metabolic dysfunction has been identified in the presence
of apparently acceptable tissue oxygenation, where both diffusion impaired oxygen
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diffusion and mitochondrial dysfunction have been implicated as alternative forms of
restriction to oxidative metabolism in the presence of a normal PbrO2 or OEF [6].
Protocols for the management of patients with ABI typically seek to maintain PbrO2
above a ‘critical’ threshold for anaerobic metabolism [47]. Although anaerobic meta-
bolism has typically been described when PbrO2 falls below 10mmHg, NBH and
hyperbaric hyperoxia may improve LPR and CMRO after TBI in the presence of PbrO2
values that lie within or above the normal physiological range [32,37,48]. Taken as a
whole, this suggests that mitochondrial aerobic metabolism is in some way impaired
in brain-injured patients, whether as a result of decreased substrate delivery or an
inability to use the delivered substrate. Furthermore, these studies were unable to
distinguish between impaired oxygen diffusion and mitochondrial dysfunction as a
cause for metabolic impairment – this distinction is not solely academic, but may have
clinical consequences, as impaired oxygen diffusion could potentially be overcome by
means of hyperoxia.
The mitochondrial matrix, where oxidative phosphorylation occurs, is virtually anoxic,
giving rise to a diffusion gradient for oxygen transport from the microvasculature, and
offering protection from oxidant damage. CCO has low Michaelis-Menton constant
(Km) for oxygen, meaning that oxidative phosphorylation may continue unimpeded in
isolated mitochondria with a partial pressure of oxygen (pO2) less than 1mmHg [49].
Below a critical ischaemic threshold, CCO is reduced and impaired oxygen availability
then becomes a rate-limiting factor resulting in decreased oxidative phosphorylation
[50,51].
In this context, potential explanations for the persistent increase in ∆[oxCCO] and
CMRO and reduction in LPR observed in the post-challenge period are the presence of
either oxygen diffusion limitation or mitochondrial dysfunction and hypoxia-ischaemia
despite ‘normal’ values for PbrO2. Importantly, while the [oxCCO] and LPR changes
are sustained into the post-challenge period while the markers of microvascular and
brain tissue oxygenation (TOS, [HbDiff], [HbT] & PbrO2) return to baseline values.
This suggests that hyperoxia-induced improvement in cellular metabolism persists
beyond the immediate period of normobaric hyperoxia, a supposition supported by
the elevation in estimated CMRO during this epoch.
Although the mean baseline PbrO2 of 17.5mmHg in our study would be defined
as hypoxic (<20 mmHg) by some [52], the majority of previous studies highlight
<10mmHg as the threshold at which LPR and PET markers indicate ischaemia [53,54] .
However, since both phases of the hyperoxia protocol resulted in elevation of PbrO2 to
‘normal’ physiological levels and a stepwise increase in ∆[oxCCO] and reduction in
LPR was observed in the 1.0 FiO2 epoch, our findings are inconsistent with classical
hypoxia-ischaemia.
Both diffusion oxygen abnormalities and mitochondrial dysfunction have been pro-
posed to elicit this phenomenon [6,37,55], but our findings of sustained metabolic
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improvement on post-challenge FiO2, and predicted oxygenation gradients (see be-
low), are not completely consistent with isolated diffusion limitation. Concerning the
oxygenation measurements, we found a baseline TOS of 73%, which lies within a
physiologically ‘normal’ range for NIRS-derived regional cerebral saturation [56] . As-
suming one quarter of blood volume is saturated arterial blood, this predicts a venous
saturation of 64% and approximate venous pO2 of 33mmHg (using the calculation
from Nortje et al. [37]), and thus an average difference of 15.5mmHg between venous
blood (33mmHg) and PbrO2 (17.5mmHg). Similar comparisons using PET and PbrO2
have described gradients of 10mmHg and 27mmHg in normal and impaired brain
regions [37], so our observations are consistent with a moderate diffusion distance
between the microvasculature and tissue interstitium.
One explanation for these results is the occurrence of cerebral oedema, which
is typically maximal at 24–72 hours after acute brain injury [57,58]. Limitations to
oxygen diffusion are the main barriers to oxygen delivery following TBI [55] and it is
thus possible that hyperoxia increases the capillary-mitochondrial diffusion gradient
sufficiently to drive oxygen in to the hypoxic mitochondrion. Alternatively, hyperoxia
may have a direct effect on cerebral oedema itself, a hypothesis that could be tested in
the future through the use of diffusion magnetic resonance or NIRS-measurement of
water concentration.
CCO oxidation increased by 0.32 µM during a mean PbrO2 change of 30.9mmHg,
and returned to 0.22 µM in the post-challenge epoch. Assuming a total concentration of
approximately 5µM [40], the CCO changes that we observed are therefore likely to reflect
an approximate 6% change in its oxidation and is higher than that observed in healthy
volunteers during increases in cerebral oxygen delivery in Chapter 4 and previously [25,
42] or during functional activation [22,41], but equivalent to that described previously
in TBI [32]. The oxidation status of CCO is modified by both mitochondrial pO2
and metabolic factors (such as adenosine 5’-diphosphate (ADP) concentration and
the NADH:nicotinamide adenine dinucleotide (NAD+) ratio), and our findings are
consistent with both an increase in aerobic metabolism and/or increased mitochondrial
pO2. Earlier studies and our findings in Chapter 4 have shown an association between
cerebral oxygen delivery and CCO oxidation in healthy volunteers [25,59] and, in
animal models, with brain ATP concentrations [40] and brain lactate [60]. Likewise, the
persistent CCO oxidation in the post-challenge epoch suggests either increased aerobic
metabolism (consistent with the measured LPR and estimated CMRO) and/or an altered
Km for O2.
Furthermore, perturbations of nitric oxide (NO·) metabolism could partially explain
the observed changes. NO· is subject to complex perturbations following ABI, with
both increases and reductions in NO· reported after TBI and SAH [61]; these have
been implicated in the development of delayed cerebral ischaemia and vasospasm
after SAH [62]. NO· competes with oxygen to bind CCO, and can also inhibit CCO
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activity [63,64] and has been shown to do so after experimental TBI [65]. The CCO-NO·
interaction is the proposed basis of hypoxic vasodilation and its obverse, hyperoxic
vasoconstriction [66,67] . Competitive reversal of this effect has been proposed as
the basis of the therapeutic action of hyperoxia following ABI, with NBH leading to
increased ATP generation and paradoxically increased CBF because of pre-existing
NO· excess [37] . This would also explain absence of hyperoxic vasoconstriction seen
in our study and several others (Diringer et al., 2007; Nortje et al., 2008; Tisdall et
al., 2008), as oxygen displaces otherwise-bound NO· and prevents its degradation.
Further evidence of a dose-responsive hyperaemia induced by hyperoxia was found by
Rockswold and colleagues who showed that hyperbaric hyperoxia induced a larger
increase in both arterial oxygen partial pressure and CBF than NBH [68]. Furthermore,
NO· is known to increase the Km of CCO, and the proposed mechanism of action for
normobaric and hyperbaric hyperoxia is the reversal of this nitric oxide effect. Thus our
results could theoretically represent the hyperoxia-induced breakdown of NO· rather
than a direct effect of elevated mitochondrial pO2 [69], although the effect of NO· on
the CCO response to hyperoxia is more difficult to predict, as NO· can cause the CCO
complex to remain in both oxidised- and reduced-inhibited forms [70].
A further means by which normobaric hyperoxia may have increased aerobic meta-
bolism may have been by means of upregulation of pyruvate dehydrogenase com-
plex (PDHC) function. PDHC is responsible for the conversion of pyruvate to acetyl-
coenzyme A (discussed in Chapter 1.3.3), and is thus a rate-limiting step for substrate
entry in to Kreb’s cycle and thus oxidative metabolism. In hypoxic conditions, PDHC is
deactivated by downstream effects of hypoxia-inducible factor 1α (HIF-1α); this has
been proposed as a protective mechanism that minimises the generation of reactive
oxygen species during hypoxic conditions [71]. The reversal of hypoxia/ischaemia
induced HIF-1α expression by hyperoxia has been proposed to reduce both lactate and
pyruvate concentrations [37]. This would thus explain observed increases in CMRO
and ∆[oxCCO], but not the reduction in LPR.
One final aspect of brain injury pathophysiology is that of ‘electron leak’ from the
electron transport chain and consequent generation of ROS. Whilst this study builds on
an increasing body of evidence and opinion [72–74] regarding the beneficial effects
of hyperoxia, there is widespread and increasing concern regarding the potentially
deleterious effects of hyperoxia, in particular with the potential for generation of
cytotoxic mitochondrial reactive oxygen species [75–77]. ROS are generated as a result
of normal metabolism but in particular during periods of mitochondrial hypoxia [78];
there are a wide variety of inbuilt mechanisms for their neutralisation[79,80]. When
these protections are overcome, mitochondrial elimination and/or apoptosis ensue
[80,81]. The generation of ROS occurs as the result of ‘leak’ from electrons from the
electron transport chain, with the consequence that their potential is not harnessed to
generate the mitochondrial chemosmotic gradient required for ATP generation, thus
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decoupling substrate oxidation from ATP generation, a phenomenon seen in animal
models of TBI [82]. One would expect this to result in a reduction in the oxidised
fraction of CCO (as fewer electrons are delivered to the end of electron transport chain)
and an increase in LPR (as the leak of electrons prevents the generation of NADH
with consequent effects on lactate dehydrogenase). If hypoxia-induced electron leak
[78] were reduced by hyperoxia, it could explain the increase in CCO oxidation and
reduction in LPR we observed.
These findings highlight the difficulties in establishing thresholds for hypoxia and
ischaemia in the injured brain. The wide variation in CCO oxidation and LPR responses
to hyperoxia suggests the need for individualised patient-specific targets for the avoid-
ance of secondary brain injury. The deconvolution of the variously measured signals to
establish appropriate interventions to minimise secondary brain injury – for example,
to establish measures of CBF, arterial and venous volumes and true CMRO – may be
possible through the use of mathematical models of cerebral circulation and metabolism
may assist in this regard [83–85].
5.4.3 Relationship between measures of hypoxia/ischaemia and metabolism
A significant proportion of our patient cohort had either brain-tissue hypoxia (defined
as PbrO2<20 mmHg) or ischaemia (defined as microdialysate LPR > 25) [38,52] at
baseline. In order to examine whether the occurrence of baseline hypoxia or ischaemia
influenced the response of LPR, ∆[oxCCO] and CMRO to hyperoxia, we split the
patients into two groups on the basis of these hypoxic & ischaemic thresholds, as
shown in Tables 5.5 & 5.6 and conducted post-hoc correlation analysis between the
baseline PbrO2 or LPR and ∆[oxCCO] during the 1.0 FiO2 Epoch and CMRO during
the post-challenge epoch. Post hoc correlation analysis (using Spearman’s rank-sum)
showed no correlation between the PbrO2 or LPR at baseline and ∆[oxCCO] at 1.0
FiO2 or CMRO during the post-challenge Epochs. However, our study was not powered
to carry out such analyses, and inspection of Tables 5.5 & 5.6 suggest that a larger
effect in terms of changes in LPR and CMRO is seen in hypoxic/ischaemic patients.
∆[oxCCO] showed a larger change in patients with baseline brain hypoxia, but not in
patients with baseline brain ischaemia.
Given the concordance between the various measures of oxidative metabolism on a
group level, it was surprising that we did not find a stronger relationship between the
variables when comparisons were made between the variables. There was a significant
relationship between PbrO2 and ∆[oxCCO] (p<0.0001), but the relationship between
LPR and ∆[oxCCO] was not statistically significant (p = 0.19). On further examination
of the data, it was apparent that one patient had microdialysate evidence of critical
ischaemia, with a baseline LPR of 65 and glucose concentration of 0.04 mM. Further-
more, this patient displayed significant increase in LPR with hyperoxia, with LPR rising
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VAR IABLE BASE L INE NORMOX IC BASE L INE HYPOX IC
n 9 6
Baseline LPR 23.5 (22.2–24.6) 25.8 (24.5–33.9)
Baseline PbrO2 25.8 (23.8–27.0) 12.2 (10.9–16.6)
∆LPR at 1.0 FiO2 Epoch -1.4 (-2.2 – -1.9) -2.7 (-3.9 – -1.8)
∆[oxCCO] at 1.0 FiO2 Epoch (µM) 0.13 (0.09–0.34) 0.18 (0.08–0.62)
CMRO during post-challenge Epoch (%) 104.3 (100.8–113.2) 109.4 (98.0 – 115.8)
Table 5.5 – Comparison of changes in measures of oxidative metabolism between patients with brain tissue
normoxia (i. e. . PbrO2>20mmHg) and hypoxia (PbrO2<20) at post-challenge. All figures median
(interquartile range (IQR))
.
VAR IABLE BASE L INE NOT I SCHAEMIC BASE L INE I SCHAEMIC
n 8 7
Baseline LPR 23.4 (21.7–24.0) 33.5 (31.4–38.4)
Baseline PbrO2 24.4 (16.3–26.4) 12.2 (11.4–18.2)
∆LPR at 1.0 FiO2 Epoch -1.6 (-3.3 – -1.3) -2.3 (-3.2 – -0.5)
∆[oxCCO] at 1.0 FiO2 Epoch (µM) 0.28 (0.09–0.92) 0.15 (0.06–0.39)
CMRO during post-challenge Epoch (%) 100.9 (96.6–114.3) 109.8 (103.4 – 116.0)
Table 5.6 – Comparison of changes in measures of oxidative metabolism between patients with signs of
ischaemia (i.e. LPR>25) without signs of ischaemia (LPR<25) at baseline. All figures median (IQR)
.
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to 71 and 79 during the 0.6 FiO2 and 1.0 FiO2 epochs, respectively. We speculate that
in this patient the microdialysis catheter was placed in critically ischaemic brain and
was thus non-responsive to hyperoxia. After post-hoc exclusion of this single patient, a
statistically significant association between LPR and ∆[oxCCO] was demonstrated (χ2
=32.9, p = 0.003).
Comparisons between ∆[oxCCO] & PbrO2 and ∆[oxCCO] & LPR with mixed model
analysis revealed significant random effects in both cases. This suggests that the relation-
ships that exist between ∆[oxCCO] and PbrO2 or LPR show significant inter-individual
variation. This is compatible with the clear heterogeneity of brain injury pathophysio-
logy; each of the pathophysiological phenomena described above could exist in varying
degrees in different brain injuries, and each should influence the relationship between
∆[oxCCO] & PbrO2 and ∆[oxCCO] and LPR.
Taken as a whole, these findings suggest that ∆[oxCCO] is a valid marker of cerebral
oxidative metabolism, showing a distinct relationship with PbrO2 and microdialysiate
LPR, but that this relationship cannot be linearly defined on a group basis, but shows
significant variation between individual patients. As discussed above, the pathophysiolo-
gical basis of these variations could be further elucidated though the use of cerebral
haemodynamic and metabolic models [83–85] .
5.4.4 Strengths and limitations
This study is, to our knowledge, the first report of broadband SRS in clinical use in the
adult human brain. The use of broadband SRS as opposed to the discrete-wavelength
methodologies employed by most commercially available NIRS apparatus [56] allowed
us to resolve for changes in cerebral water content, which could feasibly have confoun-
ded accurate measurement of chromophore concentration. Another significant strength
is the size of the cohort included in the study: other similar studies have typically
included numbers of patients in the single-figures [32,35–37].
In the absence of a single ‘gold-standard’ measurement of cerebral oxidative metabol-
ism, it was necessary for us to utilise multiple measurement modalities and corroborate
the changes between these multiple modalities in order to construct inferences about
the pathophysiological basis of the observed changes. A significant strength of this
study is that the multimodal monitoring array covered the entire cascade of oxygen
metabolism from the microvasculature (measured with TOS and [HbDiff], through to
the tissue interstitium (PbrO2), to mitochondria (∆[oxCCO] and composite measures
of oxidative metabolism (CMRO and LPR). Considered as a whole, this array might
allow the differentiation between limitation of oxygen diffusion and mitochondrial
dysfunction.
Each of the individual monitoring modalities used in our study is subject to their own
limitations. Differential spectroscopy NIRS methodologies, such as the one we used
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to measure haemoglobin concentrations and ∆[oxCCO] in this study, are subject to
significantly more extracranial ‘contamination’ than SRS methodologies [56]. However,
we have shown in Chapter 4 that CCO is a brain-specific chromophore, with negligible
changes seen in extracranial tissues, overcoming this concern [25]. Furthermore, we
used an individual-specific DPF and found no significant changes in optical scattering,
excluding these potential confounders of accurate CCO oxidation measurement [40].
The differential spectroscopy methodology we used to measure changes in CCO oxida-
tion is based upon the modified Beer-Lambert law and is only able to quantify relative
changes in chromophore concentration from an unknown baseline, as opposed to
providing absolute concentrations of oxidised and reduced CCO or a CCO ‘saturation’
analogous to that of haemoglobin described by TOS [56]. To our knowledge, there
are no apparatus that are currently able to provide such measures, but time-resolved
spectrometers capable of doing so are on the horizon [56,86].
Microdialysate LPR is an imperfect measure of cerebral aerobic metabolism. It
reflects the activity of cytosolic lactate dehydrogenase, which is in large part reflective
of intracellular NADH:NAD+ ratio and thus related to the ability of mitochondria
to produce ATP; there are circumstances, including electron leak from the electron
transport chain (discussed below), during which LPR can remain unchanged in the face
of an inability for cells to generate energy [87].
It is also likely that our different monitoring modalities each interrogated a different
area of tissue. In order to minimise this effect, we placed the microdialysis catheters
peri-lesionally, or in the case of patients with SAH, in the tissue most likely to develop
delayed cerebral ischaemia, in line with consensus guidelines [21,88], and attached
NIRS optodes in the frontal region as close as possible to this site. Similarly, it is difficult
to know exactly what tissue volume is represented by our CMRO measure. CMRO was
derived from VMCA – itself a relatively global measure of hemispheric CBF [89–91] –
and TOS, a regional measure of tissue oxygenation [56].
5.5 CONCLUS ION
We have demonstrated an increase in several invasively and non-invasively measured
markers of cerebral aerobic metabolism during NBH in patients with ABI. The changes
observed underline the potential utility of measurement of CCO oxidation as a clinically
relevant marker of energy metabolism following ABI.
Furthermore, the changes observed in the various markers of cerebral metabolism
provide further confirmation for the existence of mitochondrial dysfunction as a con-
sequence of brain injury and suggest that limitations to oxidation diffusion may play
a key role in brain injury pathophysiology. Standard clinical therapy following ABI
fundamentally aims to avoid mitochondrial hypoxia in order to minimise secondary
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tissue ischaemia and worse clinical outcomes, and while PbrO2 and microdialysate
LPR have been used as surrogates of mitochondrial oxygen availability and its effect
on mitochondrial redox status at the bedside, clinical application and interpretation of
such techniques requires clearly defined thresholds for ‘ischaemia’.
Our results demonstrate an increase in ∆[oxCCO], reduction in LPR and increase
in estimated CMRO during and following normobaric hyperoxia. These findings are
consistent with increased aerobic metabolism at PbrO2 levels higher than those typic-
ally recognised as ‘ischaemic’ thresholds. Such oxygen-limited metabolism suggests
that hypoxia-ischaemia secondary to oxygen diffusion limitation or mitochondrial dys-
function might be prevalent after acute brain injury, and complicate assessment of
ischaemia using measurement of PbrO2 in isolation. Simultaneous measurement of
microvascular, tissue and cellular oxygenation and metabolism has potential to redefine
our understanding of ischaemia after acute brain injury. Measurement of the oxidation
status of CCO as a bedside, continuous assessment of mitochondrial energetics over
multiple regions of interest has considerable potential to guide treatment after acute
brain injury.
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Part III
CONCLUS IONS AND FUTURE WORK
6
CYTOCHROME C OXIDASE IN ACUTE BRAIN INJURY: WHERE ARE WE
NOW, WHERE TO GO NEXT?
The overarching goal of the work reported in this thesis is to establish the potential for
near infrared spectroscopy (NIRS)-based measurement of cytochrome c oxidase (CCO)
to be a useful biomarker of cerebral energy status in order to detect and thus guide the
prevention or treatment cerebral ischaemia
In this final chapter, we consider whether the experiments described in chapters 4
and 5 support this notion, as well as considering what obstacles remain to developing
a practical bedside CCO monitor.
6.1 DEVELOPMENT OF CL IN ICAL MONITORS
Unlike drugs, which have a recognised regulatory pathway and framework for develop-
ment, the development of biomarkers by necessity follows more heterogenous paths [1].
In this context, it is useful to consider the USA National Institutes of Health Research
definition of a biomarker, which is ‘a characteristic that is objectively measured and
evaluated as an indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention’ [2]. Thus, once technical devel-
opment of specific instrumentation is complete, it is necessary to define the behaviour
of the biomarker in normal function, in response to disease and in response to treatment
– a schema for doing so is shown in Figure 6.1.
6.2 CCO AS A B IOMARKER : WHERE ARE WE NOW?
In the case of CCO, I believe the work presented in this thesis now places us squarely
within the ‘Clinical Development’ phase shown in Figure 6.1. Why has it taken four
decades to move here from Jöbsis’s initial description of NIRS-measured CCO oxidation
in cat brain to the potential for use of this measurement in the clinical arena? The current
status and future directions of CCO as a biomarker of brain oxidative metabolism have
been recently reviewed elsewhere [3]; the obstacles that I have identified are related
to technical aspects of measurement, the practicalities of running studies in complex
clinical environments and finally, the challenge of interpreting the (patho)physiological
relevance of results.
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Conception
In vitro development 
Technical development in:  
⁃ simulated biological tissue
⁃ ex vivo biological tissue 
In vivo pre-clinical development
Use of animal models and/or healthy human 
volunteers  to:
⁃ validate against ‘gold standard’, if available
⁃ define normal values in health
⁃ corroborate with other physiological 
variables,  in concordance with physiological 
first principles 
Clinical development
Measurements during routine clinical practice to: 
⁃ validate against ‘gold standard’, if available
⁃ corroborate with other physiological 
variables, in concordance with known 
principles of pathophysiology
⁃ define abnormal values in disease
⁃ relate perturbations of monitored variable to 
outcome
Clinical deployment
Adoption of treatment strategies based on use of 
clinical monitor to: 
⁃ refine of apparatus, including user-friendliness
⁃ develop and refine treatment strategies and 
protocols
⁃ prove the effect of treatment strategies (and 
thus utility of biomarker monitoring) on 
clinical outcome
Clinical use and experience
⁃ refinement of apparatus, including user-
friendliness
⁃ development of confidence, through 
behaviour of biomarker in concordance with 
pathophysiological principles
⁃ increased adoption with increased 
understanding of biomarker relevance
Figure 6.1 – Proposed schema for biomarker monitor development
6.2.1 Technical challenges
The relatively indistinct spectral characteristics of CCO, as discussed in Chapter 3.2.4,
combined with the submicromolar changes that we have been seeking to demonstrate,
in the context of haemoglobin concentrations that are an order of magnitude higher,
has presented a significant challenge to the accurate measurement CCO oxidation [4] .
Our use of a charge-coupled device (CCD) based system has allowed 2-dimensional
measurement in both spectral and spatial dimensions [5]. As CCD size has reduced and
resolution has increased in line with Moore’s Law [6], we have been able to achieve
the signal-to-nose ratios necessary to accurately measure CCO oxidation in the adult
human head.
Having achieved the ability to resolve the minuscule spectral changes induced by
submicromolar changes in CCOoxidation, the following challenge has been establishing
the veracity of the observed changes. There is a relatively poor understanding of CCO
physiology in vivo, because the only means of directly measuring its oxidation state
is through light spectroscopy. Although CCO oxidation can be measured with visible
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light spectroscopy, the poor penetration of visible light through biological tissue means
that this must be performed invasively in the human brain, or via exposed cortex. A
key challenge facing the validation of CCO-measuring apparatus like the hybrid optical
spectrometer (pHOS) is the circular argument that CCO physiology can only be defined
through measurements by unvalidated apparatus, and yet we seek to use these CCO
measurements in order to validate this very apparatus!
This ‘validation’ of the biomarker has thus involved corroboration with other measures
of cerebral metabolism and evaluating whether observed changes in CCO oxidation
state are consistent with those that are seen in these other measures, based on our
understanding of cerebral physiology. This has been performed in a number of animal
models [4,7–9] and healthy volunteers [10,11]. The studies we report in Chapter 4
confirm these findings, as well as excluding the important confounders of pathlength
and scattering changes on the NIRS-measured variables. I believe that this weight of
evidence is sufficient for us to accept the CCO oxidation state measured with the pHOS
as largely veracious.
6.2.2 Practical challenges
From a practical perspective, the apparatus are large and cumbersome. The pHOS –
shown in Figure 6.2 – used in the studies described in this thesis was as large as a
domestic fridge (and thus only deployable in the neurocritical care unit in the early
hours of the night without causing significant disruption to clinical activities). Although
this was approximately one third the size of the previous generation of broadband
systems used by our group [11], I believe that significant further miniaturisation is
necessary for more widespread use to be feasible. Other practical impediments include
a need for reference spectrum recording for the broadband spectrograph and suscept-
ibility of recordings to significant artefact from any optode movement – for example
through patient repositioning or coughing, with the need for manual identification and
decontamination of data.
In order to conduct the experiments described in this thesis, we have been required to
construct breathing circuits to manipulate inspiratory gas mixes, site invasive intracranial
monitoring, educate staff in the use of this monitoring, conduct ultrasound recording
of cerebral blood flow, package the NIRS apparatus into a form suitable for use in a
clinical environment, and interface and synchronise the various devices. Although
each individual patient experiment reported in Chapter 5 recorded data for only 210
minutes, I estimate that at least 15 hours of preparation, followed by 15 hours of data
analysis and manipulation was also required. In addition, for both patient and volunteer
studies, approximately 25% of experiments failed due to the equipment malfunction
– not only the NIRS apparatus, but also in particular pumps and analysers. Overall,
after the data had been summarised in to single points for each variable in each Epoch,
6.3 CL IN ICAL ADOPT ION OF CCO AS A B IOMARKER : WHERE NEXT? 163
the study in Chapter 4 yielded over 80,000 and the study in Chapter 5 yielded over
6000 individual data points for statistical analysis. This volume of data was necessary
to provide corroboration to ‘validate’ the CCO oxidation measure that could not be
directly measured by other means.
6.2.3 Challenges in interpretation
The technical and practical challenges described above will, in my view, inevitably
be overcome, as advances in electronics manufacture and the ubiquity of consumer
electronics filters through to medical devices, with resulting increases in ease-of-use
and miniaturisation. However, understanding the physiological meaning of observed
changes in CCO oxidation remains a major obstacle to clinical development and
deployment of this biomarker. This is also intertwined with the technological limitations
of current equipment. The use of continuous wave, modified Beer-Lambert Law-based
algorithms means that observed CCO changes can only be reported from a necessarily
unknown baseline, as discussed in 3.2.2, rather than being able to provide an absolute
measure. In Chapters 4.4.5 and 5.4.3, we limited ourselves to using either qualitative
explorations or statistical models to explore the (patho)physiological basis of the CCO
changes we observed. Yet, the relationships that exist between differently observed
physiological variables are not defined by statistical models, but rather by physiological
cascades. Nevertheless, our findings in Chapter 4 confirm that CCO oxidation state is
a brain-specific and noninvasive measure of cerebral oxidative metabolism and our
findings in Chapter 5 confirm the notion that the measurement of CCO oxidation state
provides insights into acute brain injury (ABI) pathophysiology that are not apparent
from other monitoring modalities.
6.3 CL IN ICAL ADOPT ION OF CCO AS A B IOMARKER : WHERE NEXT?
The work I have undertaken in this thesis leads me to conclude that NIRS-based CCO
oxidation monitoring can be a useful part of an array of clinical monitors to guide the
treatment of patients with ABI in order to guide prevention of secondary brain injury
and thus improve functional outcome. There is a parallel between measurement of CCO
and haemoglobin oxidation state, in that the advent of spatially-resolved spectroscopy
(SRS)-based monitors for haemoglobin oxidation state gave rise to measurement of tissue
oxygen saturation (TOS) and its equivalents, a simple measure that is easily understood
by clinicians. When, in an exploratory analysis not reported in this thesis, we attempted
to perform broadband SRS in order to resolve for a ‘CCO oxygen saturation’ (COS)
on a number of the volunteer datasets reported in Chapter 4, we found that the noise
introduced from the use of multiple detectors overwhelmed the underlying signal.
Improvements in CCD technology or the deployment of time-resolved spectroscopy
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(a) Viewed from rear
(b) In use on neurocritical care unit
Figure 6.2 – Hybrid system
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(TRS)-based apparatus may overcome this important hurdle and turn CCO oxidation in to
a ‘approachable’ measure for clinicians. It would also, as an absolute measure, overcome
the issue of reporting changes from an unknown baseline, and that of reproducibility,
with the potential for intermittent, rather than continuous recordings, as has been
previously been performed for TOS in ABI [12]. The simultaneous incorporation of a
diffuse correlation spectroscopy array [13] allows the simultaneous measurement of
cerebral blood flow and TOS, with derivation of (CMRO)asperformedinChapter 5[14,
15].
I believe that when COS can be reliably measured, providing apparatus can be
miniaturised to the extent that it is easily deployable in the neurocritical care unit by
regular clinicians, rather than dedicated researchers, the next stage will be to conduct
outcome studies, aiming to relate outcome after ABI to COS. The heterogeneity of injury
pattern and outcome following ABI mandates large studies in order to achieve adequate
statistical power, and this in turn mandates that the apparatus are simple enough to be
used by clinicians without specialist expertise in NIRS.
If perturbations in COS are shown to be associated with outcome following ABI,
the ultimate goal must be the formulation of treatment strategies incorporating the
use of COS, but also other brain monitoring modalities. It is notable that the only
randomised, controlled trial involving the use of NIRS – that of a treatment strategy
based on the maintenance of TOS above 75% [16] during cardiopulmonary bypass –
involved interventions guided by other physiological variables including respiratory
and haemodynamic variables. The incorporation of mathematical models of cerebral
haemodynamics and metabolism [17,18] in addition to computer aided decision
support systems will, I anticipate, be necessary to assist clinicians in interpreting and
acting upon what is already a potentially overwhelming amount of physiological
data. For example, in Chapter 5, we considered simultaneous changes in multiple
physiological variables from across a broad-based monitoring array to make inferences
about the pathophysiological processes at play. A real-time model might, for example,
be able to distinguish between mitochondrial dysfunction, classical ischaemia and
impaired oxygen diffusion as a cause for reduced oxidative metabolism, allowing for
the institution of appropriate corrective measures. Importantly, the work in this thesis
provides a corpus of data with which these models can be refined and validated in the
future.
A significant advantage of NIRS-measured CCO oxidation over invasively measured
biomarkers of cerebral metabolism is the potential for multichannel arrays of monitoring.
Whilst rates of complication following invasively-placed catheters are low [19], they
cannot be placed in eloquent cortex or in close proximity. ABI pathophysiology shows
significant spatial heterogeneity [20]. Multichannel NIRS arrays capable of simultaneous
chromophore measurement in multiple regions are now being developed, with the
potential to reveal new aspects of ABI pathophysiology, as shown in Figure 6.3.
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Figure 6.3 – Reconstructed images showing a time series of spontaneous slow oscillations of , [HHb] and
∆[oxCCO] at four time points over a 600-second period in a patient with a right frontal intracerebral
haemorrhage. The changes in∆[oxCCO] are spatially and temporally distinct from those of haemoglobin. D
Highton, personal communication.
6.4 CONCLUS ION
This thesis describes current understanding of the pathophysiology of ABI and the
current state of the art of NIRS. We have conducted experiments in healthy volunteers
that confirm that observed CCO changes are physiologically plausible – from which
we infer that the CCO oxidation measure is veracious –and are better localised to brain,
when compared to other NIRS-measured chromophores. Experiments in patients with
ABI have shown the feasibility of CCO measurement in a clinical setting, with the
measurement of CCO oxidation allowing us to infer additional insights that would not
be apparent with state-of-the-art brain clinical monitors. The findings underline the
potential for measurement of CCO oxidation to be a valuable adjunct to accepted brain
monitoring modalities in the treatment of acute brain injury.
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